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Integrin αvβ3 is a transmembrane receptor recognizing arginine-glycine-aspartic acid 
(RGD) tripeptide. However, the expression and functions of integrin αvβ3 in intestinal epithelium 
in diarrhea, particularly due to E. coli infection, have been poorly understood. Therefore, we per-
formed a series of experiments to fill the gap information. 
We found that integrin αvβ3 is localized on the plasma membrane, the cytoplasm, and 
the nucleus of IPEC1 cells. The expression of integrin αvβ3 on IPEC1 decreased at 15 minutes but 
returned to normal after 90 minutes of infection with E. coli F4 (P<0.05). The light, fluorescent 
and electron microscopy, western blots, and 96-well plate binding assays showed the presence of 
integrin αvβ3-like protein domain in E. coli F4. The data from binding assays on 96-well plates 
also suggests that E. coli F4 may have an RGD-like sequence binding to host integrin αvβ3. 
Immunohistochemistry showed normal porcine jejuna strongly expressed integrin αvβ3 
in the nucleus and the apical surface of epithelia as well as crypts. Integrin αvβ3 expression was 
decreased in the epithelium but increased in the vascular endothelium of the jejunum infected 
with E. coli or E. coli associated with Salmonella (P<0.05). Immunogold electron microscope 
confirmed the presence of integrin αvβ3 in the porcine jejunal epithelium and E. coli. 
Flow cytometry showed that RGDSK-HRNs did not significantly increase dead IPEC1. 
RGDSK-HRNs improved IPEC1 cell survival upon E. coli infection compared with E. coli infec-
tion alone group (P<0.05). Western blot showed that in E. coli infection, RGDSK-HRNs-FITC 
significantly decreased the level of p-p53 compared with monoclonal anti-integrin αvβ3 antibody 
treatment, and the level of p-p38MAPK compared with RGDSK-FITC group (P<0.05).  
The data from ex vivo villus adhesion assays showed that RGDSK-HRNs-FITC signif-
icantly reduced the number of E. coli adhering to villi for up to 12 hours compared with the E. 
iii 
 
coli-only challenged group (P<0.05). Both RGDSK-FITC peptide and monoclonal anti-integrin 
αvβ3 antibody were effective in inhibiting the E. coli binding to villi for up to 24 hours compared 
with the E. coli-only challenged group (P<0.05). Consistently, in the in vivo porcine gut loop 
model, RGDSK-HRNs-FITC significantly decreased the number of E. coli binding to villi com-
pared with E. coli treatment group (P<0.05). RGDSK-HRNs-FITC did not significantly decrease 
the number of E. coli colonies in the supernatant. 
In conclusion, our study highlighted that integrin αvβ3 was involved in E. coli coloniza-
tion in the porcine intestine. Also, the novel RGDSK-HRNs-FITC could inhibit the attachment of 
E. coli to the epithelium, suggesting a potential intervention in combination with antimicrobial and 
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CHAPTER 1.  INTRODUCTION 
The financial losses due to intestinal diseases are in billions of dollars every year in Can-
ada (95) and America (74). Moreover, infectious diarrhea caused more than 2 million deaths in 
children below five years old in many countries, such as Nigeria, Congo, Pakistan, India, and 
China (20). The intestine is a unique organ of the body that is continuously exposed to the envi-
ronment through food (160). In addition to the resident microbiome, the intestine also has the 
potential of entry for pathogens from the environment, such as E. coli (19). Although E. coli has 
been studied for many decades, the recent interventions cannot wholly control intestinal diseases 
and foodborne illness due to E. coli because of the continual change of E. coli characteristics (mu-
tations), and multiple virulence factors (34, 35, 185, 247). 
Integrin αvβ3 recognizes Arg-Gly-Asp (RGD), and plays an essential role in cell adhesion 
to the extracellular matrix, cell signalling transduction, cell-cell interaction, cell survival, angio-
genesis and leukocyte migration (98, 121, 159, 199, 220, 260). The integrin αvβ3 integrates the 
external milieu with the intracellular cytoskeleton (98, 227, 231, 243). Dysregulating integrin αvβ3 
signal can disrupt tissue homeostasis, and contribute to important stages in the pathogenesis of 
many diseases (17, 62, 121, 199, 255, 260), such as diabetes (171), hyperglycemia (171), osteopo-
rosis (101), angiogenesis (199), tissue repair (199), tumour growth (5, 199), and rheumatoid ar-
thritis (260). Integrin αvβ3 also appears to be the receptor for a wide range of virus families such 
as rotavirus, coxsackievirus A9, parechovirus 1, and tat protein of HIV (243). 
Recently, a wide range of applications of nanotechnology in drug development and de-
livery has been studied (132). The helical rosette nanotubes (HRNs), invented by Dr. Hicham Fen-
niri in 2001 (39, 63, 64), are one of the highly novel nanomaterials known till now. These nano-
tubes are synthesized from guanine-cytosine (G˄C) motif building blocks through a rapid 
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hierarchical self-assembly process in water, becoming a novel metal-free, organic, water-soluble, 
tunable, biologically-inspired, and biocompatible nanomaterial (63, 64, 223). Scientists have 
found numerous potential applications of HRNs, notably in the medical areas such as potential 
targeted drug delivery for chondrification, bone regeneration, and cancer (39, 134, 224, 268-270). 
Recently, RGD peptide sequences have been integrated into nanomaterials to bio-functionalize 
them (83, 125, 155). In our study, Arg-Gly-Asp-Ser-Lys (RGDSK) peptide-functionalized helical 
rosette nanotubes (RGDSK-HRNs-FITC) were designed to target integrins for specific medical 
and biological applications by RGDSK, and can be visualized under a fluorescent microscope by 
FITC (39, 225). In 2017, House and colleagues performed an isolated perfused lung model in male 
Sprague-Dawley rats where intravascular RGDSK-HRNs-FITC administration reduced cell acti-
vation measured through the elaboration of adhesion molecules and ROS production (99). 
However, to our knowledge, the effects of RGDSK-HRNs-FITC on the adhesion of E. 
coli to gut epithelium via interactions with integrin αvβ3 have not been investigated. Therefore, in 
this study, we tested the hypothesis that RGDSK-HRNs-FITC would localize along the integrin 




CHAPTER 2. REVIEW OF THE LITERATURE 
2.1. INTEGRINS 
In 1986, integrins were named by Dr. Hynes as an integral complex of type I glycopro-
teins on the cell surfaces to connect the extracellular matrix and the cytoskeleton (102, 231, 243). 
The adhesion of the extracellular matrix to the cell via these integrins receptors is critical for cell 
integrity (90). For more than three decades, the structure, biology, and therapeutic applications of 
integrins have been widely studied (29, 187). In 2016, commercial drugs, mostly α4-series integ-
rins inhibitors such as vedolizumab to treat ulcerative colitis and Crohn’s disease, made more than 
three billion U.S. dollars (187). 
Horton and co-authors described that integrins are a superfamily of heterodimeric trans-
membrane receptors composing of two subunits, α and β (98). Twenty-four heterodimers of integ-
rins are reported from the mixture of eighteen subunits α including α1- α11, αE, αv, αIIb, αL, αM, 
αX, and αD and eight subunits β including β1- β8 (17, 29, 229, 243). The reasons for the specific 
pair of subunit such as αv with β1, β3, β5, β6, β8 but not with β2, β4, or β7 are unknown (11). 
Each integrin heterodimer is formed by the extended structure of α and β chains in building an N-
terminal globular head portion (98). The extracellular domain of integrins has a cysteine-rich seg-
ment, and the cytoplasmic domain has a tyrosine residue which can be phosphorylated by tyrosine 
kinase (231). The tail of both α and β chains connects with the cytoskeleton by their intracellular 
C-termini (98, 243). 
Scientists have described the activity of integrins in transducing signalling. Each subunit 
of integrins has an extracellular domain, a single transmembrane region, and a short cytoplasmic 
domain (8). The extracellular domain, known as a ligand-binding site, can bind various extracel-
lular matrix proteins (26, 137) to transmit signals from outside into the cell interior and vice versa 
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to the affinity of their ligand-binding site (11, 29, 229, 266). Although smaller than the extracellu-
lar domains, the cytoplasmic domains activate integrins by their association with adaptor proteins, 
including tyrosine kinases (26, 137), actin-binding proteins (26, 137), Src, focal adhesion kinase, 
integrin-linked kinase, kindlin, paxillin, talin, and vinculin (103, 170). Consequently, these inter-
actions rearrange cytoskeleton, thus affecting not only the structure and function of extracellular 
domains but also cell migration (103). The activation state of the integrins is characterized by the 
separation, twisting, pistoning, and hinging of their tails (103).  
The binding ability of each integrin depends on its affinity to different integrin ligands. 
The integrins can bind to extracellular matrix ligands, cell-surface ligands, and soluble ligands 
(229). For example, αv integrins have high-affinity binding to fibronectin, one of the extracellular 
matrix proteins (179). Moreover, eight out of 24 integrins in total recognize aminoacid Arginine-
Glycine-Aspartic acid (RGD) triad in the native ligands (17, 199), known as a general integrin-
binding motif (29). These integrins are five αv integrins, two β1 integrins (α5β1, α8β1), and αΙΙbβ3 
(29, 196). Some extracellular matrix ligands exposed their RGD sequence upon denaturation or 
proteolytic cleavage to bind these integrins (17). The RGD amino acid sequence may contain dif-
ferent specificity interaction with many receptors but through the same mechanism (184, 196). The 
molecular mechanisms involving the RGD sequence have been studied for many decades (184). 
Recently, RGD-containing peptides and mimics have been studied to develop new therapeutics for 
diseases via targeting integrins (196). Scientists have developed a radio-labelled form such as 
RGD-mimetic to determine accurate affinity and binding kinetics to integrins, not only αvβ3 but 
also αvβ1, αvβ5, αvβ8, α5β1, and α8β1) (89). 
The integrins with a highly bent physiologic conformation have a low affinity for binding 
biological ligands (230). The affinity of integrins for binding to ligands may also depend on 
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kindlins, also known as fermitins (194). In general, this kindlins family binds to the tail of β integ-
rin to activate the integrin. Consequently, this activated integrin can bind to a ligand, so the cell 
adheres, spreads, and migrates (194). Among three kindlins, kindlin-2, which binds to the tails of 
integrin β3, is expressed ubiquitously, notably in striated and smooth muscle cells. 
The integrins are expressed in many species such as mammals, chicken, zebrafish, 
sponges, the nematode Caenorhabditis elegans (two alpha and one beta subunits, forming two 
integrins) and the fruit-fly Drosophila melanogaster (five alpha and one beta, forming five integ-
rins) (17, 29, 229, 243). The expression of integrins is enhanced by some cytokines such as trans-
forming growth factor (TGF)-β1 (93, 170, 187), and a growth inhibitor of normal hepatocytes and 
HCC cells that induces apoptosis and cellular senescence in the liver (166). The sizes of integrin 
α subunits vary from 120-180 kDa, containing seven repetitions of 60 amino acid tandem (98). 
The integrin β chains have sizes varying from 90-110 kDa (98). In 1985, Pytela and colleagues 
described integrins as the specific vitronectin receptor, having 125 kDa and 115 kDa molecular 
weight, bound to Arg-Gly-Asp tripeptides in vitronectin while the specific fibronectin receptor has 
140 kDa molecular weight protein in human MG-63 osteosarcoma cell line (184). The authors 
classified that these two different receptors expressed at the cell surface (184). They also men-
tioned that the RGD containing peptides possibly had one binding site interfering with the fibron-
ectin receptor and another specifically interacting with the vitronectin receptor (184). 
The integrin functions show their involvement in cancer (αvβ6) (89), fibrosis (αvβ6) (89), 
thrombosis, inflammation, and pathogenesis of some diseases due to their interaction with their 
ligands and cytokines such as activating TGFβ (187). In detail, integrins were found as signalling 
molecules in tumour stroma remodeling, the survival, proliferation, differentiation, migration, and 
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invasion of cancer cells (90). The survival of different cell-types is dependent on the regulation of 
cellular processes through interactions of specific ligands with integrins (90, 93, 170).  
The association of integrins with extracellular matrix supports the survival of a variety 
of cell types. For example, during serum starvation culture condition, Caco-2 gut epithelial cells, 
ureteral epithelial cells, and human umbilical vein endothelial cells (HUVECs) showed more nu-
clear fragmentation (151). In suspension without extracellular matrix, the endothelium showed 
both morphological and biochemical characteristics of apoptosis, including shrinking, membrane 
blebbing, fragmented nuclei, and apoptosis-specific gene expression (151). Additionally, scientists 
reported that the survival of early chick sympathetic neurons depended on the molecular interac-
tion between the extracellular matrix and integrins (59). The extracellular matrix, particularly lam-
inin, is responsible for mediating proliferation and development of avian sympathetic neurons (59). 
The laminins are also essential for the early survival and differentiation of neuronal cells (114). 
However, fewer live neuronal cells were observed on other extracellular matrices such as fibron-
ectin or a substrate of molecules from heart cell-conditioned medium in vitro (59). Different from 
these above cells, Meredith and colleagues noted that without extracellular matrix coating, meso-
thelial cells and fibroblasts can still maintain their survival in suspension (151). It is explained that 
integrins stimulate actin remodeling for adhesion and survival signals via the phosphoinositide 
(PI) 3 kinase or mitogen-activated protein kinase (MAPK) pathway (80, 152). The absence of 
integrin can activate p53 or jun N- terminal kinase (JNK) death signals, and down-regulate Bcl-2 
expression and function of the endothelium (152). 
2.2. ALPHA V INTEGRINS (αv) INVOLVEMENT IN DISEASE 
The αv integrins subunit is a partner of integrins β1, β3, β5, β6, β8 (22). Scientists have 
addressed the role of αv integrins through the use of inhibitors such as C8 (an integrin αvβ1 
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inhibitor) (22), DC9711 (an inhibitor of integrin αvβ6) (22), MABT207 monoclonal antibody 
(αvβ1, αvβ3, αvβ5, αvβ6, αvβ8) (22), SB273005 (22) and Cilengitide (16) (inhibitors of integrin 
αvβ3 and integrin αvβ5), and GSK3008348 small molecule (an integrin αvβ6 inhibitor in a trial 
study of pulmonary fibrosis) (89). In 2011, Weis and colleagues noted that integrin αv activation 
aggravates tumour cell invasion, growth, and metastatic spread (255). They found that blockage 
of integrin αv could inhibit the angiogenesis by slowing down the adhesion, migration, and prolif-
eration of endothelium in cancer (255). 
Numerous interventions to αv integrins have been developed clinically (187). For in-
stance, a human antibody to αv integrins-abituzumab could inhibit TGFβ, consequently reducing 
trans-differentiating fibroblasts into myofibroblasts, and their extracellular matrix products such 
as collagen in scleroderma (118, 187). Although this product likely could work in the phase II trial 
for scleroderma, it was not feasible because of some difficulties in patient enrollment and risks 
such as inflammatory and cancerous development potentially associated with this drug (118, 135, 
187). 
Targeting αv integrins may have the potential for clinical therapeutics for most fibrotic 
diseases. For example, Bon and co-workers recently demonstrated that αv integrins associate with 
the production and accumulation of extracellular matrix proteins during the interaction with renal 
fibroblasts and human primary renal proximal tubular epithelia co-cultured in vitro (22). This as-
sociation reveals a crucial role for αv integrins in the tubulointerstitial fibrosis of chronic kidney 
diseases causing renal failure (22). They also found that in the co-culture of renal fibroblasts with 
human primary renal proximal tubular epithelia, blockage of αv integrins dramatically down-reg-
ulated the levels of total spontaneous extracellular matrix proteins and individual extracellular ma-
trix components such as fibronectin, as well as collagen I and III (22). Among these blocking 
8 
 
substrates, CWHM12, a pan αv integrins inhibitor, could block the full range of αv heterodimers 
(αvβ1, αvβ3, αvβ5, αvβ6, αvβ8) (22). This small molecule was the most effective inhibitor reduc-
ing total production and accumulation of extracellular matrix in that study (22), suggesting that 
individual αv integrins have varying severity effects such as on fibrotic diseases on their own (94). 
Another example is that in 2013, Henderson and co-authors published a paper describing 
that deleting αv integrins attenuated hepatic fibrosis by carbon tetrachloride and pulmonary as well 
as renal fibrosis by Pdgfrb-Cre in murine models (94). Besides, this group found that the pharma-
cological CWHM 12 blocked αv integrins and moderated both liver and lung fibrosis in a mouse 
model (94). Additionally, Bagnato and colleagues previously reported that cilengitide could block 
both integrins αvβ3 and αvβ5, preventing the fibrosis and renal vascular abnormalities in the 
chronic reactive oxygen species - induced systemic sclerosis murine model (16). 
In human lung fibrosis, the expression of αv integrins was increased in pneumocytes of 
the alveolar ducts and alveoli (97). The αv integrins were known as one of the tissue-restricted 
stimulators of transforming growth factor (TGF) β, an initiator of fibrosis characterized by the 
pathological deposition of excess extracellular matrix (97). An RGD motif in latent TGFβ binds 
to αv integrins, consequently activating the TGFβ (9). The TGFβ1 induced alveolar epithelial cell 
apoptosis, triggering epithelial - to - mesenchymal cell transition, as well as epithelial injury, and 
thus worsening the fibrosis (122). Therefore, αv integrins inhibition is one of the selected strategies 
to modulate TGFβ (97). The expression of αv integrins and integrin αvβ6 was augmented notice-
ably in cutaneous and lung injury, as well as bleomycin treatment (162). Blockage of the protein 
by low doses of monoclonal anti-αvβ6 integrin antibodies partially restricted TGFβ, lessen the 
fibrosis injury (hydroxyproline content in the lung, collagen reporter transgene expression), but 
without aggravating inflammation in murine bleomycin-induced pulmonary fibrosis model (97). 
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Recently, Bon and colleagues reported that the precursor form of TGFβ released latency-
associated-peptide binding back to the mature TGFβ homodimer (22). This latency-associated 
peptide of TGFβ1 and TGFβ3 contains the RGD motif, which can activate αv integrins, including 
αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8 (22). Other scientists have also added that integrin αvβ6 activate 
TGFβ (9), a centre mediator of fibrosis in many organs such as lungs (162), biliary tract (251), and 
kidney (145). 
2.3. BETA 3 INTEGRINS (β3) INVOLVEMENT IN DISEASE 
β3 integrins were found in endothelium and engaged in vascular permeability as well as 
the maintenance of vascular integrity (76). β3 integrins also play a part in the mechanism of virus 
entry, depending on the virus species, cell types, and host species (161). This was exemplified in 
work undertaken by Gavrilovskaya and colleagues in 1999 that hantaviruses invaded human vas-
cular endothelium via β3 integrins as an entry receptor of the virus (75). These viruses caused 
hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome (75). More than ten 
years after that, Matthys and co-workers found that human β3 integrins have aspartic amino acid 
residue at position 39 (D39) in an N-terminal plexin-semaphorin-integrin domain which was re-
quired for Andes virus infection, causing a fatal hantavirus pulmonary syndrome in Syrian hamster 
model and humans (147). This amino acid was suggested to be crucial for Orthohantaviral entry 
in primates (161). However, β3 integrins are not present in Apodemus agrarius mouse field strain, 
although this mouse strain is susceptible to Hantavirus (161). A likely explanation is that the virus 
may use other alternate receptors to enter the primate or rodent cells of the host (161). These vi-
ruses use β3 integrins to dysregulate endothelial migration as part of the disease pathogenesis (76).  
Recently, Wu and co-workers reported that the mRNA level of β3 integrins was increased 
upon nickel chloride (NiCl2) exposure, consequently causing lung and skin cancer (262). The 
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authors explained that NiCl2 activated TGF-β signalling, enhancing vascular endothelial growth 
factor (VEGF) product (262). VEGF plays a pivotal role in angiogenesis (33). This factor binds to 
VEGF receptors on the endothelium to promote angiogenesis in embryonic development, wound 
healing, and cancer (33). The VEGF contributes to the formation of new abnormal vasculature in 
and around the tumour, stimulating its exponential growth (33). The blood vessels in the tumour 
have irregular, tortuous structure and shape with dead ends. They do not develop well as venules, 
arterioles, and capillaries. They are malfunctioning, leaky, and hemorrhagic vessels leading to an 
increase in interstitial pressure, and hypoxia (33). 
2.4. INTEGRIN ALPHA V BETA 3 (αvβ3) 
2.4.1. Integrin αvβ3 biology 
In 1985, “vitronectin receptor” was revealed firstly in human osteosarcoma (MG-63) by 
Dr. Pytela and co-workers as it bound to RGD containing peptide on human vitronectin plasma 
protein (184). One year after that, the proteins were cloned and sequenced by Dr. Suzuki and co-
workers (227). After that, this class of receptors was proposed as integrin αvβ3 to highlight its 
function in integrating the external milieu with the intracellular cytoskeleton (98, 227, 231, 243). 
In 1986, Suzuki and co-workers illustrated that the αv subunit (150 kDa) comprises of a disulfide 
bonding a heavy chain (125 kDa) and a light chain (25 kDa) derived from a proteolytically cleaved 
precursor (227). The 125 kDa chain has an NH2-terminal amino acid sequence homologous with 
the one of lymphocyte function-associated antigen 1 (LFA-1) and macrophage antigen 1 (Mac-1), 
implying its function likely as adhesion receptor of leukocytes (227). These scientists also men-
tioned that the β3 subunit has 115 kDa molecular weight (227). However, in 1997, Horton and 
colleagues described that integrin αvβ3 has a bigger molecular weight of αv chain and smaller β3 
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chain in tissue, exhibiting many typical structures and functions as a member of the integrin su-
perfamily (98). The integrin αv chain (160 kDa) has a 25 kDa C-terminal fragment, which is re-
leased on the proteolytic cleavage process in reduced condition (98). The integrin αv gene is re-
vealed at 2d31-32, synthesizing 1018 amino acids with 13 N-linked glycosylation sites and four 
typical N-terminal repeated motifs (98). The integrin β3 chain (85 kDa) has a gene located at 
17q21, synthesizing 762 amino acids (98). 
2.4.2. Integrin αvβ3 expression and functions in organs 
Integrin αvβ3 was expressed in osteoclasts and vascular endothelium (98). The expres-
sion of integrin αvβ3 on neovascular endothelial cells is intense (220). Similarly, its expression 
augmented during angiogenesis, osteosarcoma (98), and ovarian carcinoma (200). Integrin αvβ3 
is also found in bronchial vasculature in the lung, epithelium of the small intestine, bile duct, and 
renal proximal convoluted tubules in the pig, dog, and cattle (213). Moreover, integrin αvβ3 was 
detected in COS-1 cells and human primary fibroblasts by FACS analysis (178). Integrin αvβ3 is 
also expressed on the apical uterine luminal epithelium and conceptus trophectoderm of pig and 
sheep, respectively (107). Through binding with secreted phosphoprotein 1, this receptor stimu-
lates cell-cell adhesion and communication, contributing to the adherence of the conceptus to the 
uterus for implantation (107). 
In 2000, Dr. Singh and co-authors reported that integrin αvβ3 was expressed in the vas-
cular bed, endothelium, vascular smooth muscle, and large bronchial epithelium of normal rat 
lungs, implying its function in the microvascular system and airway (210). Interestingly, integrin 
αvβ3 was not found in the blood vessels of the liver, brain, skeletal muscle, and skin from rats, 
although the protein was present in other cells outside the blood vessels of these organs (210). For 
example, in the rat liver, the weak positive staining of integrin αvβ3 occurred in a branch of the 
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portal vein. In the brain, integrin αvβ3 is present in occasional cells. In skeletal muscle, integrin 
αvβ3 was found in connective tissue. In skin, integrin αvβ3 was observed in epithelium and con-
nective tissue (210). 
However, the absence of integrin αvβ3 on these organs above under resting conditions 
may change in different conditions. For example, Okada and colleagues reported that integrin αvβ3 
was not found in normal basal ganglia of baboons (167). Interestingly, in the nonhuman primate 
model of MCA:O/R cerebral ischemia, integrin αvβ3 was present in middle cerebral artery occlu-
sion, suggesting the function of integrin αvβ3 in this condition (167). These authors explained that 
in the ischemia condition, the increased expression of fibroblast growth factor could stimulate the 
transcription of integrin αvβ3 gene (167). 
Immunohistochemistry of anterior mouse segment of eyes indicated that integrin αvβ3 is 
present at the trabecular meshwork, sclera, and ciliary body (62). Similarly, in human eyes, integrin 
αvβ3 is also observed within the inner wall of Schlemm’s canal in the corneal epithelium, ciliary 
muscle (62). Immunofluorescence and FACS analysis confirmed the presence of integrin αvβ3 on 
human trabecular meshwork cells, and its expression increased in dexamethasone-induced glau-
coma group (71). Activating integrin αvβ3 by AP5 antibody elevated intraocular pressure in mouse 
eyes (62). The enhanced intraocular pressure causes glaucoma, risking irreversible blindness (41). 
The deficiency of β3 integrins significantly reduced intraocular pressure, which is the fluid pres-
sure inside the eyes (62). A small decrease of the integrin αvβ3 level could also affect the function 
of trabecular meshwork and decreased intraocular pressure in a tamoxifen eye drops – inducible 
Cre+/ – β3flox/flox mouse model (62). These results implied the critical function of integrin αvβ3 in 
glaucoma (62). In contrast, in 2007, Jacqueline and co-authors reported that integrin αvβ3 was not 
present at the retina and cornea of cats, cows, dogs, horses, pigs, and rats (175). The findings from 
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this observation suggested that the absence of integrin αvβ3 on the eyes of these animals could 
inhibit its ligands such as angiostatin from the program cell death of these cells, or it may be related 
to other eye diseases. 
About twenty years ago, Singh and his colleagues demonstrated that integrin αvβ3 was 
present on the bronchiolar epithelia, and alveolar macrophages in healthy human lungs (211) as 
well as in the lungs of cattle, dogs, and pigs (213). Its expression is increased in macrophages in 
human septic lungs (211). These scientists also reported that the expression of integrin αvβ3 was 
induced in neutrophils and whole lung in Streptococcus pneumonia infected rat model (105). In-
terestingly, the level of integrin αv and integrin β3 subunits was decreased in E. coli infected rat 
lungs compared to normal control and S. pneumoniae infection groups (105). These authors ex-
plained that the levels of integrins were changed because of the crosstalk between integrins (105). 
In 2017, Brilha and co-workers also reported that integrin αvβ3 controlled the collagenase activity, 
adhesion, and migration of monocyte (27). The over-expression of integrin αvβ3 in diseases has 
suggested that inhibiting integrin αvβ3 activation to calm down the immune system can be a 
promising targeted therapy (27, 125).   
Additionally, in 1995,  the Bhattacharya laboratory found that integrin αvβ3 might regu-
late hydraulic conductivity across the pulmonary vascular barrier (239). This group reported that 
an antibody against integrin αvβ3 attenuated the up-regulation of lung capillary hydraulic conduc-
tivity (239). Using oil split drop technique, these scientists also reported that endothelial integrin 
αvβ3-vitronectin interaction enhanced transcapillary fluid, which was involved in complement-
mediated pulmonary edema in rat lung (239). These results suggested that integrin αvβ3 on endo-
thelium plays a part in cellular adherence and maintenance of vascular integrity (239).  
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Integrin αvβ3 plays a role in macrophage activation, osteoclast development, bone re-
sorption, and inflammatory angiogenesis, involving the mechanism of rheumatoid arthritis and 
other arthropathies (260). Humanized monoclonal antibody IgG1 – Vitaxin/MEDI-522 was stud-
ied to block integrin αvβ3 from other ligands such as osteopontin and vitronectin, expecting to 
slow down the process of the pathogenesis of the arthropathies (260). Besides, integrin αvβ3 on 
osteoclast can bind RGD amino acid sequence on vitronectin, osteopontin, and bone sialoprotein. 
The integrin αvβ3 can manage the activity of this cell, including its adhesion, migration, bone 
resorption, cytoskeletal organization, and polarization (57), which is crucial for the remodeling 
process of the bone (101). Some nonpeptide antagonists of integrin αvβ3 was studied for prevent-
ing osteoporosis, such as 3(S)-(6-methoxypyridin-3-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-[1,8]-
naphthyridin-2-yl)propyl]imidazolidine-1-yl] propionic acid 6 compound (101). This oral antago-
nist compound is a small molecule mimicking the structure of RGD binding site to specific integrin 
αvβ3 and was recommended as its good pharmacokinetics in rat, dog, and rhesus monkey (101). 
Integrin αvβ3, known as vitronectin receptor, plays an essential role in cell adhesion to 
the extracellular matrix, cell signalling transduction, cell-cell interaction, cell survival, angiogen-
esis, and leukocyte migration (98, 121, 159, 199, 220, 260). Dysregulating integrin αvβ3 signal 
can disrupt tissue homeostasis and contribute to important stages in the pathogenesis of many dis-
eases (121, 199, 260), for instance, tumour (5), diabetes (171), hyperglycemia (171), osteoporosis 
(101), angiogenesis (199), tissue repair (199), tumour growth (199), and rheumatoid arthritis (260).  
Interestingly, in 2013, Gagen and co-authors reported that the activation of integrin αvβ3 
by dexamethasone could inhibit the phagocytosis by regulating the integrin αvβ5-FAK-mediated 
pathway in human trabecular meshwork cells (71). Dexamethasone increased the level of integrin 
αvβ3 but not integrin αvβ5 (71). Likely, activated integrin αvβ3 and integrin αvβ5 have 
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antagonistic roles in phagocytosis (71). It could be explained that the activated integrin αvβ3 pos-
sibly mediated the actin cytoskeletal rearrangement and filament recruitment in phagocytosis ac-
tivities (41, 71). However, in an earlier study using mouse bone marrow neutrophils and peritoneal 
macrophages, Friggeri and colleagues reported that high mobility group box protein 1, a protein 
in the extracellular milieu, could reduce the efferocytosis of macrophage to apoptotic neutrophils 
(68). These scientists explained that this protein could block the interaction of integrin αvβ3 on 
macrophage, milk fat globule EGF factor 8 opsonin, and phosphatidylserine on the surface of 
apoptotic neutrophils (68).  
In 1995, Lawson and colleagues described that the presence of integrin αvβ3 on the 
leading edge is higher than that on the rear of migrating neutrophils (133). At the leading edge of 
migrating neutrophils, integrin αvβ3 stays along with F-actin, which is localized with talin (133). 
These authors also reported that integrin αvβ3 was endocytosed and recycled, which belonged to 
Ca(2+) and calcineurin-dependent pathway (133). Additionally, the distribution of integrin αvβ3 
on the extending pseudopod helps migrating neutrophils adhering to vitronectin (133). Moreover, 
the tight binding of integrin αvβ3 to ligands, such as fibronectin make the polarized distribution of 
integrin αvβ3 (133), and facilitates the migration of cells. About ten years after that, Aulakh and 
co-authors added that integrin αvβ3 is distributed on the lipid raft of neutrophils (14). These 
scientists reported the role of integrin αvβ3 in the migration of neutrophils via its binding to RGD 
on angiostatin protein, which is an endogenous angiogenic inhibitor cleaved from plasminogen 
(14). These authors also highlighted that this binding consequently deactivated neutrophils and 
prevented their migration (14). Also, blocking integrin αvβ3 by LM609 antibody partially 
prevented the effects of angiostatin, such as recovering neutrophil polarization (14). 
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In the blood vessel, integrin αvβ3 promotes angiogenesis, including endothelial cell 
adhesion, migration, and survival under the control of kindlin-2 (141). Integrin αvβ3 is also the 
key mediator of smooth muscle cell filopodia formation and migration in hyperglycemia (171). 
Integrin αvβ3 was stimulated by thrombospondin ligand and was modulated by Rap1 (171). In 
detail, integrin αvβ3 is activated during hyperglycemia due to its interaction with the high level of 
thrombospondin, vitronectin, and osteopontin ligands secreted by the vascular smooth muscle (42). 
This activation leads to the stimulation of MAP kinases, resulting in the proliferation and migration 
of smooth muscle, mitogenic response, and atherosclerosis (42). 
Integrin αvβ3 is a biomarker and a cell adhesion molecule, involved in angiogenesis and 
cancerous metastasis (5, 38, 53). Angiogenesis is a crucial factor for tumour growth and metastasis, 
depending on some signaling molecules and pathways (256). One example of this is the study 
carried out by Brooks and co-workers in 1994 that ligation of integrin αvβ3 induced vasculogenesis 
(28). Therefore, integrin αvβ3 was noticed early as a potential therapeutic target for suppressing 
angiogenesis in cancer (5). Antagonists of integrin αvβ3 were used to down regulate the 
development and spread of cancer cells (38). About three decades ago, scientists found that 
angiogenesis on human tumours transplanted onto the chick choriollantic membrane was disrupted 
by a cyclic peptide or a functional monoclonal antibody antagonist of integrin αvβ3 (28). These 
antagonists enhanced apoptosis of angiogenic blood vessels (28). 
As mentioned above, antiangiogenics targeting selective integrin αvβ3 imply the poten-
tial of exploiting this integrin for therapeutics of pathological conditions such as cancer and in-
flammatory diseases. One of such is RGDechiHCit comprising of a cyclic RGD motif and two 
echistatin moieties (199). The disintegrin RGDechiHCit prohibits the intracellular mitogenic sig-
nalling, proliferation, and tube forming of the endothelial cell line. This disintegrin also delayed 
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wound healing in the murine model. However, although blocking the function of integrin αvβ3 or 
integrin αvβ5 may suppress neovascularization and tumour growth, others reported that deficiency 
of β3 integrins or β5 integrins support tumorigenesis by enhancing tumour growth, tumour angio-
genesis and vascular endothelial growth factor (VEGF) – induced blood vessel growth and angio-
genic response to hypoxia in a mouse model (190). Overall, it is agreed that the integrin αvβ3 
promotes angiogenesis through the suppression of apoptosis in endothelial cells and the promotion 
of their migration through interactions with cytoskeleton. 
2.4.3. Integrin αvβ3 association with other receptors 
Integrin αvβ3 can bind extracellular matrix protein, comprising of fibronectin, vitron-
ectin, von Willebrand factor, tenascin, osteopontin, fibrillin, fibrinogen, bone sialic protein, and 
thrombospondin (100, 243). In addition to those, integrin αvβ3 can recognize soluble ligands, in-
cluding fibrinogen, cysteine-rich angiogenic protein 61, mouse connective tissue growth factor 
(Fisp12/mCTGF), matrix metalloproteinase, endostatin, angiostatin, tumstatin (243). The activity 
and role of integrin αvβ3 are complex to understand and depends on the nature of the proteins, 
extracellular matrix composition, organs, stage of diseases, conditions, environment (91, 121), 
other networks of signalling activators (62, 91) and cross-talk with other receptors (86). Weis and 
co-workers also mentioned that the ligation of an integrin to a specific matrix protein created a 
signal of cross-talk between integrins (256) 
Integrin αvβ3 engaged the activities of other integrins through its interaction with the 
extracellular matrix. An example of this is the study performed by Blystone and co-workers in 
1999 (21). The lab explained that the activation of integrin αvβ3 by binding with its ligand gave 
the signal to Ser752 of the β3 cytoplasmic tail to suppress the activation of calcium- and 
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calmodulin-dependent protein kinase II (CamKII) (21). This suppression restricted the function of 
integrin α5β1 on mediating both phagocytosis and migration of human peripheral blood monocyte-
derived macrophages in an in vitro study (21). These scientists also reported that although mutation 
of the Ser752 residue on the β3 subunit had no impact on the ability of integrin αvβ3 binding to its 
ligand, this mutation still deleted the effect of integrin αvβ3 on integrin α5β1 (21). 
The extracellular domain of integrin αvβ3 but not β1 integrins can interact with trans-
membrane protein such as insulin receptor (202), platelet-derived growth factor receptor-β (PDGF-
Rβ) (23, 202), and vascular endothelial growth factor receptor-2 (VEGF-R2) (23, 243). The PDGF-
Rβ associates sufficiently with the extracellular domain of the β3 subunit, while VEGF-R2 needs 
αv subunit for the interaction (23). These two receptor tyrosine kinases were stimulated by growth 
factors, promoting the proliferation and migration of cells adhering to vitronectin through its in-
tegrin αvβ3 (23). In 1993, Juliano and co-authors noted that the importance of integrin αvβ3 as a 
receptor in transducing signals to the cellular interior via tyrosine phosphorylation (113). The in-
volvement of these cell-matrix interactions in the cellular response to growth factors implicates 
the crucial role of integrin αvβ3 in tissue regeneration, angiogenesis, and tumour metastasis (202). 
The cytoplasmic domain of integrin αvβ3 has an association with cytoplasmic intracel-
lular proteins. For example, in 1994, Vuori and co-authors revealed that integrin αvβ3 on FG hu-
man pancreatic carcinoma cell line interacted with insulin receptor substrate 1 (IRS1) (248). The 
IRS1 could bind to growth factor receptor-bound protein two, as well as phosphatidylinositol-3’ 
kinase to control insulin signalling (248). The association between integrin αvβ3 and IRS1was 
enhanced by insulin challenging (248). These researchers reported that the insulin treatment in-
creased the expression of integrin αvβ3 on the FG cells plated on vitronectin, and that expression 
was higher than that on cells plated on collagen, a ligand more specific for integrin β1 (248). 
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As mentioned above, the topic “cross-talk” between the integrin αvβ3 and other integrins 
such as integrin α5β1 was brought up with evidence many years. For example, in 2002, a group of 
researchers reported that the decreased expression of integrin αvβ3 might trigger the activity of β1 
integrins, activating angiogenesis in a mouse model (190). In an in vitro study carried by Gonzalez 
and co-workers in the same year, they found that blocking both integrin α3β1 and α6β1 by anti-
bodies MKID2, and 6S6 may change the activity of integrin αvβ3 (87). Interestingly, blocking 
integrin αvβ3 by LM609 antibody could indirectly inhibit integrin α3β1 and α6β1 on immortalized 
human bone marrow endothelial cells adhering to laminin-5 ligand (87). However, entirely knock-
ing-out the integrin αvβ3 triggered integrin α3β1and α6β1 function on angiogenesis in a mouse 
model (87). These results suggested that the function of integrin αvβ3 may depend on integrin 
α3β1 and α6β1 and vice versa. An explanation for the interaction was that integrin αvβ3, and in-
tegrin α3β1 interacted with the ligand G domain of laminin α4 subunit which distributed in the 
basement membrane of blood vessels, where the interaction was involved in vascular development 
in a mouse model (87). LM609 antibody blocking integrin αvβ3 could prevent endothelial cells 
from adhering to the G domain (87). 
Another example of the cross-talk was described in the study of Ly and co-workers in 
2003. They revealed that integrin αvβ3 was activated and responsible for mediating integrin α5β1-
lacked Chinese hamster ovary B3 cells (CHOB3) adhering to and migrating on fibrinogen (144). 
LM609 function-blocking antibody significantly prevented CHOB3 cells binding to fibrinogen 
(144). The adhesive function of integrin αvβ3 on CHOB3 cells to fibronectin was not influenced 
even under soluble MnCl2 agonist, implying the stable and high affinity of integrin αvβ3 in these 
cells (144). However, MnCl2 agonist activated integrin αvβ3, enhancing the adherence of Chinese 
hamster ovary B3C5 (CHOB3C5) cells to fibrinogen (144). Interestingly, CHOB3C5 cells 
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expressing both integrin αvβ3 and integrin α5β1 have the lower adhesive ability of cells to fibrin-
ogen compared with CHOB3 cells (144). Impressively, Chinese hamster ovary X5C5 cells without 
integrin αvβ3 did not bind to fibrinogen (144). The authors suggested that integrin αvβ3 mediated 
the cellular adhesive activity under the regulation of integrin α5β1, which depended on the cyto-
plasmic tail of the α chain and independent of ligand agonist binding (144). 
This distinction is further explained in a study by Orr and co-workers in 2006. In an in 
vitro study of shear stress on bovine aortic endothelial cells, these scientists found that Protein 
Kinase (PK) A and C play a critical part in the crosstalk of integrin αvβ3 and others (86, 169). 
Fibrinogen and fibronectin bind to integrin αvβ3, and the simultaneous onset of flow activates the 
PI3-kinase with subsequent stimulation of PKCα (169). These activations lead talin to suppress 
integrin α2β1 (169). However, in the presence of collagen-binding to integrins, the junctional 
mechanoreceptor complex gets the signal from the onset of flow to activate PI3-K, subsequently 
stimulate integrin α2β1 (169). These actions activate matrix-specific PKA to effect on talin, re-
sulting in suppressing integrin αvβ3 (169). Inhibiting PKA with chemical kinase inhibitor such as 
14-22 myristoylated trifluoroacetate restore ligand affinity of integrin αvβ3 (169). 
Reversely, integrin αvβ3 activity also depends on other integrins. For example, it is 
known that fibronectin binds both integrins αvβ3 and α5β1 on endothelium, providing a signal for 
angiogenesis (86). In 2010, Gonzalez and colleagues showed that blocking integrin α5β1 by anti-
integrin β1 antibody could perturb integrin αvβ3 binding to fibronectin, eventually preventing an-
giogenesis (86). Additionally, the expression of β1 integrin can affect the mRNA transcription 
stability of β3 integrins, leading to reduced expression of integrin αvβ3 in GD25 cells derived from 
murine embryonal stem cells (86). Another example is that kindlin-2 is well-known as an important 
activator of integrin αvβ3 (216). Integrin αvβ3 expression is up-regulated in pathogen-infected 
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macrophages in vitro (10, 27, 129, 205). Several researchers reported that kindlin-2 deficiency 
deactivated integrin αvβ3, inhibited the recruitment of macrophages and their productions, thus 
reducing the resistance to therapy in breast cancer (216). 
2.4.4. Integrin αvβ3 association in the pathogenesis of diseases 
Integrin αvβ3 plays a crucial role in cellular development and numerous diseases (17, 62, 
255). Many scientists have also revealed the importance of integrin αvβ3 for neovascularization 
of tumour, which is necessary for the nutrition and survival (245), growth (113), differentiation 
(113), proliferation (245), and metastasis (245) of tumour cells, particularly in human melanoma 
(243, 245). Moreover, integrin αvβ3 can recognize toxins such as disintegrins in snake venoms 
(243). Recently, treatments targeting integrin αvβ3 have been attractive topics to interfere with 
pathogens - host cell interaction to control infectious diseases (22, 218), and cancer (200). 
RGD peptides have been used to target integrin αvβ3 expressed in the tumours (5, 196, 
200). For example, blocking integrin αvβ3 by a high dose of RGD-labelled ultrasmall superpara-
magnetic iron oxide (RGD-USPIO) to decrease endocytosis and adhesion activity of glioma cells 
in the brain tumour (120). Dijkgraaf and colleagues also used radiolabeled cyclic RGD peptide 
ligands targeting integrin αvβ3 to image tumours in cancer patients, and to inhibit angiogenesis 
(54). In a study in 2004, radiotracers 125I or 18Fludeoxyglucose (18F) labelled cyclic RGDyK pep-
tide was applied in subcutaneous and orthotopic brain tumour models (38). In orthotopic MDA-
MB-435 breast cancer model, 1,4,7,10-tetraaza-1,4,7,10-tetradodecane-N,N,N′ ′,N′ ″-tetraacetic 
acid (DOTA) and 64Cu conjugated cyclic RGDyK was used to compare with 125I-c(RGDyK) and 
18F-c(RGDyK) (38). In general, these radiotracers appear to have fast blood clearance, high tu-
mour-to-blood, and tumour-to-muscle standard uptake ratio, which are surrogate parameters of the 
metabolic rate of radiotracers (38). However, 18F-c(RGDyK) and 64Cu- DOTA- c(RGDyK) had 
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lower tumour uptake than 125I analogue (38). Their results implied that different radiotracers above 
have akin effectivity but still need to be optimized to improve their kinetics and to prolong tumour 
uptake in vivo. The ability of integrin αvβ3 binding to small-molecule ligands, radiotracer, and 
radiolabeled RGD peptides, such as triazole RGD mimics-base integrin αvβ3 selective radiotracer 
[3H]ZMPZAT71 or [18F]FDR-Aoa-c(RGDfK) radiotracer (bioconjugation of 18-Fluoride 5-
fluoro-5-deoxyribose to aminooxyacetyl functionalized cyclo(Arg-Gly-Asp-D-Phe-Lys)), also de-
pends on integrin αvβ3 expression and activation status (8). For example, these bindings were 
increased when integrin αvβ3 was activated at the presence of Mn2+ or talin head domain transfec-
tion of PC3 prostate cancer cells and U87MG glioblastoma cells (8). Recently, Sartori and col-
leagues conjugated c(AmpRGD) peptide (alias aminoproline-base RGD cyclotetrapeptide) and a 
tyrosine kinase inhibitor sunitinib to target integrin αvβ3, then receptor tyrosine kinase associated 
with drug resistance intracellularly, consequently affect the cross-talk between integrin αvβ3 with 
other receptors in the cancer cells (200). 
Integrin αvβ3 also appears to be the receptor for a wide range of viruses such as rotavirus, 
coxsackievirus A9, parechovirus 1, and tat protein of HIV (243). Integrin αvβ3 function varied 
depending on the virus. Adenovirus (particularly Adenovirus 2/5) used integrin αvβ3 for cell entry, 
signalling, and endosome escape while Herpesvirus (particularly Human Cytomegalovirus, 
HCMV) utilized integrin αvβ3 for cell entry and signalling (218). Integrin αvβ3 is essential for the 
attachment and entry of Hantavirus (particularly Sin Nombre virus, SNV), Picornavirus (Foot-and-
mouth disease virus, CA9, EV9), and Reoviridae (Reovirus) (218). Recently, a study confirmed 
that integrin αvβ3 was a primary receptor for virulent Foot-and-mouth disease virus type O1 (164). 
Numerous publications noted that various microbial pathogens exploited integrin αvβ3 
to invade host cells (218). For example, in 1994, Cuzange and co-workers demonstrated that 
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integrin αvβ3 is a receptor for Adenovirus. This virus has an RGD motif present in one of the 
capsid proteins (50) is involved in the internalization of the virus into M21 melanoma cells and 
human Hela cervical cancer cells via interaction with integrin αvβ3 (96, 178, 259). Moreover, 
human cytomegalovirus (HCMV), which is a β-herpesvirus causing congenital disabilities in new-
born and severe immunocompromised diseases, contains an envelope glycoprotein B (gB) and gH 
for efficient cell signalling, fusion, and infection (252). The gB consisted of the RX6-8DLXXF 
consensus sequence of metalloprotease-15, 23 (ADAM), which targeted integrin αvβ3 (218, 252) 
as a coreceptor with epidermal growth factor receptor (EGFR) (252). The integrin αvβ3 is trans-
located to lipid rafts and plays a role in EGFR signalling (252). The ADAM has a sequence similar 
to the reprolysin family of snake venomases, sharing the metalloproteinase domain with matrix 
metalloproteinases, involving integrin αvβ3 activity in cancer (156). Moreover, Van Der Flier con-
firmed before that integrin αvβ3 could play a role in cell-cell adhesion through its interaction with 
CD31 or with a disintegrin and metalloprotease (ADAM) 15 or with ADAM-23 (243). Parry and 
colleagues also reported that gH ectadomain, a virion envelope glycoprotein of Herpes simplex 
virus type 1 (HSV1), had essential RGD motif for virus entry via integrin αvβ3 in an experiment 
on monkey kidney epithelium Vero cell line and Chinese hamster ovary (CHO) cell line (174). 
Hantaviruses cause diseases such as hemorrhagic fever with renal syndrome (HFRS) and 
hantavirus pulmonary syndrome (HPS) (75) characterized by disrupting the functions of endothe-
lium and platelet, rendering clotting defects and acute pulmonary edema (218). In 1998, Gav-
rilovskaya and co-workers noted that integrin αvβ3 allowed the entry of hantavirus, particularly 
New York 1 (NY-1) and Sin Nombre virus (SNV) via RGD interactions, into the monkey kidney 
epithelium Vero E6 and CHO cells (77). The hantavirus invasion was partially or entirely pre-
vented by fibronectin (Prospect Hill virus, PHV), vitronectin (SNV and NY-1), or MAB1976 
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antibody to integrin αvβ3 (SNV and NY-1) (77). Later on, it was also shown antibodies against 
integrin αvβ3, or vitronectin prevented the infection of human umbilical vein endothelial cells and 
Vero E6 cells from HFRS-causing hantaviruses Hantaan, Seoul, and Puumala, but did not affect 
the nonpathogenic Hantaviruses (75). Interestingly, the surface glycoprotein of these hantaviruses 
did not have an RGD sequence, and RGD treatment did not inhibit the virus entry (75). These 
findings added information that the complex hantaviruses-integrin αvβ3 interaction may be at a 
specific region of integrin αvβ3, and that interaction was likely blocked sterically by vitronectin 
(75) or that another molecule may be acting as a bridge between the integrin and the viruses. Sim-
ilarly, the antibodies to both integrin αv and β3 or vitronectin but not RGD peptide prevented  
Rotavirus infection of  CHO cell line and monkey kidney epithelium MA-104 cell line (88, 177). 
Moreover, integrin αvβ3 expression was increased in African green monkey Vero E6 cells and 
porcine intestinal epithelial cells (IECs) infected porcine epidemic diarrhea virus (PEDV) (138). 
Replication of PEDV on Vero E6 cells was reduced by RGD peptide, polyclonal antibodies anti-
integrin αv, and polyclonal antibodies anti-integrin β3 treatments via its interaction with integrin 
αvβ3 (138). 
Some bacteria, such as Staphylococcus aureus, or their components, appear to utilize 
integrin αvβ3 on the epithelial surface as its receptor (58, 123, 149, 164). Cilengitide that inhibited 
integrin αvβ3 on human endothelial cell line reduced the attachment of E. coli and Staphylococcus 
to the cell (73, 149), potentially decreased the effect of these bacteria in early sepsis (73). Moreo-
ver, Kim and colleagues reported that Shigella flexneri effector OspE and Salmonella could inter-
act with integrin-linked kinase to reinforce host cell adherence to maintain infection in a guinea 
pig model, thus implying that the bacteria may use integrin αvβ3 to colonize gut epithelium (123). 
Also, invasins such as AfaD and AfaDE tip complex, purified from bacterial fimbriae, 
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communicated with the mammalian host cells through integrin αvβ3 receptor (52). More than three 
decades ago, Charbit and colleagues described the role of RGD residues in the bacteriophage 
Lambda receptor of E. coli in the attachment to mammalian cells (36, 184). These phage receptor 
areas are in Lam B protein in the integral outer membrane of E. coli K12 suggesting a role in 
binding to integrins αvβ3 receptor (36, 184). It has been reported that RGD peptide could prevent 
Treponema pallidum attachment to human epithelial Hep-2 cells and human tumour HT1080 cells 
(236). 
Moreover, integrin αvβ3 could be a receptor for fungi. For example, in 1990, a group of 
researchers reported that RGD peptide, a fibronectin-binding sequence, down-regulated fungus 
Pneumocystis carinii attachment to rat alveolar macrophages in vitro (182). The RGD sequence of 
Discoidin-I synthesized by Dictyostelium discoideum also plays a role in cell-cell cohesion pro-
cess, fruiting body forming, and aggregation of the amoeba (181, 184, 217).  
Taken together, the data show that integrin αvβ3 has multiple roles that regulate cell 
division and proliferation through its ability to generate and regulate signals that alter cell shape, 
migration, and adhesion (Figure 2.1). The integrin is also established as a receptor for various 





Figure 2.1. Integrin αvβ3 functions 
Integrin αvβ3 functions in normal cells (left side) and pathogenesis of diseases (right side). Integ-
rin αvβ3 binds to appropriate ligands by its extracellular domains, and adaptor proteins by its 




2.5. HELICAL ROSETTE NANOTUBES (HRNs or RNTs) 
Nanotechnology has been a rapidly growing multidisciplinary field dealing with the cre-
ation and investigation of functional materials and nano-devices by manipulating matter in the 
nanoscale range at approximately 1–100 nm for more than two decades (48, 132). The application 
of nanotechnology in drug development and delivery, such as protection from degradation, has 
been studied (132). Nanomaterials such as gold nanoparticles, carbon nanotubes, and magnetic 
nanoparticles have a large number of potential applications (131, 250). However, the use of these 
carbon and metallic nanoparticles is challenging due to their poor solubility, distribution, and cy-
totoxicity, causing biological impacts on the environment, and health such as cellular proliferation 
and differentiation (131, 224, 250). 
The helical rosette nanotubes (HRNs)  were invented by Dr. Hicham Fenniri in 2001 (39, 
63, 64), and these are one of the highly novel nanomaterials known till now. The structure of the 
twin rosette shape of these nanotubes is more stable than single base rosette nanotubes under phys-
iological conditions (63, 64, 223). HRNs are a novel class of metal-free, organic, water-soluble, 
tunable, biologically-inspired, and biocompatible nanomaterials (63, 64, 223). These nanotubes 
are synthesized from guanine-cytosine (G˄C) motif building blocks through a rapid hierarchical 
self-assembly process in water maintained by 18 hydrogen (H) bonds, which then organize to form 
a nanotube with a central channel of 1.1 nm. G˄C motifs self-organize into hexameric macrocycles 
in rosette shape to form biocompatible architectures of rosette nanotubes due to spatial arrange-
ment of the asymmetric hydrogen-bond network in aqueous solution (64). The formed tubes are 
noncovalent yet kinetically stable and maintained by electrostatic, hydrophobic, and stacking in-
teractions (63, 64). 
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Scientists have found numerous potential applications of HRNs, notably in the medical 
areas (39, 134, 224, 268-270). One of the excellent properties of the rosette nanotube is the ability 
to tag a variety of functional groups at the G˄C site on the surface of the tube to impart functional 
versatility for specific nanomedical or biological applications. Based on the speed and specificity 
of binding, the RNT can be functionalized by tagging peptides to interact with cell receptors and 
cell adhesion molecules, such as integrins (223). The advantages of HRNs in biocompatibility, 
water solubility, and tunability compared to other nano-materials make them more attractive for 
biomedical use (39, 63). There, however, is need to fully understand their safety for use in humans 
and animals (39, 134, 224, 268-270). Dr. Singh’s laboratory has reported that the RNTs-1G(0) did 
not have significant adverse effects on the respiratory system in vivo, indicating their biocompati-
bility with mammalian system  (112). This group has also studied the biology of lysine-function-
alized helical rosette nanotubes (RNT-K), containing lysine at the G˄C motif. The RNT-K is about 
3 nm in diameter and 50 nm to a few microns in length. The effects of this tube on macrophages 
were dependent on their size with smaller tubes have more inflammatory potential than the longer 
tubes. However, RNT-K overall did not induce any appreciable inflammatory response and cell 
death in macrophage cell lines (109, 111). RNT-K neither affected viability or induced inflamma-
tory response in pulmonary epithelial cells (110). These tubes; however, induced the production 
of proinflammatory cytokines (IL-8, TNF-α) in human U937 macrophage cells without affecting 
their viability  (111). Collectively, these data suggested that RNT-K could be used for biomedical 
applications (112). 
The established roles of integrin αvβ3 as cell signalling and adhesion have resulted in 
major interest in the biomedical applications of RGD peptides. There, however, are challenges in 
cell and tissue-specific targeting of RGD compounds. Despite major advances in deciphering the 
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molecular structures of pathogens and the identification of their receptors, we still need more pre-
cise and better-targeting molecules to reduce the side-effects of drugs. HRNs, through their inher-
ent ability to accept and display molecules, create new possibilities for precise targeting of drugs. 
(221). The Singh laboratory further investigated the potential of RNTs formed by K-RNT co-as-
sembled with Arg-Gly-Asp-Ser-Lys-functionalized RNTs (RGDSK-RNTs) as drug delivery vehi-
cles. The generated RNTs featuring RGDSK peptide and one K amino acid on their surface in 
predefined molar ratios are named Kx/RGDSKy-RNT, where x and y refer to the molar ratios of 
K-G∧C and RGDSK-G∧C, respectively. These hybrid K/RGDSK-RNTs were of course designed 
to target integrins. It was reported that K10/RGDSK1-HRNs induced cell death genes, p38 mitogen-
activated protein kinase (MAPK) phosphorylation, caspase-3 activity, and DNA fragmentation in 
human bronchial epithelial adenocarcinoma cells (226). These data showed that K10/RGDSK1- 
RNT could induce inflammation and apoptosis in tumour cells and thus showing their potential for 
use in cancer (226). The K/RGDSK-RNTs also reduced the migration of bovine neutrophils 
through inhibiting the phosphorylation of ERK1/2 and p38 MAPK (134). These data collectively 
showed the cell signals activated by K10/RGDSK1-HRNs in inducing death in cancer cells and 
modulating the chemotaxis in neutrophils. 
In 2011, Suri and colleagues provided the first evidence contrary to expectations that 
intravenous administration of K⁹⁰/RGDSK¹⁰-RNT aggravates the proinflammatory effect of an 
acute lipopolysaccharide (LPS) - induced lung inflammation in a mouse model (225). LPS and 
K⁹⁰/RGDSK¹⁰-RNT treatment groups notably showed increased infiltration of neutrophils in bron-
choalveolar lavage fluid compared with the saline control (225). Compared with LPS alone, the 
combination of LPS and K⁹⁰/RGDSK¹⁰-RNT significantly increased in the expression of interleu-
kin-1β, MCP-1, MIP-1, and KC-1 in the bronchoalveolar lavage fluid, and myeloperoxidase 
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activity in the lung tissues. These researchers concluded that K⁹⁰/RGDSK¹⁰-RNT, in conjunction 
with LPS, promoted acute lung inflammation, leading to an exaggerated immune response in the 
lung via up-regulating P38 MAPK cascade (225). This underscores the need for further work in 
understanding the biology of these novel compounds. 
Novel HRNs with unique physiochemical properties are posing challenges to understand 
the full spectrum of interactions at the nano-bio interface, particularly in the bone. In 2008, Zhang 
and colleagues applied K-HRNs to enhance the osteoblast adhesion for bone healing in vitro (269). 
However, they did not mention the effect of K-HRNs on the osteoclast, a different subtype of 
macrophages (269). The data also showed that composites of HRNs- nanocrystalline hydroxyap-
atite could be a possible material for bone tissue engineering applications due to HRNs ability to 
mimic the helical nanostructure of collagen in bone (270). RGDSK-conjugated nanotubes could 
enhance osteoblast adhesion and proliferation due to an increase of fibronectin by RGDSK surface 
chemistry and a favorable cell environment from nanoscale biomimetic features of nanotubes 
(268). In 2013, Childs and colleagues found that TB-RGDSK:TBL (RGDSK-HRNs) promoted the 
chondrogenic adhesion and differentiation of bone marrow mesenchymal stem cell from human 
(hMSC) on poly(l-lactic acid) scaffolds, implying a potential therapeutics for cartilage regenera-
tion (39).  
As mentioned above, RGDSK-TB is a twin G∧C – based RNTs functionalized with ar-
ginine-glycine-aspartic acid-serine-lysine (RGDSK) peptide, one of the most popular ligands that 
can bind integrin αvβ3 (196). The fluorescein isothiocyanate (FITC) conjugated twin G∧C – based 
RNTs is another valuable functional group to observe HRNs. The mixture of these two materials 
forms stable RGDSK-HRNs-FITC in which RGDSK functionalized group is displayed on its sur-
face to target integrin αvβ3. Furthermore, the RGDSK-HRNs-FITC can be visualized with a 
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fluorescent microscope (Figure 2.2) (39, 225). The RGDSK-HRNs-FITC exploited the integrin 
αvβ3 to enter the endosomes of dendritic cells (99). House and colleagues performed an isolated 
perfused lung model in male Sprague-Dawley rats with RGDSK-HRNs-FITC intravascular ad-
ministration to report minimal cell activation measured through the elaboration of adhesion mole-
cules and ROS production (99). Further works are required to elucidate the mechanisms of action 





Figure 2.2. Schematic of RGDSK-HRNs-FITC 
(A) RGDSK-TB modules forming RGDSK-HRNs, (B) FITC-TB modules forming FITC-HRNs, (C) 
the mixture of RGDSK-TB and FITC-TB modules forming RGDSK-HRNs-FITC. (used with per-
mission of Dr. Hicham Fenniri) 
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2.6. BACTERIAL INTERACTION WITH THE HOST 
Attachment to the specific host cell receptor is the first step of bacterial pathogen infec-
tion (32, 124). Up to date, many scientists have revealed names of cellular membrane proteins 
could bind and mediate the adherence of bacteria (130). In 2006, Simpson and co-workers also 
confirmed that bacterial – epithelial cross-talk was recognized as a fundamental feature for the 
colonization of bacteria in host tissues (209). Studies have been identifying the molecular adhesion 
receptors driving the intracellular bacteria entering non-phagocytic cells. For example, a group of 
scientists pointed out that the immobilized invasin of Yersinia pseudotuberculosis enteric bacte-
rium targeted integrins α3β1, α4β1, α5β1, and α6β1 receptors (104).  
Moreover, scientists reported that bacteria could bind to the extracellular matrix and pro-
teins containing RGD peptide (32, 257). The extracellular matrices, comprising of collagens, gly-
cosylated protein laminin, and fibronectin (a proteoglycan containing protein-bound glycosamino-
glycan chains), are present under the epithelium, endothelium, and around connective tissue (130, 
150, 257). These materials regularly interact with host cells and play a role in the metabolism and 
differentiation of cells (148). Therefore, by using these materials, bacteria can either directly or 
indirectly affect the biology of the host. For example, scientists revealed that mycobacterial iso-
lates could interact with soluble fibronectin (189). Another example is that cell surface proteins of 
Staphylococcus aureus and Streptococci could bind to both fibronectin and collagens (24, 128). 
Of course, the extracellular matrix components, such as fibronectin, bind to integrins such as in-
tegrin αvβ3, which creates a potential of applications of RGD-conjugated HRNs. 
Enterobacteria with their fimbriae also could bind to extracellular matrix proteins (168, 
215, 257, 258). In detail, in 1993, Collinson and colleagues reported that aggregative fimbriae SEF 
17 of enteropathogenic Salmonella bound human fibronectin (45). Other examples in the past are 
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that some strains of E. coli under different condition could bind and activate plasminogen via its 
G fimbria (127), or adhered to fibronectin via its lectin-like component type 1 fimbriated CSH-50 
(215), or immobilized fibronectin via its P fimbriae (258), or fibronectin and laminin via its curli 
(168). 
2.7. E. COLI 
E. coli is frequently found in the environment, food, and intestine of animals and humans 
(31, 233). These bacteria have been globally studied for many decades due to their unstable char-
acteristics and multiple virulence factors (247). The non-pathogenic E. coli is harmless and con-
trollable (233). Other pathogenic E. coli can infect many organs, such as the intestinal, urinary, 
and respiratory systems (115). 
Pathogenic E. coli strains are categorized according to their elements, eliciting the host’s 
immune response, as follows: 174 O antigens in the lipopolysaccharide layer, K antigen in the 
capsule, 53 H antigens in the flagellin, and F antigen in the fimbriae (31, 47). Two types of path-
ogenic E. coli are enteric pathogenic E. coli (also named diarrheagenic E. coli), and extraintestinal 
pathogenic E. coli (ExPEC) such as subgroup uropathogenic E. coli (UPEC), infecting urinary (31, 
47). Enteric pathogenic E. coli includes enteropathogenic E. coli (EPEC), Shiga toxin-producing 
E. coli (STEC edema disease), Verocytoxin-producing E. coli (VTEC) such as enterohemorrhagic 
E. coli O157:H7 (EHEC), enteroaggregative E. coli (EAEC), enterotoxigenic E. coli (ETEC), dif-
fusely adherent E. coli (DAEC), adherent invasive E. coli (AIEC), enteroinvasive E. coli (EIEC) 
(31, 47). 
Adhesive factors and toxins are two virulent factors taking part in the diseases. For ex-
ample, VTEC has E. coli attaching and effacing (eae) gene, which was found in many isolates 
from severe diarrheal cases in cattle and humans (143). The eae gene in enterohemorrhagic E. coli 
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promotes its attachment to and desquamation of colonic epithelial cells with consequent recruit-
ment of inflammatory cells and edema formation (56). Another example is that E. coli O101 strain 
possesses a Shiga-like toxin, causing hemorrhagic colitis and hemolytic-uremic syndrome in hu-
mans (66). E. coli O101 infected pigs could be a reservoir transmitting the bacteria to humans (30, 
66). 
The adhesive properties of E. coli are complex to understand. The majority of the strains 
of commensal and pathogenic E. coli possess type 1 fimbriae (70). When one adhesive receptor is 
inhibited, other specific adhesive receptors could be activated and compensated for each other (F4, 
F41, F1, …) (70). In 1982, Gaastra and colleagues illustrated that the typical composition of ad-
hesion subunits of E. coli F4 (K88) had arginine (R), glycine (G), aspartic acid (D), serine (S), and 
lysine (K) (70). The amino acid sequences of fimbriae for the adhesive function are varied and 
unclear, depending on the strains of E. coli, phase variation, evolution, and environmental condi-
tions such as temperature and growth media (70).  
Among E. coli related diseases, E. coli infection outbreak associating with food poison-
ing, and persistent diarrhea with a high mortality rate has occurred in both developing countries 
and developed countries (20, 34, 35, 60, 185). Enterotoxigenic E.coli (ETEC) is the most common 
bacteria causing diarrhea in animals (31)and humans (240). ETEC can penetrate the mucus layer, 
then use flagella, fimbria, or F4 (K88) to bind directly to the luminal surface of enterocytes to 
colonize in the small intestine (240) (Figure 2.3). 
F4 positive (F4+) E. coli, also named E. coli K88, was firstly reported in Ireland and 
Germany (70, 197). E. coli F4 is associated with both pre-weaning and post-weaning diarrhea in 
pigs (61, 222). Diarrhea occurs after one to five days of E. coli infection when the E. coli popula-
tion is more than 109 in pigs (222). Post-weaning diarrhea by E. coli is characterized by watery 
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feces and decreased performance, causing an economic loss for the swine industry. E. coli F4 
colonizes in the small intestine and release enterotoxins such as heat-stable toxin (ST) and heat-
labile toxin (LT) to stimulate epithelial cells to secrete fluid into the lumen of the gut through the 
cystic fibrosis transmembrane conductance regulator (CFTR), causing enteritis (31, 61, 70). It was 
reported that E. coli F4ab and E. coli F4ac could agglutinate erythrocytes of guinea pigs, but F4ac 
antigen could not agglutinate chicken erythrocytes (70). 
In 1982, Gaastra and co-authors described F4 antigen as thin, flexible threads, having a 
fimbria-like structure with 2.1 nm diameter and covered with filamentous appearance material 
(70). These researchers noted that the F4 fimbrial adhesion was maintained via hydrophobic or 
electrostatic interactions between adjacent subunits in F4 fimbriae but not the disulfides bridges 
(70). Although fimbriae have been found to play an essential role in the attachment of E. coli F4, 
the receptor for F4 antigen adhesion, the interaction of F4 with other receptors, and the detailed 
mechanism of adhesion is not yet fully understood (70). 
In 1999, Francis and co-authors reported that receptors in brush borders of host cells for 
F4 fimbriae on E. coli are an intestinal mucin-type sialoglycoprotein (IMTGP), intestinal transfer-
rin (GP74), and an intestinal neutral glycosphingolipid (IGLad) (65). It is explained that variable 
glycolipids and glycoprotein receptors with varied sizes in the intestinal mucus and brush border 
membranes are due to E. coli F4 variants, swine breeds, and different sites of attachment in the 
small intestine. Moreover, Jin and colleagues reviewed in 2000 that receptors in brush border were 
age-independent (106). 
In addition to enterotoxins, ETEC has other factors including O serogroup on lipopoly-
saccharide, H serogroup on flagella, colonization factor antigens (CFAs), and other adhesive fac-
tors on fimbria of ETEC surface (261). CFAs play an essential role in allowing ETEC to adhere to 
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epithelial cells of the small intestine, and also serve as virulence factors (261). In 2006, Simpson 
and colleagues described that the adhesive forces were strong enough to resist the flushing action 
of the gut peristalsis (209). These scientists also mentioned that these interactions contribute to the 





Figure 2.3. Enterotoxigenic E. coli infection 
In general, the intestinal mucosa is lined by a single layer of epithelium, allowing the absorption 
of nutrients. This layer also forms the frontline barrier against the entry of pathogens into the host 
systems. The initial adhesion of the microbes with the gut epithelium is the first stage in the path-
ogenesis of gut diseases. The adherent bacteria and their enterotoxins such as a heat-labile toxin 
(LT), and a heat-stable toxin (ST), leads to electrolyte and fluid efflux through the cystic fibrosis 
transmembrane conductance regulator (CFTR). This reaction causes water and electrolyte loss 




However, till now, most interventions cannot completely control intestinal diseases and 
foodborne illness worldwide due to E. coli infection (37, 40, 119, 139, 158, 206, 208, 209, 234, 
263, 273). Therefore, many studies on this public health concern have been ongoing to decipher 
better knowledge at the molecular and cellular levels. For example, a few years ago, Garas and co-
workers reported that milk from human lysozyme transgenic goats could protect piglets from 
ETEC infection in term of less severe diarrhea, fewer bacteria translocated into the mesenteric 
lymph nodes, lower mucin 1, and higher tumour necrosis factor – α (72). Moreover, many scien-
tists recommended that obstructing the receptor adhesion sites to inhibit the primal step of E. coli 
attachment to the intestine, particularly epithelium, can lead to the development of novel interven-
tions to modify this enterotoxigenic pathogen-induced diarrhea (106). 
There was no data to demonstrate that prokaryotes expressed integrins (203). Therefore, 
E. coli was used for many specific protein productions. For example, in some studies, E. coli 
MG1655 and E. coli EC410 were transformed with vectors to produce RGD containing peptide 
and recombinant integrin αvβ3, respectively (203, 228). However, recently, scientists reported that 
integrins were involved in activities of E. coli. For example, in 2003, in an in vitro experiment on 
HeLa cell line, Laarmann and co-workers suggested that integrin αv (CD51) was the potential 
receptor of adhesin involved in diffuse adherence-I (AIDA-I) protein of E. coli K12 (130). These 
researchers discussed that integrin αv and AIDA-I interaction could mediate the attachment of E. 
coli to mammalian cells (130). Another example is the study of De Greve and co-workers in 2007 
(46, 52). Their laboratory revealed that Invasins, such as AfaD and AfaDE tip complex, were found 
on pathogenic E. coli strains, causing chronic diarrhoeal and urinary tract infections such as cystitis 
and pyelonephritis (46, 52). These Invasins could communicate with the mammalian host cells 
through integrins αvβ3 and α5β1 receptor (46, 52). Moreover, Hemolysin (HlyA) toxin from 
40 
 
uropathogenic E. coli was mediated by β2 integrins in U-937 human monocytic cell line, demon-
strating the involvement of β2 integrins in the sensitivity of the cell to toxins from E. coli (191).  
Till now; however, there are no data on the expression and role of integrin αvβ3 on E. 
coli bacteria. This integrin may play a role in the attachment of E. coli to gut epithelium as one of 
the first steps towards colonization. Considering that the gut epithelia in pig and calf express the 
integrin αvβ3, it is crucial to examine the expression of this integrin on E. coli and to understand 
its role in E. coli adhesion to gut epithelium.  
2.8. GUT LOOP MODEL 
One of the major health issues in animals and humans globally is intestinal diseases. The 
intestine interacts with the environment through the handling of the food traveling through it (2, 
237). Therefore, the mucosal immune system of the intestine is critical since this organ is exposed 
to many pathogens. The intestine is protected by many factors, including the intestinal microbiota, 
mucus layer, surface epithelium, and immune cells (165, 176). The complex activities and inter-
action of these factors influence the dynamic ecosystem, condition, and functions of the intestine 
in defending pathogens (165). For example, the intestinal microbiota, known as commensal mi-
croorganisms, resides in numerous pits to protect the host substances from the colonization of 
external pathogenic organisms (2, 165, 237). Besides that, the unique and heterogeneous epithelial 
lining of the intestine is the first barrier that has a well-developed system to manage the bacterial 
populations in the gut (2, 237). Moreover, pathogens are recognized by intestinal epithelial cells 
and immune cells via pattern-recognition receptors such as Toll-like receptors (TLRs) and intra-
cellular Nod-like receptors. Among TLRs, TLR4 has important functions on the trigger of the 
inflammatory response and being able to sense bacteria (246). TLR4 likely transduces lipopoly-
saccharide (LPS) signal across the plasma membrane (180). 
41 
 
The usage of animal models is applicable for scientific research and cannot be replaced 
by any alternative methods to study the intestinal mucosal immune system, pathogenesis, and new 
interventions for intestinal infectious diseases (6, 195). Appropriate animal models provide possi-
bilities for further clinical studies in humans (117). It is generally understood that discoveries of 
new therapeutics made in rodent models usually fail to translate to other species, including domes-
tic animals and humans. Therefore, the availability of physiologically relevant animal models is 
critical to investigate biological phenomena to advance our knowledge and develop better drugs 
and vaccines (117). 
Among animal models, large animals have been used for many years for preclinical re-
search because outcomes from these animals are close to and can be predicted in clinical studies 
on humans. For example, pigs, dogs, lambs, bovines, and horses are the superior resources for 
efficiently studying nutrition, biomedicine, microbiology, immunopathology, or particularly host-
pathogen interaction (6, 7, 117, 165, 195). Besides non-human primates, pigs have recently been 
used in many in vivo preclinical models because of their similarities with humans regarding their 
biological development (117, 195). Pigs have a similar immune system and pathogen susceptibility 
when compared to human (154). Another reason is that pigs likely have similar genetic homology, 
physiology, and anatomy as humans (79, 154, 165, 195). Besides that, other advantages are the 
availability of pigs, and the ready immunological toolbox of the pig for feasible experimental de-
sign (116). 
Dr. Volker Gerdts and his colleagues have developed a gut loop model to study the in-
teraction of pathogens and epithelium, as well as other immune cells in pigs, sheep, and lambs (51, 
78, 153) (Figure 2.4). This superior model can analyze mucosal immune responses and the effect 
of multiple treatments to identical, independent segments of the intestine in the same animal, 
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reducing the variability associated with large outbred animals, and eliminating genetic variability 
(78). Because of animal ethics and the effort of minimizing the number of animals used for exper-
iments, the gut loop model is suitable for many research aims. For example, in 2002, Dr. Mutwiri 
and co-workers applied the gut loop model in lambs to test three different porcine serum albumin 
encapsulated in alginate microspheres (163). Each loop provided independent but identical sites 
for testing the mucosal immune responses (163). They found that these porcine serum albumins 
enhanced antibody-secreting cells in humoral immune responses but not T-cell responses (163). 
Another example is that in 2009, Meurens and co-workers applied the gut loop model in pigs to 
study the host’s response to Salmonella Typhimurium infection (153). In that study, the Salmo-
nella treated loops displayed the specific response of the host intestine to Salmonella infection 
compared with normal control loops (153). The Salmonella-infected group had a higher level of 
inflammatory cytokine mRNA (IL6, IL8/CXCL8, and TNFα), as well as T-helper type 1 cytokine 
mRNA (IL12p53, IL12p40, IL27p28, and IFN gamma) than normal control group (153). Moreo-
ver, in 2011, Vandenbroucke and co-workers applied the loop model in porcine ileum to study the 
interaction between mycotoxin deoxynivalenol and Salmonella Typhimurium (244). They found 
that deoxynivalenol induced the susceptibility of the intestinal epithelium to Salmonella Typhi-
murium infection (244). 
Taken together, the gut loop model has been widely applied in many projects because the 





Figure 2.4. Schematic diagram of the porcine gut loop model 
Schematic representation of surgically created sections for the experiment, which were named 
loops. The rest of the sections between loops were named interspaces. The intestine was seg-
mented, and two ends of each segment were tightened. The continuity of the intestinal system was 
re-established by end-to-end anastomosis. These loops were independent, identical with the same 
length, and condition for analyzing mucosal immune responses in vivo. Then the intestine was 




CHAPTER 3.  OBJECTIVES AND HYPOTHESES 
3.1. Objectives and rationales 
RGD peptides bind to integrin αvβ3 expressed on various cells, including intestinal 
epithelial cells (39). We have been exploring the functions of novel helical rosette nanotubes 
(HRNs) in inflammation. Recently, we have developed HRNs that are conjugated to RGDSK 
peptides that bind to integrin αvβ3. Building on these studies, I propose to investigate the interac-
tions of RGDSK-HRNs with integrin αvβ3 in the context of interactions of E. coli with the intes-
tinal epithelium, specifically the binding of E. coli to the jejunal epithelium.  This study aims to 
contribute fundamental knowledge to the biology of RGDSK-HRNs and their applications in ther-
apeutics of infectious diseases. 
1. Determine the expression of integrin αvβ3 in the intestinal porcine epithelial cell line 1 
(IPEC1) and E. coli upon infection. 
2. Investigate the functions of RGDSK-HRNs in blocking the attachment of E. coli to IPEC1 
in vitro and porcine villi ex vivo. 
3. Explore the effect of RGDSK-HRNs exposure on apoptosis and survival of IPEC1 upon 
E. coli infection. 
4. Investigate the effects of RGDSK-HRNs on E. coli infection in a porcine gut loop model. 
3.2. Hypotheses 
1. Integrin αvβ3 is expressed in IPEC1, and its expression will change upon E. coli infection. 
2. RGDSK-HRNs will bind to integrin αvβ3 expressed in IPEC1 and block the attachment of 
E. coli to IPEC1. 
3. RGDSK-HRNs enhance the apoptosis of intestinal epithelium upon E. coli infection. 
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CHAPTER 4.  INTEGRIN αvβ3 EXPRESSION IN THE INTESTINAL PORCINE EPI-
THELIAL 1 CELL LINE (IPEC1) UPON E. COLI INFECTION IN VITRO  
We performed immunohistochemistry to confirm the expression of integrin αvβ3 in the 
normal porcine gastrointestinal tract, as reported previously in Dr. Singh’s lab (213). We found 
that integrin αvβ3 was expressed in the epithelium (Figure 9.1 in supplemental results). However, 
up to date, there are no data on the role of integrin αvβ3 in the intestinal epithelium, especially in 
E. coli infection. Therefore, we used intestinal porcine epithelial cell line 1 (IPEC1) and E. coli F4 
to find the gap information. This chapter focused on determining the expression of integrin αvβ3 
in IPEC1 and E. coli F4 upon infection in vitro.  
4.1. ABSTRACT 
Integrin αvβ3 is expressed in endothelium, epithelium, and various immune cells such as 
neutrophils, macrophages, and platelets. It binds to bacteria, viruses, and acute-phase proteins such 
as vitronectin. However, there are no data on the expression of integrin αvβ3 in E. coli, and its role 
in adhesion to the intestinal epithelium that expresses integrin αvβ3. Therefore, we used porcine 
intestinal epithelial cell line 1 (IPEC1) and E. coli F4 to explore the hitherto unknown expression 
of integrin αvβ3 in vitro with fluorescent and electron immunocytochemistry, immunoprecipita-
tion, and western blots.  
Integrin αvβ3 was localized on the plasma membrane, the cytoplasm, and the nucleus of 
IPEC1 cells. The expression of integrin αvβ3 in IPEC1 decreased at 15 minutes but returned to 
normal after 90 minutes of infection with E. coli F4 (P<0.05). Immuno-gold quantification showed 
changes in the subcellular expression of integrin αvβ3 in IPEC1. The light, fluorescent and electron 
microscopy, and western blots showed the novel expression of integrin αvβ3 in E. coli F4. The 
presence of this protein was confirmed by a 96-well plate binding assay, and preliminary mass 
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spectrometry analysis. In conclusion, these are the first data to show the expression of integrin 
αvβ3 on intestinal epithelium infected with E. coli. These results suggest that this protein may play 
a role in E. coli infection. 
Key Words: integrin αvβ3, intestinal epithelium, E. coli 
4.2. INTRODUCTION 
Enterotoxigenic Escherichia coli (ETEC) is one of the common causes of diarrheal dis-
eases worldwide in humans and animals (4, 20). ETEC infection has a high economic impact on 
swine production, poses a threat to pork food products, and is an important public health concern 
(204, 238, 249, 261). For example, E. coli F4 causes neonatal and post-weaning diarrhea in pigs 
(69). However, treatment for enteric diseases is challenging because of the emergence of antibiotic 
resistance, the side effects of prolonged medication, and multiple virulence factors in enterotoxins 
(60, 186, 271). Because of the ongoing morbidity, mortality, and economic losses, there is a press-
ing need to develop better protocols to manage the impact of enteric infections in humans and 
animals. 
The mechanisms of the induction of diarrhea by enteric pathogens are not fully under-
stood. In general, the intestinal mucosa is lined by a single layer of epithelium, allowing the ab-
sorption of nutrients and sampling of the antigens. This barrier forms the frontline offense against 
the entry of pathogens into the host systems; for example, it prevents many normally-resident bac-
teria such as Clostridium perfringens and E. coli from entering the gut. The epithelia are activated 
by both bacterial adherence and through interaction with bacterial molecules such as toxins. There-
fore, the initial adhesion of the microbes to the gut epithelia is the first stage in the pathogenesis 
of the gut disease (136, 157). 
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Recent studies have been identifying the molecular adhesion receptor driving the entry 
of bacteria into non-phagocytic cells (104, 164). Integrin α3β1, α4β1, α5β1, and α6β1 can bind the 
immobilized invasin of Yersinia pseudotuberculosis enteric bacterium (104). β2 integrins in U-
937 human monocytic cell line mediated hemolysin (HlyA) toxins from uropathogenic E. coli, 
demonstrating the involvement of β2 integrins in the sensitivity of the cell to toxins from E. coli 
(191).  
Integrin αvβ3 expressed on epithelial cell surfaces is known to act as a receptor for some 
bacteria and viruses (123, 164), including adenoviruses (50). In 2008, Tchesnokova and colleagues 
reported that E. coli K12 had an integrin-like allosteric site on FimH, an adhesive subunit of type 
1 fimbriae of E. coli (232). However, there are no data on the expression of integrin αvβ3 on E. 
coli and its role in the attachment of E. coli to the intestinal epithelium. Therefore, in this paper, 
we explored the hitherto unknown expression of integrin αvβ3 on E. coli and the intestinal porcine 
epithelial 1 cell line (IPEC1). The results support our hypothesis that E. coli F4 has integrin αvβ3-
like protein. Also, integrin αvβ3 is expressed on IPEC1, and its expression on IPEC1 decreased 
upon E. coli F4 infection. 
4.3. MATERIALS AND METHODS 
4.3.1. Materials 
pFPV꞉꞉tdTomato plasmid was a generous gift from the laboratory of Professor Douglas 
Call, Washington State University, USA. E. coli DH5α was obtained from Professor Janet Hill’s 
laboratory at the University of Saskatchewan, Canada. 
E. coli F4 strain EC52, serotype O101:K30+:K99- and IPEC1 were gifts from Dr. Fran-
cois Meurens and Dr. Heather L. Wilson at Vaccine and Infectious Disease Organization - 
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International Vaccine Centre (VIDO-InterVac). IPEC1 cells were developed from the jejunum of 
unsuckled, mixed-bred piglets less than 12 hours old (85). IPEC1 cells were cultured in 75 cm2 
flask in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 at 37oC in a humidified 5% 
CO2 incubator (84, 126). 
Mouse MAB1976 monoclonal integrin αvβ3 antibody (clone LM609, Chemicon Inc., 
Temecula, USA), rabbit polyclonal antibody anti-integrin beta 3 (EMD Millipore, Temecula, 
USA), Rabbit anti-human integrin αv polyclonal antibody (EMD Millipore, Temecula, USA), 
Alexa Fluor 633 conjugated secondary antibody polyclonal goat anti-mouse immunoglobulins 
(Thermo Fisher, Rockford, USA). RGDSK-FITC (American peptide company, Sunnyvale, CA 
94086, USA), secondary polyclonal goat anti-rabbit immunoglobulins/HRP (Dako), Bio-plex cell 
lysis kit (Bio-rad, Mississauga, ON, Canada), SureBeads™ magnetic beads immunoprecipitation 
kit (Bio-rad, Mississauga, ON, Canada), Detergent Compatible (DC) Bradford protein assay kit 
(Bio-rad, Mississauga, ON, Canada) were purchased commercially. 
4.3.2. pFPV꞉꞉tdTomato plasmid transformation to visualize E. coli under a confocal mi-
croscope 
The visualization of E. coli under the confocal microscope was based on 
pFPV꞉꞉tdTomato fluorescent protein. E. coli strain DH5α and F4 were treated with morpholinopro-
panesulfonic acid, rubidium chloride, and calcium chloride to become chemically competent cells. 
After that, pFPV꞉꞉tdTomato plasmid was transformed into competent E.coli by heat shock follow-
ing a previous standard method (198). The transformant E. coli was selected on Luria broth agar 
having ampicillin. Successful pFPV꞉꞉tdTomato plasmid transformed E. coli had red fluorescence 




4.3.3. E. coli preparation 
E. coli F4 having pFPV::tdTomato fluorescence protein was cultured for 18 hours on 
Luria broth supplemented with ampicillin. The concentration of bacteria was determined by ad-
justing the optical density at 620nm (OD620) to 1 to achieve 4x10
9 CFU/ml as determined by prior 
CFU counting. E. coli was centrifuged at 16,200 xg for 5 minutes, followed by a wash in 0.1M 
PBS supplemented with ampicillin at pH=7.4. Serial dilution was done to reach the desired con-
centration of the bacteria for the assay later, according to previously cited (126). 
4.3.4. Immuno-gold electron microscopy for integrin αvβ3 
E. coli F4 and E. coli DH5α were cultured overnight in tryptone soya broth (TSB) me-
dium. E. coli was washed three times in 0.1M PBS and resuspended in 0.1M PBS for immuno-
gold staining for integrin αvβ3. For challenging IPEC1, E. coli F4 was resuspended in DMEM/F12 
medium without serum. The experiment was performed in 1.5ml microcentrifuge tubes. For con-
trol experiments, IPEC1 (1x106/ml) were challenged with 108 E. coli F4 or DMEM/F12 medium 
only for 15 minutes. Healthy IPEC1, IPEC1 exposed to E. coli F4 for 15 minutes, E. coli F4, and 
E. coli DH5α only were fixed in 2% paraformaldehyde and 0.1% glutaraldehyde in 0.1M sodium 
cacodylate buffer for 3 hours at 4C. The samples were pelleted in 1% agarose, dehydrated, and 
infiltrated in acrylic LR white resin. Next, the samples were sectioned at 100nm thickness on nickel 
grids. The non-specific bindings were blocked by BSA 1% in Tris-buffered saline before one-hour 
incubation in the anti-integrin αvβ3 antibody (50µg/ml). The sample stained without primary an-
tibody served as a negative control. 
After three washes in Tris-buffered saline, the sections were incubated for one hour in a 
15 nm gold-conjugated anti-mouse secondary antibody (1:100). Aqueous uranyl acetate served as 
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an indicator of negative staining. Besides, we used Reynold’s lead citrate to enhance the electron-
scattering properties of biological components inside the cells. The electron micrographs were 
imaged using a transmission electron microscope (Hitachi HT7700 - XFlash 6T160, Germany) 
operated at 80KV. The gold particles positive integrin αvβ3 in the nuclei, cytoplasm, and plasma 
membrane of ten cells were objectively counted for statistical analysis. 
4.3.5. Immunoprecipitation and western blot for integrin αvβ3 
IPEC1 at 1x106 cells concentration were seeded into 25 cm2 flasks. The cells became 
confluent after overnight incubation, and these were challenged with 1ml of 108 E. coli F4 for 15, 
30, 60, 90 minutes. The supernatant from the experiment was collected and stored at -80ºC for 
future use. Cells were lysed and immunoprecipitated for integrin αvβ3 following manufacturer’s 
protocols (Bio-rad, Mississauga, ON, Canada). Briefly, the treatment reaction was stopped by add-
ing ice-cold wash buffer to the cells. Samples were homogenized by adding a lysing solution. The 
protein concentrations of samples were measured by using a detergent compatible Bradford protein 
assay kit (Bio-rad, Mississauga, ON, Canada). The samples were diluted to have the same protein 
concentration, and the same amount of total protein for immunoprecipitation. The general principle 
is that integrin αvβ3 protein in samples binds magnetic beads-conjugated monoclonal anti-integrin 
αvβ3 antibody, followed by their pull-down by the magnet in the rack. The elution of integrin αvβ3 
was finished in 1X Laemmli buffer boiling 70ºC in 10 minutes. The beads were magnetized, and 
the eluent was collected into a new vial. 
The western blot procedure was appropriately modified from a previous protocol (105). 
We first probed for integrin αv (n = 4 each group for IPEC1 experiment, n=3 times for E. coli 
lysates). The membranes were incubated with rabbit anti-human integrin αv polyclonal antibody 
(1:750, EMD Millipore, Temecula, USA), and secondary polyclonal goat anti-rabbit 
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immunoglobulins/HRP (1:2000, Dako). Incubation without primary antibody served as a negative 
control. The detection of proteins was accomplished by Amersham ECL western blotting detection 
reagents kit (GE Healthcare, Freiburg, Germany). Finally, the membranes were scanned using Bio-
rad ChemiDoc MP Imaging system scanner and Imagelab 5.2.1 software (Bio-rad, Mississauga, 
ON, Canada). For detecting integrin β3, the probed membrane was stripped with the blot restore 
membrane rejuvenation kit (Millipore, Billerica, MA, USA) before being re-probed with rabbit 
polyclonal antibody anti-integrin β3 (1:750, EMD Millipore, Temecula, USA) and secondary pol-
yclonal goat anti-rabbit immunoglobulins/HRP. About semi-densitometric quantification, we used 
ImageJ software to evaluate the relative density of integrin αv, integrin β3 in all groups, and com-
pared with a loading control. 
4.3.6. Immunofluorescent staining integrin αvβ3 on IPEC1 
For immunofluorescent staining, 2x105 IPEC1/well were seeded into 24-well plates with 
a cover slide at the bottom. After being confluent overnight, IPEC1 cells were washed by 1 ml per 
well of fresh DMEM/F12 without serum. Cells were then treated with 107 E. coli F4/ml resus-
pended in medium. Medium without bacteria was used for normal healthy control. Samples were 
fixed by 4% paraformaldehyde. Non-specific binding was blocked by 10% BSA. The samples 
were incubated in monoclonal integrin αvβ3 antibody (1:50, clone LM609, Chemicon Inc., Temec-
ula, USA.) then in Alexa flour 633-conjugated goat anti-mouse IgG secondary antibody (1:100). 
Cells were incubated for 5 minutes in 0.33µg/ml DAPI for staining the DNA of nuclei. We imaged 
the samples by using a confocal scanning laser microscope Leica TCS SP5 LSCM, with a 63 
objective lens under oil immersion. Negative controls for the specificity of primary, secondary 
antibody, and protocol include mouse IgG1 isotype control, the omission of primary antibody, or 
both primary antibody and Alexa flour 633-conjugated secondary antibody. 
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4.3.7. Immunocytochemistry staining integrin αvβ3 for E. coli 
E. coli F4 and E. coli DH5α were cultured overnight in tryptone soya broth (TSB) me-
dium. Both strains of E. coli were washed three times in 0.1M PBS. Then the bacteria were cyto-
spun on microscope slides and fixed in 4% paraformaldehyde. Endogenous peroxidase, and non-
specific binding to samples were blocked by 3% H2O2 in PBS and 1% BSA in PBS, respectively. 
To confirm whether these strains of E. coli had an integrin αvβ3-like protein, samples were incu-
bated with monoclonal anti-integrin αvβ3 antibody (clone LM609, Chemicon Inc., Temecula, 
USA.) and appropriate polyclonal anti-mouse immunoglobulins/HRP secondary antibody. The 
color development from HRP of secondary antibody was carried out with Vector® VIP peroxidase 
substrate kit. Samples that were stained with isotype antibody matching control (mouse IgG) in-
stead of the primary antibody or were omitted primary antibody served as negative controls. 
4.3.8. In vitro anti-integrin αvβ3 antibody binding assay 
In vitro anti-integrin αvβ3 antibody binding assay was modified from previous protocols 
(27, 149) to examine whether E. coli has an integrin αvβ3-like protein domain which can be 
blocked by RGDSK peptide. In brief, 96-well high binding plates were precoated overnight with 
50µl of 5µg/ml mouse monoclonal integrin αvβ3 antibody (clone LM609, EMD Chemicon Inc., 
Temecula, USA.) in 100 mM HCO3¯/CO3
2¯ coating buffer. Coating buffer only was used as a 
negative control. The wells were washed gently with 100µl of 0.1% sterile Tween-TBS then were 
incubated in 1% BSA to prevent non-specific binding. E. coli F4 having pFPV::tdTomato fluores-
cence protein was added at seven different concentrations (50 µl of 10x106, 5x106, 2.5x106, 
1.25x106, 0.62x106, 0.31x106, 0.15x106 CFU per well). After a one-hour incubation, unbound E. 
coli was removed by rinsing with PBS ampicillin. Binding E. coli on the bottom of the 96-well 
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plate was fixed in 2% paraformaldehyde. pFPV::tdTomato fluorescence from binding E. coli was 
measured at 530nm excitation /570nm emission in POLAR Start OPTIMA microplate fluores-
cence reader. Fluorescence intensity was adjusted with the background fluorescence of the wells 
without adding E. coli. The experiment was repeated four times. 
In vitro, anti-integrin αvβ3 antibody binding assay was again modified from previous 
protocols (27, 149) to examine whether E. coli has a protein domain similar to integrin αvβ3. In 
brief, 96-well high binding plates were precoated overnight with 50µl of 6 different concentration 
(5µg/ml, 2.5 µg/ml, 1.25 µg/ml, 0.625 µg/ml, 0.3 µg/ml, 0.15 µg/ml) of mouse monoclonal integ-
rin αvβ3 antibody (clone LM609, EMD Chemicon Inc., Temecula, USA) in 100 mM HCO3/CO3 
coating buffer. Coating buffer only was used as a negative control. The wells were washed gently 
with sterile 100µl of 0.1%Tween-TBS then were incubated in 1% BSA to prevent non-specific 
binding. E. coli F4 having pFPV::tdTomato fluorescence protein was added (50 µl of 5x106 
CFU/ml per well). After one-hour incubation, non-adhering E. coli was removed by rinsing with 
PBS ampicillin. Bound E. coli was fixed in 2% paraformaldehyde. pFPV::tdTomato fluorescence 
from bound E. coli was measured at 530nm excitation /570nm emission in POLAR Start OPTIMA 
microplate fluorescence reader. Fluorescence intensity was adjusted with background fluorescence 
from well without adding E. coli. The experiment was repeated three times. 
4.3.9. Mass spectrometry analysis 
E. coli lysis and the immunoprecipitation for integrin αvβ3 protocols were followed as 
per manufacturer’s protocols as a briefly described protocol above (Bio-rad, Mississauga, ON, 
Canada). The immune-precipitates were sent to the Canadian Centre for Health and Safety in Ag-
riculture (CCHSA) Mass Spectrometry Laboratory, the University of Saskatchewan for amino acid 
sequencing following a previous protocol (55). In brief, in-gel protein bands were digested using 
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trypsin buffer. Trypsin digestion reaction was quenched by adding trifluoroacetic acid (TFA), and 
tryptic peptides were extracted from gel samples using TFA in acetonitrile. After that, samples 
were transferred to a mass spectrometry vial for liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) analysis.  An Agilent 6550 iFunnel quadrupole time-of-flight (QTOF) mass spec-
trometer, equipped with an Agilent 1260 series liquid chromatography instrument, and an Agilent 
Chip Cube LC-MS interface analysed all mass spectrum. 
The chromatographic peptide separation was accomplished using a high-capacity Agilent 
C18 Polaris Chip. The spectral data were converted to a mass/charge data format using Agilent 
MassHunter Qualitative Analysis Software and were processed against the SwissProt Human da-
tabase (UniProt release 2017_09), using Spectrum Mill as the database search engine. Search pa-
rameters included a fragment mass error of 50 ppm, a parent mass error of 20 ppm, trypsin cleavage 
specificity, carbamidomethyl as a fixed modification of cysteine and oxidized methionine as a 
variable modification.  The spectrum Mill validation was performed at peptide and protein levels 
(1% false discovery rate).  
4.3.10. Statistical analysis 
We used the GraphPad Prism version 5.04 software (San Diego, CA, USA.) to analyse 
data. Quantitative results were expressed as mean ± SEM, and error bars represented standard 
error. The normal distribution of residuals was tested by histogram and Shapiro-Wilk test. Data 
were analyzed by Analysis Of Variance (ANOVA), followed by Bonferroni multiple comparison 






4.4.1. Integrin αvβ3 expression on IPEC1 decreased upon E. coli infection 
To understand the role of integrin αvβ3 and how integrin αvβ3 interact with bacteria, we 
performed immunofluorescent staining for the integrin on IPEC1. The results showed that integrin 
αvβ3 was expressed in the nucleus, cytoplasm, and plasma membrane of IPEC1 (Figure 4.1). The 
expression of integrin αvβ3 in IPEC1 cells decreased upon E. coli F4 infection (Figure 4.1).  
To further understand the fine distribution of integrin αvβ3 on the cells, we performed 
immuno-gold electron microscopy on normal IPEC1 cells, and E. coli F4 infected IPEC1 cells. 
The immuno-gold staining data were consistent with the confocal results. Normal IPEC1 had ap-
proximately double the number of gold particles for integrin αvβ3 in all compartments than the 
cells exposed to E. coli F4. (Figure 4.2). Densitometry semi-quantification from immunoprecipi-
tation and western blot showed that the expression of integrin αvβ3 on IPEC1 decreased at 15 




Figure 4.1. Immunofluorescent staining of integrin αvβ3 on IPEC1 
Negative controls stained with BSA instead of integrin αvβ3 antibody (3rd row from top), IgG1 
isotype control (last row from top) shows only DAPI blue color of the nucleus. Intense staining 
(green) for integrin αvβ3 is observed in normal IPEC 1 control (1st row on top). The intensity of 
positive staining in IPEC1 decreased upon E. coli F4 infection (2nd row from top). Green: Integrin 




Figure 4.2. Immuno-gold electron micrograph of integrin αvβ3 in normal IPEC1and E. coli F4 
infected IPEC1. 
Transmission immuno-electron micrographs illustrated that integrin αvβ3 (arrows) is ubiquitously 
present in the nucleus (Nu), cytoplasm, and plasma membrane of medium-treated healthy control 
IPEC1 (A, F). The cross-sections of E. coli F4-challenged IPEC1 (B, C, D, E, and G) showed the 
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membrane ruffles at the site of contact with E. coli (C). The elongated microvilli of IPEC1 engulfed 
E. coli (G). Figure D showed an intracellular E. coli after one hour of challenge. Immuno-gold 
staining images illustrated the presence of integrin αvβ3 on E. coli and IPEC1, particularly on the 
binding site of E. coli and IPEC1 (B, C), internalized E. coli (D, G), vesicles (E), and nucleus (G). 
The statistical analysis of the number of gold particles (H) showed a decrease (*=P<0.05; n=10 
IPEC1) in all compartments (nucleus, cytoplasm, and plasma membrane) in E. coli F4 -treated 
compared to medium-treated IPEC1. Data were expressed as mean ± SEM. Error bars indicate 





Figure 4.3. Immunoprecipitation for integrin αvβ3 following western blot for integrin αv and β3 
subunits in normal control IPEC1 and E. coli F4 infected IPEC1 
 (A) Western blots performed on IPEC1 showed the light chain of integrin αv expressed at about 
27 kDa, and integrin β3 at about 85 kDa. The densitometric analyses (B) showed decreased integ-
rin αv and integrin β3 on IPEC1 at 15 minutes of E. coli F4 infection compared with normal 
control IPEC1. Data were expressed as mean ± SEM. Asterisk (*) indicates a significant difference 




4.4.2. Characterization of integrin αvβ3 in E. coli 
The immunocytochemistry on the cytospin of E. coli showed that E. coli DH5α lab-strain 
(Figure 4.4C) had the weak staining of integrin αvβ3 while E. coli F4 (Figure 4.4D) had intense 
integrin αvβ3 staining. To have deeper understanding of the expression of integrin αvβ3 in E. coli, 
which can interact with RGD motif, we used immuno-gold electron microscopy. The results from 
immuno-gold staining showed E. coli F4 (K88) had more gold particle positive staining with anti- 
integrin αvβ3 antibody compared with E. coli DH5α (Figure 4.4.H). We also found that E. coli F4 
(Figure 4.4.G) expressed integrin αvβ3 on the plasma membrane and cytoplasm of the bacteria. 
To semi-quantify the levels of integrin αvβ3, we performed immunoprecipitation to pull down 
integrin αvβ3 complex using anti-integrin αvβ3 antibody. Then, this immunoprecipitated protein 
was western blotted with integrin αv antibody and integrin β3 antibody (Figure 4.4. A). Densitom-
etry quantification from western blot showed that E. coli F4 had more integrin αvβ3 than E. coli 
DH5α (Figure 4.4.B, E). We continued using immunoprecipitated protein from anti-integrin αvβ3 
antibody on E. coli lysates for a mass-spectrometry analysis. The pilot study showed that although 
the protein from the band in gel was lacking stability and was not in high concentration, E. coli F4 
had distinct/unique valid peptides same as in human integrin alpha v (SPSHSk, YDPnVYSIk, 
VSCFNVRFCLkADGk, QEREPVGtCFLQDGTKTVEYAPCR, LQEVGQVSVSL, 
qDKILACAPLYHWRTEMk, LEVSVDSDQKK matching with database accession number 
P06756) and distinct/unique valid peptides same as in human integrin beta 3 (IGDTVSFSIEAK-




Figure 4.4. Integrin αvβ3-like protein in E. coli.  
Immunoprecipitation for integrin αvβ3 following western blot for integrin αv and integrin β3 (A) 
on E. coli lysate show integrin αv band at about 27 kDa. (the light chain), and integrin β3 at about 
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85 kDa. The densitometric analyses (B, E) showed that E. coli F4 had more integrin αvβ3 than E. 
coli DH5α. Data were expressed as mean ± SEM. Asterisk (*) indicates a significant difference 
from E. coli DH5α (P<0.05, n=3). The immunocytochemistry (C, D, purple: integrin αvβ3, light 
green: methyl green-stained DNA), immuno-gold electron staining (E, F, arrow) and statistical 
analysis of quantity of integrin αvβ3 gold particles (H) showed E. coli F4 (D, G) had stronger 
positive staining with integrin αvβ3 than E. coli DH5α (C, F) (*=P<0.05; n=10). Data were ex-





To confirm that E. coli had an integrin αvβ3-like protein, we performed in vitro binding 
assays in 96-well high binding plates coated with anti-integrin αvβ3 antibody. The principle is that 
the measured fluorescence intensity depends on the number of E. coli bound to the integrin αvβ3 
antibody-coated on wells, which is the representative of the presence of the integrin αvβ3-like 
protein on E. coli. Data showed that with the same dose of E. coli, a significantly higher number 
of E. coli binding to the anti-integrin αvβ3 antibody-coated wells comparing with uncoated ones 
(P<0.05) (Figure 4.5). These data suggested that E. coli had an epitope of integrin αvβ3 which can 
bind to anti-integrin αvβ3 antibody. 
Here, we also found that the number of E. coli binding to the well plate depended on the 
different concentrations of the integrin αvβ3 antibody used for coating on the plate wells (Figure 





Figure 4.5. Binding assay on anti-integrin αvβ3 antibody-coated 96 well plates. 
E. coli F4 pFPV::tdTomato at seven different concentrations was added to monoclonal integrin 
αvβ3 antibody-coated wells and uncoated wells of high binding plates. pFPV::tdTomato fluores-
cence from binding E. coli was measured at 530nm excitation /570nm emission in POLAR Start 
OPTIMA microplate fluorescence reader. Fluorescence intensity was adjusted with the back-
ground fluorescence of the wells without adding E. coli. Data were expressed as mean ± SEM. 
Error bars indicate SEM. Asterisk (*) indicates a significant difference from the uncoated well 





Figure 4.6. E. coli binding to anti-integrin αvβ3 antibody-coated well plates. 
E. coli F4 pFPV::tdTomato was added to high binding plates, which were coated with six different 
concentrations of monoclonal antibody anti-integrin αvβ3. E. coli has an integrin αvβ3-like pro-
tein domain which can bind to anti-integrin αvβ3 antibody-coated well plates. Data were ex-
pressed as mean ± SEM. Asterisk (*) indicates a significant difference compared with an uncoated-





There are no data on whether the epithelial integrin αvβ3 has an impact on the cellular 
attachment and uptake of E. coli. In this study, a series of experiments were conducted to demon-
strate that the integrin αvβ3 has a role in the binding of E. coli bacteria to the cell surface. 
Although integrin αvβ3 expression was not reported in prokaryotes in the past (203), 
Tchesnokova and colleagues recently revealed that E. coli K12 had an integrin-like allosteric site 
on FimH, an adhesive subunit of type 1 fimbriae of E. coli (232). Moreover, micronemal adhesin 
MIC2 of Toxoplasma gondii had integrin-like A domain to interact with LAMTOR1 and 
RNaseH2B proteins of the host cell during parasite invasion (253). In this study, we found integrin 
αvβ3-like protein in E. coli F4. These data were collected with many methods. The immunohisto-
chemical expression of the integrin was further confirmed through Western blots and immuno-
gold electron microscopy. Interestingly, there was a difference in the expression of integrin αvβ3 
between two strains of E. coli, and reasons for these differences remain unknown. The identity of 
the protein being detected by the antibodies in microscopy and Western blot was confirmed with 
blotting of the immuno-precipitates with integrin αvβ3 antibody. Lastly, the pilot sequencing of 
the immunoprecipitated protein bands showed the homology with the human integrin αv and β3 
sequences. Taken together, our data prove that E. coli expresses an integrin αvβ3-like protein do-
main. 
Our data also show the novel role of integrin αvβ3 in the adherence of bacteria. The in 
vitro assay on plate wells coated with integrin αvβ3 antibody showed the binding of integrin αvβ3 
antibody concentration-dependent binding of E. coli. It is possible that integrin αvβ3 is important 
in the uptake of E. coli by IPEC1 cells. Our in vitro experiment using IPEC1 cell line showed that 
E. coli infection decreased the expression of the integrin αvβ3 on the cell line. The data were 
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collected by western blot, immune-gold, and immunofluorescent staining. The implications of the 
downregulation of the integrin expression are not clear, but it may be a mechanism that E. coli 
uses it to prevent the activation of the cells or to down regulate the immune response. The integrin 
has previously been shown to be a receptor for pathogens such as virulent Foot-and-mouth disease 
virus type O1 (164) and Staphylococcus aureus binding to integrin αvβ3 on the endothelium lead-
ing to endothelial dysfunction (149). The attachment of E. coli and Staphylococcus to human en-
dothelial cells was reduced by Cilengitide through inhibiting integrin αvβ3 (73, 149). As is well 
known, the integrin αvβ3 binds to RGD peptides, which are present in extracellular matrix mole-
cules such as fibronectin, osteopontin, collagen, and vitronectin (196, 220). The integrin αvβ3 
regulates cell functions such as activation, proliferation, and adherence through a variety of signals 
(196, 220). We confirmed that E. coli F4 efficiently binds to the IPEC1 cell line in vitro (126). 
Therefore, our data showed that the integrin might also be a receptor for E. coli, thus creating a 
possible route to interference with its adherence to the intestinal epithelium of pigs (106). 
Overall, the results in this chapter indicate that integrin αvβ3 was expressed on IPEC1. 
We also found that E. coli has an integrin αvβ3-like functioned protein. The information on the 
expression of integrin αvβ3 on IPEC1 and E. coli upon infection is the initial essential understand-
ing to develop a new approach to modulate intestinal diseases. The next chapter, therefore, should 
move on to discuss the function of integrin αvβ3 on intestinal epithelium. 
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CHAPTER 5. THE EFFECTS OF RGDSK-HRNs-FITC AND INTEGRIN αvβ3 INTER-
ACTION ON INHIBITING E. COLI ADHERENCE TO IPEC1 IN VITRO AND 
PORCINE VILLI EX VIVO 
To manage outbreaks of intestinal diseases and foodborne illness, numerous scientists 
have attempted to reduce the bacterial colonization in the intestines. Results from the previous 
chapter suggested that integrin αvβ3 was involved in E. coli F4 infection. Integrin αvβ3 recognizes 
and binds the RGD peptide. There are no data on whether the integrin αvβ3 in the jejunum has an 
impact on the cellular attachment of E. coli F4. Therefore, in this chapter, we used RGDSK-HRNs 
and further investigate its functions in blocking the attachment of E. coli to IPEC1 in vitro and 
porcine villi ex vivo. 
5.1. ABSTRACT 
Intestinal diseases and foodborne illness, particularly due to E. coli infection, cause many 
deaths and economic losses worldwide. One of the strategies to reduce the incidence of these dis-
ease outbreaks is to reduce bacterial colonization in the intestines. Integrin αvβ3 recognizes argi-
nine-glycine-aspartic acid (RGD) sequences and has important functions in cell adhesion, signal-
ling, and survival. However, the role of the integrin αvβ3 in the adhesion of E. coli F4 on the 
intestinal epithelium remains elusive. To study this gap of information, we performed a series of 
experiments using a novel RGDSK-HRNs-FITC, the intestinal porcine epithelial 1 cell line 
(IPEC1), porcine villi, and E. coli F4. 
In this study, we found that RGDSK-FITC peptides and RGDSK-HRNs-FITC bound to 
integrin αvβ3 on both IPEC1 and E. coli F4. RGDS peptides blocked the attachment of E. coli F4 
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to IPEC1 (P<0.05) and reduced the survival of E. coli F4 (P<0.05). RGDSK-HRNs-FITC pretreat-
ment at 1 µM concentration mediated a half of the attachment of E. coli F4 to IPEC1 (P<0.05). 
The data from binding assays on 96-well plates showed that the number of E. coli binding to the 
integrin αvβ3 coated wells was significantly higher than that binding to uncoated wells with the 
same dose of E. coli (P<0.05). We then performed ex vivo villus adhesion assays on scraped villi 
from porcine jejunum. The data showed that in F4 receptor-positive villi, RGDSK-HRNs-FITC 
significantly reduced the number of adhering E. coli for up to 12 hours compared with the E. coli-
only challenged group (P<0.05). Both RGDSK-FITC peptide and monoclonal anti-integrin αvβ3 
antibody were effective in inhibiting the E. coli binding to villi for up to 24 hours. Confocal mi-
croscopy confirmed the binding of RGDSK-HRNs-FITC to both villi and E. coli F4. 
In conclusion, these are the first data showing the function of the integrin αvβ3 in the 
adherence of E. coli to the intestinal epithelium, and showing that novel RGDSK-HRNs-FITC 
intervention, maybe a potential alternative to antibiotics, can inhibit the attachment of E. coli to 
the epithelium. 
Key Words: integrin αvβ3, nanotubes, porcine epithelium, E. coli 
5.2. INTRODUCTION 
E. coli is usually found in the environment, food, and the intestines of animals and hu-
mans (233). Although some E. coli strains are harmless and controllable (233), others infect the 
intestinal, urinary, and respiratory systems (115). The first step of infection is the adhesion of 
bacteria to the epithelium via their fimbrial binding or other mechanisms (124). Some specific 
adhesive receptors have been reported that are used as an alternate by E.coli to bind to the intestinal 
epithelium when any one of them is inhibited (F4, F41, F1, …) (70). Because of redundancy in 
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adhesive receptors, changes in biological characteristics, and many virulence factors, concerted 
global efforts to manage and control E. coli infections have been only partially successful (34, 35, 
185, 247). Therefore, we need to identify other putative receptors for E. coli binding and exploit 
them to reduce intestinal colonization by these bacteria. 
Integrin αvβ3, a heterodimeric glycoprotein, recognizes and binds arginine-glycine-as-
partic acid (RGD) sequences (159, 220). Integrin αvβ3, known as a transmembrane receptor, plays 
a key role in bidirectional signalling across the membrane, and cell-matrix adhesion of cells (155, 
159, 193, 220). Some bacteria and viruses likely use integrin αvβ3 on the surface of the epithelium 
as their receptors (58, 123, 149, 164). Our lab reported that integrin αvβ3 was abundantly 
expressed in the porcine gut epithelium in addition to those of calves and dogs (213). However, 
the role of integrin αvβ3 in the adhesion and colonization of E. coli to gut epithelium remains 
unknown. 
Nanotechnology has ushered in a new area of material design, starting from the atomic 
scale (1, 142). There are novel nanomaterials with potential applications in bacterial infection 
treatment or cancer diagnostics  (1, 142). One of the novel nanomaterials is the helical rosette 
nanotubes (HRNs), which are non-metallic, organic, bio-compatible, and water-soluble (63, 64, 
134). The HRNs are synthesized through a novel system where guanine (G) - cytosine (C) bases, 
also known as a G∧C- motif, assemble themselves in a helical rosette shape. The HRNs present 
many sites for the attachment of various functional groups and their display on the surface  (63, 
64, 134). 
Researchers have integrated RGD peptide sequences into nanomaterials to bio-function-
alize them (83, 125, 155). The reason for functionalizing RGD sequences is because the same RGD 
amino acid sequence occurs in several extracellular matrices (ECM) proteins such as fibrinogen, 
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vitronectin, and fibronectin, which mediate cell adhesion to the ECM (155). Recently, the Fenniri 
laboratory has conjugated Arg-Gly-Asp-Ser-Lys (RGDSK) peptide to HRNs (RGDSK-HRNs) to 
functionalize the tubes to target integrins for specific medical and biological applications (39). 
Based on our finding of the expression of integrin αvβ3 on E. coli, we tested the hypothesis that 
RGDSK-HRNs would localize along the integrin αvβ3 expressing IPEC1 and block the attachment 
of E. coli to IPEC1 in vitro. 
5.3. MATERIALS AND METHODS 
5.3.1. Materials 
Novel HRNs were designed by Dr. Fenniri and were supplied by his laboratory at the 
Department of Chemical Engineering, the College of Engineering, Northeastern University, Bos-
ton, USA. (39, 63, 64). 
E. coli F4 strain EC52, serotype O101:K30+:K99-: F4+ and IPEC1 were generous gifts 
from Dr. Francois Meurens and Dr. Heather L. Wilson at the Vaccine and Infectious Disease 
Organization-International Vaccine Centre (VIDO-InterVac). IPEC1 cells were developed from 
the jejunum of unsuckled, mixed-bred piglets less than 12 hours old (85). IPEC1 cells were cul-
tured in 75 cm2 flask in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 at 37oC in a 
humidified 5% CO2 incubator (84, 126). 
Mouse monoclonal integrin αvβ3 antibody (clone LM609, Chemicon Inc., Temecula, 
USA), Alexa Fluor 633 conjugated secondary antibody polyclonal goat anti-mouse 
immunoglobulins (Thermo Fisher, Rockford, USA), RGDSK-FITC (American peptide company, 
Sunnyvale, CA., USA.), and CFTM488A-Annexin V (AnV) and Propidium Iodide (PI) Apoptosis 
Kit (Biotium, Hayward, CA., USA.)  were purchased commercially. 
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5.3.2. Preparing E. coli 
E. coli strain EC52, serotype O101:K30+:K99-: F4+, having pFPV::tdTomato fluores-
cence protein, was cultured for 18 hours on Luria broth supplemented with ampicillin. The con-
centration of bacteria was determined by adjusting the optical density at 620nm (OD620) to 1 to 
achieve 4x109 CFU/ml as determined by prior CFU counting. E. coli was centrifuged at 16,200 xg 
for 5 minutes, followed by three washes in 0.1M PBS supplemented with ampicillin at pH=7.4. 
Serial dilution was done to reach the desired concentration of the bacteria for the assay later, ac-
cording to previously cited procedure (126). 
5.3.3. Preparing RGDSK-HRNs-FITC 
TBL/TB- RGDSK is a twin G∧C – based rosette nanotubes (RNTs) functionalized with 
arginine-glycine-aspartic acid-serine-lysine (RGDSK) peptide sequence which can bind to integrin 
αvβ3. The TBL/TB-FITC is a fluorescein isothiocyanate (FITC) conjugated twin G∧C – based 
rosette nanotubes (RNTs). TBL/TB-FITC and TBL/TB-RGDSK in 1:10 molar ratio of FITC and 
RGDSK were mixed to yield the composite of RGDSK and FITC functionalized helical rosette 
nanotubes (RGDSK-HRNs-FITC). This more stable self-assembling HRNs expresses RGDSK, 
and is visualized by fluorescence microscope (39, 225). The suspension was sonicated for 5 
minutes in a water bath following by 30-second vortex and one-minute heating. The mixture was 
placed at room temperature in the dark for 48 hours to allow for the synthesis of the RGDSK-
HRNs-FITC. The RGDSK-HRNs-FITC stock was stored in 4oC for future use in experiments. 
RGDSK-HRNs-FITC was diluted in an appropriate dilution buffer (0.1M PBS or DMEM/F12) at 




5.3.4. In vitro binding assay on 96-well high binding plates 
To examine whether E. coli can bind integrin αvβ3, we performed an in vitro integrin 
αvβ3 binding assay, modified from previous protocols (27, 149). In brief, 96-well high binding 
plates were precoated overnight with 50µl of 5µg/ml human integrin αvβ3 protein (CC1018, 
EMD Chemicon Inc., Temecula, USA) in 100 mM HCO3¯/CO3¯ coating buffer. Wells with 
coating buffer without integrin αvβ3 was used as a negative control. The wells were washed gen-
tly with 100µl of sterile 0.1%Tween-TBS then were incubated in 1% BSA to prevent non-spe-
cific binding. E. coli F4 having pFPV::tdTomato fluorescence protein was added at seven con-
centrations (50 µl of 10x106, 5x106, 2.5x106, 1.25x106, 0.62x106, 0.31x106, 0.15x106 CFU per 
well). After a one-hour incubation, non-adhering E. coli was removed by rinsing with PBS ampi-
cillin. The bound E. coli were fixed in 2% paraformaldehyde. pFPV::tdTomato fluorescence 
from binding E. coli was measured at 530nm excitation /570nm emission in POLAR Start OP-
TIMA microplate fluorescence reader. Fluorescence intensity was adjusted with background flu-
orescence from well without E. coli. The experiment was repeated four times. 
5.3.5. Quantifying E. coli binding to RGDSK-HRNs treated IPEC1 
For binding assay, 2x105 IPEC1/well were seeded into 24-well plate, having cover slides 
at the bottom. After being confluent overnight, IPEC1 cells were washed using 1 ml of fresh 
DMEM/F12 without serum per well. Cells were exposed to RGDS peptide (0.1, 1, 10, 50 µM) as 
controls at three different time points (5, 10, 15 minutes) or RGDSK-HRNs (containing equivalent 
0.1, 1, 5µM RGDSK) at three different time point (2, 5, 10 minutes) or media only for control. 
Cells then were treated with 1x107 E. coli F4/ml into RGDS peptide groups or 1x108 E. coli F4/ml 
into RGDSK-HRNs groups. 
76 
 
In evaluating the biological effects of RGDSK-HRNs on E. coli, the supernatants were 
collected. These supernatants were serial diluted and cultured on blood agar and Luria broth agar 
with ampicillin plates. The number of E. coli colonies on the agars as an indicator of viable E. coli 
in the supernatants were counted for statistical analysis.  
The supernatants were centrifuged at 16,200 xg for 5 minutes. Then the supernatants 
were stored at -80oC for future experiments. Pellets were washed three times in 1X PBS, resus-
pended in 1X PBS, and cytospin onto microscope slide at 1,000 rpm in 4 minutes. Samples were 
fixed in methyl alcohol and assessed Wright-Giemsa staining following manufacture insert (EMD, 
Millipore, Temecula, USA.). An average number of E. coli binding to each IPEC1 (n=10 
IPEC1/group) on cytospin slides were objectively calculated. The experiments were repeated three 
times for statistical analysis. 
5.3.6. Immunofluorescent staining integrin αvβ3 
For immunofluorescent staining, 2x105 cells/well were seeded into 24-well plates having 
cover slides at the bottom. After being confluent overnight, IPEC1 cells were washed with 1 ml of 
fresh DMEM/F12 without serum per well. Cells were exposed to 10 µM RGDSK-FITC peptide in 
5 minutes or RGDSK-HRNs-FITC (containing equivalent 5µM RGDSK) in 2 minutes or media 
only for the control group. Then cells were challenged with 107 E. coli F4/ml. 
The samples were fixed in 4% paraformaldehyde. Non-specific binding was blocked by 
10% BSA. Samples were incubated with monoclonal anti-integrin αvβ3 antibody (dilute 1:50, 
clone LM609, Chemicon Inc., Temecula, USA) then Alexa flour 633 conjugated goat anti-mouse 
IgG secondary antibody (dilute 1:100). Cells were incubated for 5 minutes in 0.33µg/ml DAPI for 
staining DNA of nuclei. Samples were observed by a confocal scanning laser microscope Leica 
TCS SP5 LSCM, with a 63 objective lens under oil immersion. Negative controls for the 
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specificity of primary, secondary antibody, and protocol include mouse IgG1 isotype control, the 
omission of primary antibody, or the omission of both a primary antibody as well as a secondary 
antibody conjugated Alexa flour 633. 
5.3.7. Ex vivo villus adhesion assay 
As already known, the uptake of E. coli F4 is related to F4 receptor (F4R) mediation 
(240). Therefore, we used both F4R positive and F4R negative pigs to explore the function of 
integrin αvβ3 in the adhesion of E. coli F4 through a villus adhesion assay method described pre-
viously (241). Briefly, a segment of jejunum was washed three times with 0.1M PBS to remove 
intestinal contents. That segment was then opened and washed in cold Krebs-Henseleit buffer 
(120mM NaCl, 14 mM KCl, 25mM NaHCO3, one mM KH2PO4) with 1% formaldehyde. Subse-
quently, porcine jejunal villi were gently scraped with a slide and let to settle at the bottom of the 
tube in this buffer. The supernatant was then discarded, and replaced by the same buffer until it 
was clear. At the time of the assay, the villi were washed in Krebs buffer to remove formaldehyde 
and were resuspended in 0.1M PBS ampicillin. To test the function of integrin αvβ3 and RGDSK-
HRNs-FITC on E. coli F4 binding, 5x108 of E. coli F4 was treated with RGDSK-HRNs-FITC 
(equivalent 5µM RGDSK) in 15 minutes. Five µM RGDSK-FITC, 5µg/ml mouse monoclonal 
integrin αvβ3 antibody (clone LM609, Chemicon Inc., Temecula, USA), 5µM TBL-FITC (nano-
tube without RGDSK group), rabbit anti-F4 antibody serum, 0.1M PBS were used as controls. 
Then, the treated E. coli F4 was added to an average of 50 villi for each treatment. Bacteria and 
villi were incubated for 4, 8, 12, and 24 hours at 37°C. Supernatants were collected and cultured 
in LB agar ampicillin to evaluate biological effects of RGDSK-FITC peptide, RGDSK-HRNs-
FITC, mouse monoclonal anti-integrin αvβ3 antibody, TBL-FITC (nanotube without RGDSK 
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group), rabbit anti-F4 antibody serum, 0.1M PBS on E. coli F4 adhesion. The number of E. coli 
F4 colonies representing E. coli F4 viability in the supernatant was counted for statistical analysis. 
To remove the unbound E. coli F4, the cultures were washed in 0.1M PBS, and samples 
were fixed in 4% paraformaldehyde to stop further E. coli F4 adhesion. After that, the number of 
bacteria adhering to 250 μm of the brush border of villi was quantified under a phase-contrast 
microscope at 1000× magnification. Five different regions were counted, and data were presented 
as the average number of bacteria adhering to 250 μm of the brush border. The experiment was 
repeated three times. 
5.3.8. Statistical analysis 
We used the GraphPad Prism version 5.04 software (San Diego, CA, USA.) to analyse 
data. Quantitative results were expressed as mean ± SEM, and error bars represented standard 
error. The normal distribution of residuals was tested by histogram and Shapiro-Wilk test. Data 
were analyzed by Analysis Of Variance (ANOVA), followed by Bonferroni multiple comparison 
test. A significant difference was set when the critical value of α was below or equal to 0.05 as 
(two-tailed, p<0.05). 
5.4. RESULTS 
5.4.1. The binding ability of E. coli depends on integrin αvβ3 in vitro. 
To examine whether E. coli can bind integrin αvβ3, we performed an in vitro binding 
assay on integrin αvβ3 coated 96-well high binding plates. Data showed that with the same dose 
of E. coli, a significantly higher number of E. coli bound to the integrin αvβ3 coated wells com-
pared with the uncoated ones (Figure 5.1). It means that coating integrin αvβ3 significantly in-
creased the binding of E. coli into the plate. With the same concentration of integrin αvβ3 protein 
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coated in each well, the fluorescence intensity as an indicator of numbers of bound E. coli into the 
plate increased with the increased concentration of the bacteria (P<0.05). We did not have control 
groups with substitute protein coated control and with different strains of E. coli. However, the 






Figure 5.1. Integrin αvβ3 protein-coated 96-well plate binding assay.  
E. coli F4 pFPV::tdTomato was added at seven concentrations to integrin αvβ3 coated high bind-
ing plates. pFPV::tdTomato fluorescence from binding E. coli was measured at 530nm excitation 
/570nm emission in POLAR Start OPTIMA microplate fluorescence reader. Fluorescence intensity 
was adjusted with background fluorescence from well without E. coli. Data were expressed as 
mean ± SEM. Error bars indicate SEM. An asterisk (*) indicates significant difference from the 




5.4.2. RGDS peptide can block the attachment of E. coli to IPEC1 and affect E. coli sur-
vival in vitro. 
We exposed IPEC1 to four different doses of RGDS (0.1, 1, 10, 50 µM) at three different 
time points (5, 10, 15 minutes), followed by a challenge with 107 E. coli F4/ml. To evaluate the 
effect of RGDS on the ability of E. coli to bind to IPEC1, we performed Wright-Giemsa staining 
the samples (Figure 5.2A), and calculated the number of E. coli binding to each IPEC1 cell. Our 
results show that the number of E. coli binding to each IPEC1 cell decreased significantly when 
IPEC1 was exposed to RGDS 5 minutes (P<0.05). However, there was no significant difference 
at a more extended time point beyond 15 minutes (Figure 5.2B). To test the biological effects of 
RGDS on E. coli, we determined E. coli viability in the supernatant by culturing it on blood agar 
and Luria broth agar with ampicillin. The number of colonies was calculated for statistical analysis. 
We found that RGDS peptide can affect E. coli survival, particularly when IPEC1 was exposed to 
50µM RGDS in 10 minutes. However, there are no significant differences at longer time points 




Figure 5.2. RGDS peptides can block the attachment of E. coli to IPEC1 and affect the survival of 
this bacteria.  
To evaluate the effect of RGDS on the ability of E. coli in binding to IPEC1, we performed Wright-
Giemsa staining (A), and calculated the number of E. coli binding to each IPEC1 (B). The number 
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of E. coli binding to each IPEC1 decreased significantly in the group that IPEC1 was exposed to 
RGDS 5 minutes. However, there was no significant difference at longer timepoint. (C) To test the 
biological effects of RGDS on E. coli, we determined E. coli survival in the supernatant by cultur-
ing on Luria broth with ampicillin. The number of colonies was calculated for statistical analysis. 
We also found that RGDS peptide could reduce E. coli colonies in the supernatant, particularly in 
the group that IPEC1 was exposed to 50µM RGDS in 10 minutes. However, there were no signif-
icant differences at a longer timepoint after 15 minutes. (A) Representative Wright-Giemsa stain-
ing pictures of E. coli binding to IPEC1, challenging with different doses of RGDS at different 
time points. Data were expressed as mean ± SEM. Error bars indicated SEM. An asterisk (*) 




5.4.3. Effect of RGDSK-HRNs on the attachment of E. coli to IPEC1 and E. coli death 
We exposed IPEC1 to 3 different doses of RGDSK-HRNs (equivalent 0.1, 1, 5 µM 
RGDSK) at three different time points (2, 5, 10 minutes) before challenging these cells to 108 E. 
coli F4/ml. To evaluate the effect of RGDSK-HRNs on the ability of E. coli to bind to IPEC1, we 
performed Wright-Giemsa staining the samples (Figure 5.3.A), and calculated the number of E. 
coli binding to each IPEC1 cell. We found that compared with the group without HRNs-RGDSK, 
the number of E. coli binding to each IPEC1 decreased significantly in the group where IPEC1 
was exposed to 5µM HRNs-RGDSK for 10 minutes before challenging with E. coli F4 (Figure 
5.3.B). We also found that compared with the media treatment group (0), the number of viable E. 
coli in the supernatant was significantly higher in the group that IPEC1 was exposed to 5µM 
HRNs-RGDSK in 10 minutes before being challenged to E. coli F4 (Figure 5.3.C). These findings 
suggested that RGDSK-HRNs blocked integrin αvβ3 of E. coli and IPEC1, thus preventing these 
bacteria from interacting with IPEC1; consequently, more E. coli F4 left in the supernatant. The 
higher number of survival E. coli left in supernatant also proved that RGDSK-HRNs did not kill 
E. coli F4, expecting nontoxic to the cell. Other groups with different strains of E. coli or another 




Figure 5.3. RGDSK-HRNs can block the attachment of E. coli to IPEC1 in vitro.  
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To evaluate the effect of RGDSK-HRNs on the ability of E. coli in binding to IPEC1, we performed 
Wright-Giemsa staining (A) and calculated the number of E. coli binding to each IPEC1 (B). To 
test the biological effects of RGDSK-HRNs on E. coli, E. coli viability in the supernatant was 
determined by cultured on blood agar with ampicillin (C). The number of colonies was calculated 
for statistical analysis. (A) This is representative pictures of the Wright-Giemsa staining of IPEC1, 
challenging with E. coli F4 as well as different doses of RGDSK-HRNs at different time points and 
E. coli colony left in the supernatant. Data were expressed as mean ± SEM. Error bars indicated 
SEM. The experiment was repeated four times. An asterisk (*) indicates a significant difference 




5.4.4. RGDSK-HRNs-FITC and RGDSK-FITC can bind integrin αvβ3 in IPEC1 and an 
integrin αvβ3-like protein on E. coli F4 
We performed immunofluorescent staining for integrin αvβ3 to observe interactions be-
tween RGDSK-HRNs-FITC and integrin αvβ3 on epithelial cell line upon E. coli infection (Figure 
5.4A). Confocal images confirmed that integrin αvβ3 was strongly expressed in IPEC1 (Figure 
5.4, row 4, column 1). The intensity of integrin αvβ3 staining on IPEC1 decreased upon a one-
hour E. coli infection (Figure 5.4, row 4, column 2). RGDSK-HRNs-FITC bound to integrin αvβ3 
in IPEC1 and an integrin αvβ3-like protein on E. coli F4 (Figure 5.4, row 2, column 3). We also 
found that RGDSK peptide at 50µM concentration blocked an integrin αvβ3-like protein in E. coli 
F4 (Figure 5.4B, row 1 column 4, and row 2 column 4) and integrin αvβ3 in all compartments of 
the IPEC1 cells (Figure 5.4B, row 3). The binding of RGDSK-HRNs-FITC or RGDSK-FITC, 
along with E. coli infection, decreased the intense positive staining of integrin αvβ3 on E. coli F4 






Figure 5.4. Representative images from immunofluorescent staining integrin αvβ3 under a confo-
cal microscope.  
(A) The interaction of RGDSK-HRNs-FITC with integrin αvβ3 on epithelial cell line upon E. coli 
infection: IPEC1 cells were pre-treated with 5µM RGDSK-HRNs-FITC for 10 minutes before be-
ing challenged with E. coli F4 for one hour. The final concentrations of treatments were 1µM of 
RGDSK-HRNs-FITC and 107 E. coli F4 in 1ml media. The concentration of RGDSK-HRNs-FITC 
means the equivalent concentration of RGDSK. (B) The interaction between RGDSK-FITC, E. coli 
and integrin αvβ3 on IPEC1: IPEC1 cells were pre-treated with 0.1µM RGDSK (row 1) or 50 µM 
RGDSK (row 2, 3) in 10 minutes before being challenged with E. coli F4 for one hour. The final 
concentrations of treatments were 0.01µM of RGDSK (row 1) or five µM RGDSK (row 2, 3) and 
107 E. coli F4 in 1ml media. Both RGDSK-HRNs-FITC and RGDSK-FITC peptide can bind integ-






5.4.5. RGDSK-HRNs-FITC could prevent E. coli adhering to porcine jejunal villi through 
interaction with integrin αvβ3 in an ex vivo villus adhesion assay 
We performed ex vivo villus adhesion assay on scraped villi from porcine jejuna, as de-
scribed above. To explore the function of integrin αvβ3-like protein on E. coli and the role of 
integrin αvβ3 on the epithelium of villi on E. coli binding, we pre-treated E. coli with RGDSK-
HRNs-FITC for 15 minutes. Control treatments included RGDSK-FITC, TBL-FITC, monoclonal 
antibody anti-integrin αvβ3, anti-F4 antibody serum, and PBS. After that, porcine villi were added 
and incubated for 4, 8, 12, and 24 hours. We used both F4R positive and F4R negative pigs to 
explore the function of integrin αvβ3 because much of the uptake of E. coli is F4 receptor-medi-
ated. Data showed that in F4 receptor-positive villi, RGDSK-HRNs-FITC significantly reduced 
the number of adhering E. coli compared with the E. coli challenged group until 12 hours (P<0.05), 
but not significant in longer timepoint (24 hours) (Figure 5.5A, Figure 5.6).  
Similarly, in F4R negative villi groups, the number of adhering E. coli in the RGDSK-
HRNs-FITC pretreated group was significantly lower than E. coli only challenge group at 4 hours 
timepoint, but not for longer incubation (P<0.05) (Figure 5.5B). These data suggested that 
RGDSK-HRNs-FITC prevented E. coli adhering to porcine jejunum villi but not over a more pro-
longed duration of exposure. Maybe long-time exposure gave a chance to the RGDSK peptide on 
the surface of nanotubes to bind both the integrin αvβ-like protein on E. coli and the villus integrin 
αvβ3; consequently, RGDSK-HRNs-FITC became a bridge between the bacteria and the 
epithelium. Other groups with diffenrent strains of E. coli or another substitute protein should be 




Figure 5.5. Ex vivo villus adhesion assay on scraped villi from porcine jejunum. 
The number of adhering E. coli per 250 µm villus length were counted using a phase-contrast 
microscope. The number of adhering E. coli of the RGDSK-HRNs-FITC treatment group was sig-
nificantly fewer than that of the E. coli infection group until 12 hours in F4 positive receptor villi 
(A). In F4 receptor negative villi, compared with E. coli only challenged group, RGDSK-HRNs-
FITC significantly reduced the number of adhering E. coli at 4 hours timepoint but not for more 
prolonged incubation (B). Data were expressed as mean ± SEM. Error bars indicated SEM. An 
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asterisk (*) indicated a significant difference compared with E. coli treatment only group (* 
P<0.05). The experiments were repeated three times. 
 
Figure 5.6. Representative pictures of villus adhesion assay 
Images from phase-contrast microscope illustrate the number of adhering E. coli on F4 receptor-
positive villi (A) was significantly higher than that in the RGDSK-HRNs-FITC pretreated group 
(B) after four-hour E. coli F4 incubation. Confocal images illustrate that RGDSK-HRNs-FITC 
bind to integrin in porcine villus and E. coli F4 (C, D, E, F, G). Red: pFPV꞉꞉td tomato E. coli F4; 
Green: RGDSK-HRNs-FITC; Blue: DAPI  
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5.4.6. RGDSK-FITC, but not RGDSK-HRNs-FITC, affects the survival of E. coli signifi-
cantly 
Supernatants from ex vivo villus adhesion assay were collected and cultured in LB agar 
ampicillin to evaluate the biological effects of RGDSK-FITC peptide, RGDSK-HRNs-FITC, 
mouse monoclonal anti-integrin αvβ3 antibody, TBL-FITC (nanotube without RGDSK group), 
rabbit anti-F4 antibody serum, and 0.1M PBS on E. coli F4. The number of E. coli F4 colonies 
representing viable E. coli F4 in the supernatant was counted for statistical analysis. Results 
showed that E. coli F4 exposed to RGDSK-FITC before being incubated with the villi had signif-
icantly lower numbers of viable bacteria in the supernatant at 12 hours than that in the media 
treatment group (P<0.05). The results from 24 hours exposure time point showed that RGDSK-
FITC or anti-F4 antibody serum had a fewer number of E. coli colonies in supernatant compared 





Figure 5.7. The number of survival E. coli left in the supernatant in the villus adhesion assay 
The number of survival E. coli left in the supernatant was counted in LB agar ampicillin culture 
plates. At the 24-hours time point, compared with the E. coli group, the number of E. coli left in 
the supernatant was significantly reduced in RGDSK-FITC peptide control and anti-F4 antibody 
serum treatment group (P<0.05), but not in RGDSK-HRNs-FITC treatment group. Data were 
expressed as mean ± SEM. Error bars indicated SEM. An asterisk (*) indicated a significant dif-





Intestinal diseases and foodborne illnesses due to E. coli infection are responsible for 
numerous deaths and many economic losses worldwide (34, 35, 185). To manage these disease 
outbreaks, one of the proposed approaches is to reduce bacterial colonization or virus entry into 
the intestine. Most of the data has focused on the identification of molecular adhesion receptor for 
the entry of the bacteria or virus into non-phagocytic cells. For example, replication of porcine 
epidemic diarrhea virus (PEDV) on African green monkey Vero E6 cells was reduced by RGD 
peptide, polyclonal antibodies anti-integrin αv, and polyclonal antibodies anti-integrin β3 treat-
ments via its interaction with integrin αvβ3 (138). Moreover, Isberg and co-workers reported that 
the immobilized invasin of Yersinia pseudotuberculosis enteric bacterium could bind integrin 
α3β1, α4β1, α5β1, and α6β1  (104). Another example is Shigella flexneri, which releases Ipa pro-
teins, forming a high molecular matrix structure, and interacting with integrin α5β1 on the epithe-
lium. This interaction activates the rearrangement of actin cytoskeletons, which allows the bacteria 
to invade the host epithelium (254).  In this study, we discovered that E. coli could bind integrin 
αvβ3 for its colonization in vitro. 
Prior studies have found that many ligands of E. coli adhered to specific receptors of the 
host. For example, Hemolysin (HlyA) toxin from uropathogenic E. coli was mediated by β2 integ-
rins in U-937 human monocytic cell line, demonstrating the involvement of β2 integrins in the 
sensitivity of the host cell to toxins from uropathogenic E. coli (191). It was also reported that eae 
gene in enterohemorrhagic E. coli enables the pathogen to attach to and desquamates colonic epi-
thelial cells, recruiting inflammatory cells and causing edema as well as microvilli loss (56). An-
other well-known example of E. coli ligands is the F4 antigen, also known as F4, which binds to 
the F4 receptor of the host (70, 197). This ligand was described as thin, and flexible threads, having 
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a fimbria like structure with a 2.1 nm diameter, covered with filamentous-appearance material (70, 
197). Despite the existing knowledge on E. coli receptors, we built our experiments on the identi-
fication of integrin αvβ3 on intestinal epithelium, and the presence of an integrin αvβ3-like protein 
on E. coli to examine the potential role of the integrin in bacterial adhesion. 
Surprisingly, our results from a binding assay on 96-well plates indicated that the number 
of E. coli binding to integrin αvβ3 coated wells increased significantly compared with that of un-
coated wells. These data suggested that the binding of E. coli F4 depended on integrin αvβ3. The 
second major finding of this E. coli O101 F4+ using PCR method is that this E. coli strain is 
negative for AIDA-1, eae, LT, STa, STb, and Stx2e toxins. We continued using this E. coli O101 
F4+ strain in our experiments to focus on studying the adherence stage of the bacteria in the path-
ogenesis of the disease. Our results supported previous findings that although some E. coli O101 
strains lacked some virulence factors, such as ST, LT, hemolysin, eaeA, they possessed a Shiga-
like toxin, causing hemorrhagic colitis and hemolytic-uremic syndrome in human (66) and diar-
rhea in calves (219). Dangerously, the pigs show no symptoms of disease yet are infected by the 
bacteria, a result with serious implications: if this strain uses the pigs as its reservoir, the bacterium 
can be transferred to humans from contaminated porcine products (30, 66). In the same way, the 
literature has shown that other E. coli strains without eaeA still adhere to the intestinal mucosa, 
causing edema disease (such as O139) (18) and colitis (such as O18, O91, O113, O117, O145) 
(143). These data create the possibility that proteins other than the already known receptors may 
be playing a role in the attachment of E. coli with the epithelium. 
One possible implication of our result is that E. coli can use integrin αvβ3 to support its 
binding in the absence of other receptors. Although we do not know for certain if E. coli contains 
an RGD peptide sequence, one theory is that integrin αvβ3 possibly binds to motifs that extend 
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beyond RGD-containing protein. Another possible explanation for this binding is that E. coli has 
a structure with the same characteristic and properties as found in RGD-containing ligands. This 
RGD-like peptide structure of E. coli, likely functioning as RGD, can bind to the identical site on 
the integrin αvβ3 of the jejunal epithelium, enabling E. coli to attach to and penetrate the intestinal 
epithelium.  
From the nanoscale bio-mimetic features of nanotubes, the novel RGDSK-HRNs provide 
RGDSK surface chemistry and a cell-favorable environment. Because little is known either about 
the molecular interaction between E. coli, RGDSK, RGDSK-HRNs, and integrin αvβ3 or the dis-
tribution of RGDSK-HRNs on the gut epithelial cell, we used FITC-conjugated RGDSK-HRNs, 
and FITC-conjugated RGDSK to visualize them in a cell culture model. Immunofluorescent stain-
ing showed that RGDSK-FITC and RGDSK-HRNs-FITC could bind integrin αvβ3 in IPEC1 and 
integrin αvβ3-like protein in E. coli F4. This study supports evidence from the previous observa-
tions about the expression of integrin αvβ3 in IPEC1 and integrin αvβ3-like protein in E. coli F4 
in the previous chapter. 
E. coli F4 efficiently binds to the IPEC1 cell line in vitro (126). To modify E. coli-induced 
diarrhea in pigs, a suggested novel intervention could be the obstruction of the receptor adhesion 
sites to inhibit E. coli attachment to the epithelium (106). A group of researchers reported that the 
RGDSK-HRNs, targeting integrin αvβ3, can enhance osteoblast adhesion and proliferation due to 
an increase of fibronectin (268). In our study, we discovered that RGDSK-HRNs mediated the 
attachment of E. coli to IPEC1 efficiently. It suggests that the delivery of HRNs has an impact on 
RGDSK activity. 
To further study the effect of RGDSK-HRNs-FITC, we then performed an ex vivo villus 
adhesion assay on scraped villi from porcine jejunum. We found that RGDSK-HRNs-FITC 
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prevented E. coli F4 from adhering to porcine jejunum villi. However, one unanticipated finding 
was that RGDSK-HRNs-FITC were less efficient than RGDSK-FITC peptide and monoclonal an-
tibody anti-integrin αvβ3 on preventing E. coli F4 binding to villi until 24 hours. The implication 
of this result is the possibility that some RGDSK-HRNs-FITC have some RGDSK bound to integ-
rin αvβ3 on the epithelium and some RGDSK bound to the integrin αvβ3-like protein on E. coli, 
leading to the observation that E. coli F4 is likely adhering to the epithelium as seen at 24 hours 
RGDSK-HRNs-FITC incubation treatment. The E. coli F4 clumps in binding to the RGDSK-
HRNs-FITC imply the next step about adding another type of functionalized group, such as an 
anti-F4 antibody or anti-integrin αvβ3 antibody, or antibiotic, on the surface of the tube in the 
future. This potential treatment can increase the efficiency of the antibiotic in targeting bacteria, 
reducing the emergence of bacterial resistance. 
Another exciting aspect of the data from our villus adhesion assay is the effect of 
RGDSK-FITC peptides and the monoclonal antibody anti-integrin αvβ3 treatment groups. There 
was clear evidence that the RGDSK-FITC peptides and the monoclonal anti-integrin αvβ3 anti-
body remained effective in significantly inhibiting the E. coli binding to villi up to 24 hours, 
whether the F4 receptor was present or not. These findings contributed to our understanding of the 
involvement of integrin αvβ3 in the attachment of E. coli to villi and to account for situations 
where F4 may not have accounted for all of the bindings of E. coli. 
Our ex vivo villus adhesion assay data showed that RGDSK-HRNs could block E. coli 
adhesion to F4R-positive porcine jejunum villi. Interestingly, results showed that after 12 hours, 
the number of viable E. coli exposed to RGDSK was significantly lower than that in the media 
treated E. coli group (P<0.05). After 24 hours, either RGDSK or serum anti-F4 antibody signifi-
cantly reduced the E. coli colonies in the supernatant, compared with E. coli control group 
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(P<0.05). The higher number of survival E. coli left in the supernatant in this experiment suggests 
that RGDSK-HRNs do not affect the growth of E. coli in LB agar as RGDSK peptide or serum 
anti-F4 antibody, expected low toxic and not to increase the endotoxin from dead E. coli. In 2017, 
Coddens and colleagues reported that cranberry extract inhibited F4ac+E. coli adhering to porcine 
jejunal villi (43). A separate incubation cranberry extract with E. coli showed that the cranberry 
extract did not influence the viability of E. coli (43). However, these authors did not mention the 
E. coli left in the supernatant in the villus adhesion assay (43). 
In conclusion, the purpose of our current study was to investigate the functions of the 
RGDSK sequence and the vehicle of HRNs in blocking the attachment of E. coli F4 to the intestinal 
epithelium in vitro. We found that integrin αvβ3 can be a receptor for E. coli F4 to adhere to the 
porcine intestinal epithelium. Secondly, the data showed that blocking integrin αvβ3 by RGDSK 
peptide-functionalized HRNs can inhibit E. coli F4 adherence to the epithelium. This report has 
provided a more in-depth insight into the mechanism of bacterial colonization. Further work is 
required to establish the therapeutic efficiency of RGDSK-HRNs-FITC and the role of integrin 
αvβ3 with other complicated factors, such as vitronectin and F4 receptor in vivo, for developing 
new interventions for intestinal diseases. 
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CHAPTER 6. THE EFFECT OF RGDSK-HRNs-FITC EXPOSURE ON THE APOPTO-
SIS AND SURVIVAL OF IPEC1 UPON E. COLI INFECTION 
Scientists have found that blocking integrin αvβ3 by a peptide or an antibody antagonist 
can up-regulate endothelium apoptosis, preventing angiogenesis. In the previous chapter, we found 
that RGDSK-HRNs declined the attachment of E. coli F4 to IPEC1 and porcine jejunal villi but 
did not decrease E. coli K88 growth in LB agar. Therefore, in this chapter, we continued exploring 
the effect of RGDSK-HRNs exposure on apoptosis and survival of IPEC1 upon E. coli F4 infec-
tion. 
6.1. ABSTRACT 
In this report, we provide data on the investigation of the effect of RGDSK-HRNs expo-
sure on the apoptosis and survival of the intestinal epithelium cell line (IPEC1) upon E. coli infec-
tion. We challenged IPEC1 with RGDSK-HRNs or other control treatments before exposure with 
E. coli. Then we performed western bot and flow cytometry analysis. Flow cytometry data showed 
that the Staurosporine-treated control but not those treated with RGDSK-HRNs increased dead 
cells significantly. Interestingly, RGDSK-HRNs improved IPEC1 cell survival upon E. coli infec-
tion compared with E. coli infection alone group (P<0.05). Western blot results showed that 
RGDSK-HRNs-FITC treatment significantly decreased the level of p-p53 compared with mono-
clonal anti-integrin αvβ3 antibody treatment in E. coli infection, and the level of p-p38MAPK 
compared with RGDSK-FITC group in E. coli infection (P<0.05). In conclusion, these are the first 
data reported that RGDSK-HRNs reduced the apoptosis of IPEC1 upon E. coli infection to main-
tain their survival. 




Integrin αvβ3 is involved in the processes of angiogenesis, osteoporosis, migration, sur-
vival, differentiation, and proliferation of the cell (155, 159, 193, 220). These vital functions are 
related to normal cellular physiology and mechanisms of disease (155, 193). Besides that, antago-
nists of integrin αvβ3, such as RGD peptide sequence induced apoptosis while agonists reduced 
cell death.  
For example, in 1994, Brooks and colleagues highlighted that the blockage of integrin 
αvβ3 by an RGD peptide or an antibody upregulated endothelial apoptosis and inhibited angio-
genesis (28). Conversely, in 2003, Morozevich and colleagues mentioned that activated integrin 
αvβ3 expression up-regulated anoikis, known as extracellular matrix-dependent apoptosis (159). 
Vice versa, inhibition of integrin αvβ3 prevented this type of apoptosis (159). These scientists also 
reported that antisense oligonucleotide down-regulated the apoptosis rate of human intestinal car-
cinoma Caco-2 cells compared with untreated controls (159). These findings imply that the integ-
rins-related apoptosis mechanism depends on cell type, nature of apoptosis-inducing signals, and 
other molecular mechanisms (152). 
Currently, there are no data on the role of integrin αvβ3 in the porcine intestinal apoptosis 
and survival. Considering the implication of apoptosis, the maintenance of the integrity of intesti-
nal epithelium in bacterial infections, we tested the hypothesis that RGDSK-HRNs enhanced the 







6.3. MATERIALS AND METHODS 
6.3.1. Materials 
Novel HRNs, which were designed and provided by the lab of Professor Hicham Fenniri 
at the Department of Chemical Engineering, the College of Engineering, Northeastern University, 
Boston, USA (39, 63, 64). E. coli F4 strain EC52, serotype O101:K30+:K99-: F4+ and IPEC1 
were gifts from Dr. Francois Meurens and Dr. Heather L. Wilson at the Vaccine and Infectious 
Disease Organization-International Vaccine Centre (VIDO-InterVac). IPEC1 cells were devel-
oped from the jejunum of unsuckled, mixed-bred piglets less than 12 hours old (85). IPEC1 cells 
were cultured in 75 cm2 flask in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 at 
37ºC in a humidified 5% CO2 incubator (84, 126). RGDSK-FITC (American peptide company, 
Sunnyvale, CA., USA.), and CFTM488A-Annexin V (AnV) and Propidium Iodide (PI) Apoptosis 
Kit (Biotium, Hayward, CA., USA.)  were purchased commercially. 
6.3.2. Preparing E. coli 
E. coli strain EC52, serotype O101:K30+:K99-: F4+, having pFPV::tdTomato fluores-
cence protein, was cultured for 18 hours on Luria broth supplemented with ampicillin. The con-
centration of bacteria was determined by adjusting the optical density at 620nm (OD620) to 1 to 
achieve 4x109 CFU/ml as determined by prior CFU counting. E. coli was centrifuged at 16,200 xg 
for 5 minutes, followed by three washes in 0.1M PBS supplemented with ampicillin at pH=7.4. 
Serial dilution was done to reach the desired concentration of the bacteria for the assay later ac-





6.3.3. Preparing RGDSK-HRNs-FITC 
TBL/TB- RGDSK is a twin G∧C – based rosette nanotubes (RNTs) functionalized with 
arginine-glycine-aspartic acid-serine-lysine (RGDSK) peptide sequence which can bind integrin 
αvβ3. Another TBL/TB-FITC is a fluorescein isothiocyanate (FITC) conjugated twin G∧C – based 
rosette nanotubes (RNTs). TBL/TB-FITC and TBL/TB-RGDSK in 1:10 molar ratio of FITC and 
RGDSK were mixed to yield the composite of RGDSK and FITC functionalized helical rosette 
nanotubes (RGDSK-HRNs-FITC). This nanomaterial is a more stable self-assemble HRNs ex-
pressing RGDSK and is visualized by fluorescence microscopy (39, 225). The suspension was 
sonicated for 5 minutes in sonicating water bath following by 30-second vortex and one-minute 
heating. The mixture was placed at room temperature in the dark for 48 hours to allow for the 
synthesis of the RGDSK-HRNs-FITC. The RGDSK-HRNs-FITC stock was stored at 4oC for fu-
ture treatment. RGDSK-HRNs-FITC were diluted in an appropriate dilution buffer (0.1M PBS or 
DMEM/F12) at preferring molar concentration regarding the equivalent RGDSK on the surface of 
HRNs. 
6.3.4. Apoptosis analysis by flow cytometry  
Apoptosis was confirmed using CFTM488A-Annexin V (AnV) and Propidium Iodide (PI) 
Apoptosis Kit (Biotium, Hayward, CA., USA.) according to the manufacturer’s instructions. 
Briefly, for examining the effect of RGDSK-HRNs on the apoptosis of IPEC1, 1x106 IPEC1 cells 
were exposed to RGDSK-HRNs (containing equivalent 5µM RGDSK) in 5 hours, 12 hours, and 
24 hours. Positive and negative controls for apoptosis were 5µM TBL making HRNs without pep-
tide conjugation, or 5µM RGDS peptide, or 0.5 µM Staurosporine. IPEC1 cells were harvested by 
trypsin EDTA, then were washed in 0.1M PBS, followed in working buffer. 
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For examining the effect of RGDSK-HRNs in association with E. coli infection on the 
apoptosis of IPEC1, 1x106 IPEC1 cells were exposed to RGDSK-HRNs (containing equivalent 
5µM RGDSK) in 15 minutes. Positive and negative controls for apoptosis were 5µM TBL making 
HRNs without peptide conjugation, or 5µM RGDS peptide, or monoclonal integrin αvβ3 antibody 
(25 µg/ml). Then cells were challenged with 1x107 E. coli CFU/ml at 37oC in a humidified 5% 
CO2 incubator in 1 hour, 5 hours, and 24 hours. Staurosporine (0.5 µM) was used as a positive 
control for apoptosis. IPEC1 cells were harvested by trypsin EDTA then were washed in 1X PBS, 
followed by a working buffer from the kit. 
After that, all cells were stained with five µl CFTM488A-Annexin V (AnV) and two µl 
propidium iodide (PI) in 15 minutes in the dark. Untreated cells stained with CFTM488A-Annexin 
V or PI dye alone are single stained compensation controls. Flow cytometry data were analyzed 
using CyFlow®Space flow cytometer (Partec, Swedesboro, NJ, USA) with commercial FlowMax 
Software © version 2.6 (Quantum Analysis GmbH, Münster, Germany). The gated population was 
determined with unstained cells based on size (forward scatter) and granularity (side scatter).  Data 
were acquired on at least 10,000 gated counts. 
6.3.5. Apoptosis analysis by western blot p-akt1, p-p38MAPK, and p-p53  
IPEC1 at 1x106 cells concentration were seeded into 25 cm2 flask. After being confluent 
overnight, cells were challenged at 24 hours with seven treatments at final concentration as fol-
lowing: (1) DMEM/F12 medium without serum, (2) 1 x 108 E. coli F4, (3) 1 µM TBL and 1 x 108 
E. coli F4, (4) RGDSK-HRNs-FITC (equivalent 1 µM RGDSK) and 1 x 108 E. coli F4, (5) 1 µM 
RGDSK-FITC and 1 x 108 E. coli F4, (6) 5 µg/ml monoclonal anti-integrin αvβ3 antibody and 108 
E. coli F4, and (7) 0.5 µM Staurosporine. The supernatant in this experiment was collected and 
stored at -80ºC for future use. Cell lysis procedures were followed as per manufacturer protocols 
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(Bio-rad, Mississauga, ON, Canada). Briefly, the treatment reaction was stopped by adding ice-
cold wash buffer to the cells. Samples were homogenized by adding lysing solution. The protein 
concentrations of samples were measured by using detergent compatible Bradford protein assay 
kit (Bio-rad, Mississauga, ON, Canada). The samples were diluted to have the same protein con-
centration to have the same amount of total protein for western blot. 
The western blot procedure was appropriately modified from a previous protocol (105). 
We first probed for mouse monoclonal antibody anti-p-p53 (1:200) and polyclonal goat anti-mouse 
immunoglobulins (1:20,000, Dako) (n = 3 each group). Incubation without primary antibody 
served as a negative control. The detection blots were performed with Amersham ECL western 
blotting detection reagents kit (GE Healthcare, Freiburg, Germany). Finally, the membranes were 
scanned using Bio-rad ChemiDoc MP Imaging system scanner and Imagelab 5.2.1 software (Bio-
rad, Mississauga, ON, Canada). For detecting p-akt1, p-p38MAPK, beta-actin, the probed mem-
branes were stripped with blot restore membrane rejuvenation kit (Millipore, Billerica, MA, USA) 
before being re-probed with another primary and appropriate secondary antibody. Densitometric 
quantification was performed using Imagelab 5.2.1 software (Bio-rad, Mississauga, ON, Canada) 
to evaluate the relative density of p-p53, p-akt1, and p-p38MAPK adjusted to beta-actin in all 
groups compared with loading control. 
6.3.6. Statistical analysis 
We used the GraphPad Prism version 5.04 software (San Diego, CA, USA.) to analyse 
data. Quantitative results were expressed as mean ± SEM, and error bars represented standard 
error. The normal distribution of residuals was tested by histogram and Shapiro-Wilk test. Data 
were analyzed by Analysis Of Variance (ANOVA), followed by Bonferroni multiple comparison 
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test. A significant difference was set when the critical value of α was below or equal to 0.05 as 
(two-tailed, p<0.05). 
6.4. RESULTS 
6.4.1. RGDSK-HRNs did not induce IPEC1 apoptosis significantly but enhanced the sur-
vival of IPEC1 upon E. coli infection 
To examine the cytotoxicity of RGDSK-HRNs to the intestinal cell, we challenged 
IPEC1 with RGDSK-HRNs. Treatment controls included RGDS peptide only, TBL nanotube 
without RGDSK functional groups, Staurosporine positive control for apoptosis. After 5, 12, and 
24 hours, we stained the IPEC1 with AnV and PI. Flow cytometry data showed that Staurosporine 
exposure for 5 hours significantly increased both early and late apoptosis of IPEC1, thus confirm-
ing the validity of the control (Figure 6.1A, and 6.1B, respectively). TBL, which is nanotubes 
without conjugate RGDSK functional groups, did not affect cell survival compared with untreated 
controls. RGDS peptide and RGDSK-HRNs modestly increased cell apoptosis compared to the 
untreated group at respective time points (Figure 6.1A, B). These results highlighted the role of 
the RGDSK peptide functional group associated with the nanotubes vehicle in early apoptosis and 
cell death.  
We then examined the effect of RGDSK-HRNs exposure on the survival of IPEC1 upon 
E. coli F4 infection. We pre-challenged IPEC1 with RGDSK-HRNs, RGDS, TBL 15 minutes be-
fore exposing IPEC1 with E. coli F4 for 1 or 5 hours. Staurosporine was used again as a positive 
treatment control for apoptosis. Then, we stained the intestinal cell with AnV and PI. Flow cytom-
etry results showed that compared with E. coli F4 infection group, RGDSK-HRNs improved E. 
coli F4 infected IPEC1 cell survival (Figure 6.1C). Five – hour staurosporine exposure 
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significantly increased cell death. TBL control group for nanotubes without conjugate RGDSK 







Figure 6.1. RGDSK-HRNs slightly induced IPEC1 apoptosis but enhanced the survival of IPEC1 
upon E. coli infection using flow cytometry analysis.  
Comparing to untreated IPEC1 at the respective time point, RGDSK-HRNs and RGDS peptide did 
not induce early (A) and late (B) apoptosis significantly. (C) Comparing to E. coli F4 treated 
group, RGDSK-HRNs improved the survival of IPEC1 upon E. coli F4 infection. Data were ex-
pressed as mean ± SEM. Error bars indicated SEM. An asterisk (*) indicated a significant differ-




6.4.2. RGDSK-HRNs-FITC could decrease the apoptotic process of E. coli F4 infected 
IPEC1 
Our results showed that at the 24-hour timepoint, the level of p-akt1 was significantly 
lower in cells treated with E. coli F4, TBL+E. coli F4, integrin αvβ3 antibody + E. coli F4, and 
staurosporine compared to the medium alone control (P<0.05). Integrin αvβ3 antibody + E. coli 
F4 group had the highest level of p-p53, and significantly higher than that of RGDSK-HRNs-FITC 
+ E. coli F4 (P<0.05). RGDSK-FITC peptide + E. coli F4 had the highest level of p- p38MAPK, 
and significantly higher than RGDSK-HRNs-FITC + E. coli F4 (P<0.05). There was no significant 
difference between RGDSK-HRNs-FITC + E. coli F4 and medium control group regarding the 





Figure 6.2. Western blots for IPEC1 apoptosis 
(A) Western blots for p-akt1 (60 kDa), p-p53 (53 kDa), p-p38MAPK (43 kDa), and beta–actin (47 
kDa, a housekeeping gene protein) were performed on IPEC1 upon six treatments and medium 
control after 24 hours. (B) The densitometric analyses showed the adjust intensity to beta-actin. 
Normal IPEC1 cell line in medium had highest level of p-akt1. E. coli infection inhibited p-akt1, 
and increased the level of p-p38MAPK compared with normal IPEC1 cell control (P<0.05). 
RGDSK-FITC peptide + E. coli F4 group had higher level of p- p38MAPK than RGDSK-HRNs-
FITC + E. coli (P<0.05). There was no significant difference between RGDSK-HRNs-FITC + E. 
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coli groups and medium control groups regarding the level of p-akt1, p-p53, p-p38MAPK. Data 
were expressed as mean ± SEM. Asterisk (*) indicates a significant difference between groups 




It is known that the mechanism of integrins-related apoptosis is involved in cell type-
specific, and apoptosis-inducing signals (152, 159). For example, antagonism of integrin αvβ3 by 
a peptide or an antibody can up-regulate endothelial apoptosis and prevent angiogenesis (28). In 
reviewing the literature, no data was found on the association between RGDSK-HRNs-FITC and 
the apoptosis of intestinal epithelium through integrin αvβ3. Hence, this is the first study on the 
cytotoxicity of RGDSK-HRNs-FITC on the intestinal epithelium by exploring the effect of 
RGDSK-HRNs-FITC exposure on the apoptosis and survival of IPEC1 upon E. coli F4 infection.  
We found that RGDSK-HRNs-FITC enhanced the survival of E. coli F4 infected IPEC1 
compared with E. coli F4 challenged group. The flow cytometry analysis results from Annexin V 
and PI staining on IPEC1 in this chapter were consistent with the previous data of the survival E. 
coli F4 left in the supernatant. The higher number of surviving E. coli F4 left in the supernatant 
suggested that RGDSK-HRNs-FITC has low toxicity to the E. coli, and therefore do not increase 
the levels of endotoxin released from the dead E. coli F4. These data again support that RGDSK-
HRNs-FITC are biocompatible to the cells (39, 223). 
Several reports have noted that integrins stimulate survival signals via phosphoinositide 
(PI) 3 kinase or mitogen-activated protein kinase (MAPK) pathway. The absence of integrin can 
activate p53 or jun N- terminal kinase (JNK) death signals, and downregulates Bcl-2 expression 
and function of the endothelium (152). Akt, named as PKB, or Rac, supports cell growth and 
prevents the apoptosis (67, 272). Therefore, in this study, we examined IPEC1 apoptosis pathway 
through the phosphorylation of p53, p38MAPK, and akt1. We performed Western blot followed 
by densitometry quantification for the level of their phosphorylation in IPEC1 cell lysate. Our 
results showed that at the 24-hour timepoint, E. coli F4 infection increased the apoptosis of 
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intestinal porcine epithelium cell line 1 through phosphorylating both p53 and p38MAPK and 
inhibiting p-akt1. Similarly, staurosporine, an apoptosis inducer, inhibited p-akt1 and activated p-
p53 and p-p38MAPK. Interestingly, blocking integrin αvβ3 by anti-integrin αvβ3 antibody inhib-
ited the phosphorylation of p-38MAPK and akt1. This inhibition led to the apoptosis of intestinal 
epithelium through activating p53 phosphorylation. Compared with RGDSK-FITC peptide, and 
staurosporine, RGDSK-HRNs-FITC decreased the apoptotic process of the intestinal porcine epi-
thelium in E. coli F4 infection. Other scientists also reported that K/RGDSK-RNTs inhibited the 
phosphorylation of ERK1/2 and p38 MAPK, consequently reducing the migration of bovine neu-
trophils (134). However, K10/RGDSK1-HRNs induce inflammation and apoptosis in human 
bronchial epithelial adenocarcinoma cells by enhancing cell death genes, p38 mitogen-activated 
protein kinase (MAPK) phosphorylation, caspase-3 activity, and DNA fragmentation (226). It sug-
gests that the effect of the RGDSK peptide functional group on HRNs may depend on the cell type 
and in combination with other functional groups. 
In summary, in our study, RGDSK-HRNs-FITC slightly induced IPEC1 apoptosis com-
pared to a normal control without treatment but enhanced the survival of IPEC1 upon E. coli F4 
infection compared to E. coli infected group. This result highlighted that the HRNs conjugated to 
RGDSK peptide functional group were not toxic to the intestinal cells. An in vivo study is required 
to continue investigating the molecular pathway of the effects of RGDSK-HRNs in the intestinal 
immune response to E. coli. 
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CHAPTER 7. THE EFFECT OF RGDSK-HRNs ON E. COLI F4 INFECTION IN A POR-
CINE GUT LOOP MODEL 
In vitro experiments in previous chapters suggested that integrin αvβ3 played a role in E. 
coli binding to the jejunal epithelium and RGDSK-HRNs could reduce the binding. In this chapter, 
we performed an in vivo porcine gut loop model, developed in Dr. Volker Gerdts’s laboratory in 
VIDO, to have a deeper understanding of the effects of RGDSK-HRNs on E. coli infection,  
7.1. ABSTRACT 
Intestinal diseases and foodborne illness, particularly due to E. coli infection, cause many 
deaths and economic losses worldwide. Integrin αvβ3 protein has important functions in cell ad-
hesion, signalling, and survival. Integrin αvβ3 acts as an adhesion and entry receptor for some of 
the bacteria and viruses. However, the expression and role of integrin αvβ3 in the adhesion of E. 
coli to the porcine jejunum epithelium is not known, and also unknown is the effect on the gener-
ation of the immune response in the gut epithelium. We used an in vivo porcine gut loop model to 
study the role of integrin αvβ3 in interactions of E. coli F4 with the gut epithelium.  
Immunohistochemistry showed normal porcine jejuna strongly expressed integrin αvβ3 
in the nucleus and the apical surface of epithelia as well as crypts. The expression of integrin 
αvβ3 decreased in the epithelium but increased in the vascular endothelium of the jejunum in-
fected with E. coli or E. coli associated with Salmonella (P<0.05). In the in vivo porcine gut loop 
model, the number of E. coli F4 binding to villi were significantly decreased in the E. coli F4 
treated with RGDSK-HRNs-FITC group compared with E. coli F4 treatment group (P<0.05). 
The number of live E. coli F4 significantly decreased in RGDSK-FITC peptide treatment group 
(P<0.05), but not RGDSK-HRNs-FITC treatment group. TUNEL assay showed no significant 
difference in DNA fragmentation in the RGDSK-HRNs-FITC treatment group compared to 
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normal control group. Immunogold electron microscope confirmed the presence of the gold par-
ticle positive staining with integrin αvβ3 on the porcine jejunal epithelium and E. coli F4. 
In conclusion, these are the first data to show the expression of integrin αvβ3 on the 
intestinal epithelium infected with E. coli F4, and that novel RGDSK-HRNs-FITC intervention 
can inhibit the attachment of E. coli F4 to the porcine villi without affecting the viability of the 
epithelial cells. 
Key Words: integrin αvβ3, nanotubes, porcine villi, E. coli 
7.2. INTRODUCTION 
E. coli infection outbreaks, mainly associated with food poisoning, edema, and persistent 
diarrhea with a high mortality rate, have occurred both in developing and industrialized countries 
(34, 35, 185). E. coli F4 causes neonatal and post-weaning diarrhea (69). Prevention of the disease 
caused by E. coli F4 is challenging due to its multiple virulence factors (271). One of the strategies 
being pursued is to reduce the colonization of the intestine by E. coli F4 (34, 35, 185, 247).  
Integrin αvβ3 belongs to the integrins family of adhesion and signalling receptors. This 
heterodimeric glycoprotein, comprising of α and β subunits, recognizes and binds arginine-gly-
cine-aspartic acid (RGD) sequences (159, 220). It was initially identified as the protein that drives 
angiogenesis in melanoma, and over the years, a much broader array of functions has been at-
tributed to this integrin. The integrin αvβ3 is blocked by RGD peptide resulting in the inhibition 
of angiogenesis and an increase in apoptosis as a potential cancer treatment (152, 228). However, 
the detailed mechanisms have not been elucidated. 
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Some studies show potential applications for nanotechnology in textiles, electronics, 
food, medicine, and environmental remediation (44, 142, 207, 235). The novel water-soluble hel-
ical rosette nanotubes (HRNs), invented by Dr. Fenniri,  have no adverse effects on the respiratory 
system in an in vivo murine model, and are not toxic to cells in vitro (112). Recent in vivo study 
illustrated that HRNs conjugated RGDSK peptide on its surface played an important role in acute 
lung inflammation (225). K90/RGDSK10-HRNs enhances an excessive immune response through 
up-regulating p38MAPK cascade in an endotoxin lipopolysaccharide (LPS) induced lung injury 
murine model (225). Interestingly, RGDSK-HRNs inhibited bovine neutrophil migration in vitro 
(134). 
This study was focused on understanding whether RGDSK-HRNs-FITC can be a new 
molecular intervention to reduce the colocalization of intestinal epithelium by E. coli F4 and to 
reduce intestinal disease. In addition to in vitro experiments above, we continued studying such in 
vivo using the superior and innovative porcine intestinal loop model, which can be applied for 
humans (153). The porcine loop model has fundamentally changed the way we can study gut im-
mune responses. In this model, the porcine gut is surgically divided into multiple loops that still 
have blood supply. Therefore, multiple treatments can be done within the same animal, thereby 
reducing the response variation due to inter-animal variation  (51, 78, 153). I hypothesize that 
RGDSK-HRNs inhibit E. coli attachment to the mucosal membrane in vivo. 
7.3. MATERIALS AND METHODS 
7.3.1. Materials 
Jejunum paraffin blocks from healthy, or E. coli, or E. coli - Salmonella infected pigs 
(n=3 each) were kindly provided from professor John Harding’s lab and Prairie Diagnostic 
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Services Inc. (PDS), respectively, at the Western College of Veterinary Medicine, the University 
of Saskatchewan. 
Novel HRNs, which was designed as a previous procedure, was kindly provided by the 
laboratory of Professor Hicham Fenniri at the Department of Chemical Engineering, the College 
of Engineering, Northeastern University, Boston, USA (39, 63, 64). E. coli F4 strain EC52 sero-
type O101:K30+:K99-: F4+ was a gift from Dr. Francois Meurens and Dr. Heather L. Wilson at 
the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac). 
Mouse monoclonal anti-F4 antibody (IMM01) was a generous gift from Dr. Eric Cox (Laboratory 
of Immunology, Faculty of Veterinary Medicine, Gent University, Belgium). Mouse monoclonal 
anti-integrin αvβ3 antibody (clone LM609, Chemicon Inc., Temecula, USA), RGDSK-FITC 
(American peptide company, Sunnyvale, CA 94086, USA), in-situ cell death detection kit-Alka-
line-phosphatase (AP) version 11.0 (Roche, Mannheim, Germany), proteinase K (Sigma-Aldrich, 
Ontario, Canada), Vector® VIP peroxidase substrate kit for peroxidase (Vector Laboratories, 
Burlingame, CA, USA), were purchased commercially. 
7.3.2. Immunohistochemical staining integrin αvβ3 for porcine jejuna. 
Paraffin blocks were sectioned at 5µm thickness for immunohistochemical staining fol-
lowing a previous protocol (213). Briefly, sections were deparaffinized, followed by quenching 
the endogenous peroxidase activity and treatment with pepsin. Following two hours blocking with 
1% BSA, the sections were incubated with monoclonal anti-integrin αvβ3 antibody (clone LM609, 
Chemicon Inc., Temecula, USA) and appropriate polyclonal anti-mouse immunoglobulins/HRP 
secondary antibody. Vector® VIP peroxidase substrate kit was used to develop the positive color 
reaction. Sections stained with the anti-endothelial marker vWF served as a positive control. 
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Sections stained with isotype antibody matching control (mouse IgG1) instead of primary antibody 
or the omission of the primary antibody served as negative controls. 
7.3.3. Immuno-gold electron microscopy for integrin αvβ3 
Porcine jejuna in LR white resin were sectioned at 100nm thickness on nickel grids. The 
non-specific bindings were blocked by BSA 1% in Tris-buffered saline before one-hour incubation 
in the integrin αvβ3 antibody (50µg/ml). Section stained without primary antibody served as a 
negative control. 
After three washes in Tris-buffered saline, the sections were incubated for one hour in a 
15 nm gold-conjugated anti-mouse secondary antibody (1:100). Aqueous uranyl acetate served as 
an indicator of negative staining. Besides, we used Reynold’s lead citrate to enhance the electron-
scattering properties of biological components inside the cells. The electron micrographs were 
imaged using a transmission electron microscope (Hitachi HT7700 - XFlash 6T160, Germany) 
operated at 80KV. 
7.3.4. Preparing E. coli 
E. coli strain EC52, serotype O101:K30+:K99-: F4+, having pFPV::tdTomato fluores-
cence protein, was cultured for 18 hours on Luria broth supplemented with ampicillin. The con-
centration of bacteria was determined by adjusting the optical density at 620nm (OD620) to 1 to 
achieve 4x109 CFU/ml as determined by prior CFU counting. E. coli was centrifuged at 16,200 xg 
for 5 minutes, followed by three washes in 0.1M PBS supplemented with ampicillin at pH=7.4. 
Serial dilution was done to reach the desired concentration of the bacteria for the assay later ac-




7.3.5. Preparing RGDSK-HRNs-FITC 
TBL/TB- RGDSK is a twin G∧C – based rosette nanotubes (RNTs) functionalized with 
arginine-glycine-aspartic acid-serine-lysine (RGDSK) peptide sequence which can bind integrin 
αvβ3. The TBL/TB-FITC is a fluorescein isothiocyanate (FITC) conjugated twin G∧C – based 
rosette nanotubes (RNTs). TBL/TB-FITC and TBL/TB-RGDSK in 1:5 molar ratio of FITC and 
RGDSK were mixed to yield the composite of RGDSK and FITC functionalized helical rosette 
nanotubes (RGDSK-HRNs-FITC). This nanomaterial is a more stable self-assembly HRNs ex-
pressing RGDSK on the surface and being visualized by fluorescence (39, 225). The suspension 
was sonicated for 5 minutes in sonicating water bath following by 30-second vortex and one-
minute heating. The mixture was placed at room temperature in the dark for 48 hours to allow for 
the synthesis of the RGDSK-HRNs-FITC. The RGDSK-HRNs-FITC stock was stored in 4oC for 
future treatment. RGDSK-HRNs-FITC was diluted in an appropriate dilution buffer (0.1M PBS 
or DMEM/F12) at preferring molar concentration regarding the equivalent RGDSK on the surface 
of HRNs. 
7.3.6. In vitro integrin αvβ3 antibody binding assay 
In vitro integrin αvβ3 antibody binding assay was again modified from previous proto-
cols (27, 149) to examine whether E. coli has the integrin αvβ3-like protein domain. In brief, 96-
well high binding plates were precoated overnight with 50µl of 5µg/ml mouse monoclonal integ-
rin αvβ3 antibody (clone LM609, EMD Chemicon Inc., Temecula, USA.) in 100 mM 
HCO3¯/CO3
2¯ coating buffer. To examine the function of the integrin αvβ3-like protein domain 
on E. coli, before adding to the monoclonal integrin αvβ3 antibody-coated wells, E. coli 
(5x107/ml) was treated with 6 different treatments (1) PBS control, (2) 1 µM TBL, (3) RGDSK-
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HRNs-FITC (equivalent 1 µM RGDSK), (4) 1 µM RGDSK-FITC, (5) 5 µg/ml monoclonal 
integrin αvβ3 antibody, (6) RGDSK-HRNs-FITC (equivalent 1 µM RGDSK) and 5 µg/ml mono-
clonal antibody anti-F4. After a one-hour incubation, non-adhered E. coli was removed by rins-
ing with 0.1M PBS ampicillin. Bound E. coli on the bottom of the 96-well plate was fixed in 2% 
paraformaldehyde. pFPV::tdTomato fluorescence from bound E. coli was measured at 530nm 
excitation /570nm emission in POLAR Start OPTIMA microplate fluorescence reader. Fluores-
cence intensity was adjusted with the background fluorescence of the wells without adding E. 
coli F4. The experiment was repeated four times. 
7.3.7. Porcine gut loop model surgery 
All experiments were approved by the University of Saskatchewan’s Animal Research 
Ethics Board & adhered to the Canadian Council on Animal Care guidelines for animal use in 
research. To explore the function of integrin αvβ3 in E. coli F4 binding in addition to the F4 re-
ceptor (F4R), we used F4 receptor-positive (F4R+) piglets. Five of three to four-week-old F4R(+) 
piglets were housed at VIDO-InterVac animal facility and were allowed to acclimatize one week 
before treatment. All pigs were injected ketamine (20 mg/kg) and xylazine (2 mg/kg) intramuscu-
larly (im.) to induce anesthesia. Isoflurane was used for maintaining anesthesia for the duration of 
surgery. 
In brief, multiple intestinal loops providing identical, and independent sites for at least 
four weeks for analyzing a variety of antigen uptake and mucosal immune responses were created 
as described before (78, 153).  A jejunal segment was isolated and subdivided into 14-16 loops (5 
cm/loop), and each separated by an interspace to prevent inter loop contamination (Figure 7.1). 
The number of loops in each animal depends on the individual pig's gastrointestinal conformation. 
All loops were identical and were assigned to 1ml of seven different treatment groups. 
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Experimental maps were designed to identify treatment and control loops. The experimental de-
sign for each pig is listed below (Sample size n = 10 loops /group). 
• Loop 1 (group 1 for normal control loop): inject 1 ml of 0.1M phosphate-buffered saline 
(PBS) with 15 mg ampicillin. 
• Loop 2 (group 2 for E. coli infected loop): inject 1ml of 5x107 E. coli F4 in 0.1M PBS 15 mg 
ampicillin. 
• Loop 3 (group 3): inject 1 ml of 5µM TBL-FITC and 5x107 E. coli F4 in 0.1M PBS 15 mg 
ampicillin. Note: this group has the same nanotubes but unconjugated RGDSK peptide. 
• Loop 4 (group 4): inject 1 ml of the mixture of RGDSK-HRNs-FITC (equivalent 5µM 
RGDSK) and 2 µg antibody anti F4, 5x107 E. coli F4 in 0.1M PBS 15 mg ampicillin. 
• Loop 5 (group 5 for testing F4 receptor control): inject 1 ml of the mixture of 2 µg antibody 
anti F4 and 5x107 E. coli F4 in 0.1M PBS 15 mg ampicillin. 
• Loop 6 (group 6 for testing the function of RGDSK-FITC peptide): inject 1 ml of 5µM 
RGDSK-FITC peptide and 5x107 E. coli F4 in 0.1M PBS 15 mg ampicillin. 
• Loop 7 (group 7 for testing function of RGDSK-HRNs-FITC): inject 1 ml of RGDSK-HRNs-
FITC (equivalent 5µM RGDSK) and 5x107 E. coli F4 in 0.1M PBS 15 mg ampicillin to inhibit 
bacterial overgrowth by existing intestinal flora. Note: FITC is a biologically inactive 
fluorescent tag. 
Experiments were in duplicate for each treatment group on the remaining loops in each 
piglet. Continuity of the intestinal system is re-established by end-to-end anastomosis. The intes-
tine was returned to the abdominal cavity, which was then closed in three layers. All pigs were 
administered flunixin meglumine post-surgically.  After four hours, the piglets were euthanized. 
125 
 
Each loop was injected 1ml of 0.1M PBS ampicillin to remove E. coli F4 not bound to the villi 
and to collect the content inside the loop. All pigs were clinically examined before and after sur-
gery. Plasma and serum were also collected before surgery and before euthanasia to confirm the 
normal status of the animal and no cross-contamination from blood circulation later. Blood in 
EDTA was analysed for total and differential leukocyte count. The segment of loops and their 
contents, the associated mesenteric lymph node, and lungs were collected. Each jejunal loop was 
subdivided into four parts: 
• The first segment (1cm) was opened and transferred to cold Krebs-Henseleit buffer (120mM 
NaCl, 14 mM KCl, 25mM NaHCO3, 1 mM KH2PO4) with 1% formaldehyde to stop E. coli 
binding. 
• The second one (1cm) was fixed in 4% paraformaldehyde and processed for paraffin embed-
ding.  
• The third one was fixed in 4% paraformaldehyde, and processed for OCT embedding. 
• The fourth one was fixed in 2% paraformaldehyde 0.1% glutaraldehyde in 0.1M sodium cac-
odylate buffer for immune-gold staining later 





Figure 7.1. Porcine gut loop model 
Multiple intestinal loops providing identical and independent sites were created (A). We treated 
E. coli F4 with six different treatments and injected them into the jejunal loops as described below 
(B, C). After four hours, the piglets were euthanized to collect samples (D). Each loop was injected 
1ml of 0.1M PBS ampicillin to remove E. coli not bound to the villi gently and to collect the content 




7.3.8. Enumerating the number of E. coli binding to jejunal villi  
Subsequently, villi from the first segment were gently scraped with a slide and allowed 
to settle at the bottom of the tube. After that, the number of bacteria adhering to 250 μm of the 
brush border of villi was quantified under a phase-contrast microscope at 1000× magnification. 
Five different regions were counted, and data were presented as the average number of bacteria 
adhering to 250 μm of the brush border. Statistical analysis was done to evaluate the invasion of 
E. coli F4 to jejunal loop after different treatments. 
The second segment from each jejunal loop embedded in paraffin was sectioned at 5 µm 
thickness. All sections were placed on poly-l-lysine coated glass slides and stained with hematox-
ylin and eosin for histopathological examination. 
7.3.9. Counting the number of survival E. coli F4 left in the jejunal content 
To investigate whether the RGDSK-HRNs-FITC control E. coli F4 viability, each loop 
was injected 1ml of 0.1M PBS ampicillin to wash unbound E. coli F4 from the villi gently and to 
collect the content inside the loop. The content (100µl) was serially diluted from 1-10 times before 
being incubated in LB-ampicillin agar plates for 24 hours at 37ºC. The number of E. coli F4 colo-
nies were counted for statistical analysis. The rest of the content was centrifuged to collect the 
supernatant and the pellet, which was preserved at -80ºC for later microbial analysis 
7.3.10. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay 
The second segment from each jejunal loop in the paraffin block was sectioned at 5 µm 
thickness. To observe the extend of apoptosis in the jejunal epithelium upon E. coli challenging 
and RGDSK-HRNs-FITC treatment, we performed Terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL) assay on the tissue sections using a commercial in situ cell death 
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detection kit-Alkaline-phosphatase following per manufacturer’s instruction. Briefly, tissues were 
de-paraffinized with xylene, re-hydrated with ethanol, then permeabilized with proteinase K. After 
that, the TUNEL reaction mixture, including enzyme terminal transferase solution and label solu-
tion, was added. The fluorescent signal was converted to a color signal by incubation in Converter-
AP, followed in a substrate solution of the kit. Finally, DNA fragmentation morphology in the 
tissue was examined under a light microscope. The tissue which was stained without enzyme so-
lution served as a negative control. 
7.3.11. Statistical analysis 
The GraphPad Prism version 5.04 software (San Diego, CA, USA.) was used to analyse 
data. Quantitative results were expressed as mean ± SEM, and error bars represented standard 
error. The normal distribution of residuals was tested by histogram and Shapiro-Wilk test. Data 
were analyzed by Analysis Of Variance (ANOVA), followed by Bonferroni multiple comparison 
test. A significant difference was set when the critical value of α was below or equal to 0.05 as 
(two-tailed, p<0.05). 
7.4. RESULTS 
7.4.1. The level of integrin αvβ3 expression changed on E. coli, Salmonella infected 
porcine jejunum 
The immunohistochemistry showed intense staining for the integrin αvβ3 on cryptal cells 
and villar epithelium with especially intense reaction on the nucleus and apical surface of the cells 
in healthy porcine jejunum. The level of integrin αvβ3 expression decreased in the epithelium but 
increased in the vascular endothelium of jejuna infected with E. coli alone or in combination with 
Salmonella. Integrin αvβ3 was also expressed in some inflammatory cells, probably plasma cells, 
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and macrophages in the infected jejuna. Interestingly, the bacteria, likely E. coli showed staining 






Figure 7.2. Porcine jejunal immunohistochemistry and immune-gold for integrin αvβ3.  
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The pictures from immunohistochemistry showed that in the jejunum section from the healthy nor-
mal pig (A, D), integrin αvβ3 positive staining (purple-pink color, arrows) is observed abundantly 
in the nucleus, cytoplasm and apical surface of the epithelium of villi (D) and crypts (A). In E. coli 
infected jejunum (B, E, F), the intensity of positive staining on epithelium decreased. Interestingly, 
maybe bacteria binding to epithelium has positive staining with integrin αvβ3 (F). In E. coli asso-
ciated Salmonella infected jejunum (C, G), integrin αvβ3 was found not very strong staining on 
the epithelium. Integrin αvβ3 is expressed on the immune cells and the endothelium of blood ves-
sels. Both figures H and I are the transmission immune-gold electron micrographs for integrin 
αvβ3 expression in porcine jejunum. On the epithelium of normal healthy porcine jejunum, integrin 
αvβ3 was expressed in the nucleus, cytoplasm, and apical surface of epithelium, especially the 
microvilli (H). The level of integrin αvβ3 on the epithelium decreased upon E. coli infection (I). 
Abbreviation: G: Gland (crypts), L: Lumen, E: Epithelium, BV: Blood vessel. Statistical analysis 
of semi-quantitative integrin αvβ3 expression from immunohistochemistry scoring of the porcine 
jejunal epithelium (J) and endothelium (K). We classified the intensity of staining that: 0, no stain-
ing; 1+, light staining; 2+, moderate staining; 3+, strong staining; and 4+, very strong staining. 





Figure 7.3. Integrin αvβ3 immunohistochemical staining controls of porcine jejunum 
The porcine jejunal section, stained with bovine serum albumin and omitted integrin αvβ3 primary 
antibody, showed only the green-blue color of methyl green counterstaining. The porcine jejunal 
section, stained with IgG1 rabbit isotype control instead of integrin αvβ3 primary antibody, also 
served as negative control and did not show any positive reaction. The porcine jejunal section, 
stained with anti- von Willebrand factor (vWF) antibody, and served as a positive control for the 
protocol, reacted only with vascular endothelium (pink-violet, arrows). Magnification: 1000.  
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7.4.2. E. coli has a protein domain functioning as integrin αvβ3 
Previous data from 96-well plate binding assay showed E. coli binding was dependent 
on integrin αvβ3 and the number of E. coli F4 binding to the plate depended on the concentration 
of E. coli F4 added and the concentration of monoclonal anti-integrin αvβ3 antibody. We then 
performed another experiment with pretreated E. coli with six different treatments. We found that 
the number of E. coli F4 binding to the well plate coated with monoclonal integrin αvβ3 antibody 
decreased if E. coli F4 was treated with either RGDSK-HRNs-FITC, RGDSK-FITC, monoclonal 
anti-integrin αvβ3 antibody, anti-F4 antibody (Figure 7.4). It can be explained that RGDSK-
HRNs-FITC, RGDSK-FITC, and monoclonal anti-integrin αvβ3 antibody block the integrin αvβ3-
like protein domain on E. coli F4. The anti-F4 antibody blocked the binding site of F4 antigen of 
E. coli F4 to F4 receptor of the host cells (242), which maybe inactivate or opsonize the bacteria 
and can reduce their proliferation or survival. This possibility was explained by the number of E. 





Figure 7.4. Binding assay on monoclonal integrin αvβ3 antibody-coated 96 well plates on pre-
treated E. coli. 
RGDSK-HRNs mediate E. coli adhering through interaction with the integrin αvβ3-like protein on 
E. coli. Data were expressed as mean ± SEM. Asterisk (*) indicates a significant difference com-




7.4.3. Evaluating E. coli F4 binding to the villi in the porcine gut loop model 
We scraped the villi from all loops and counted the number of E. coli F4 binding to villi. 
We found that the number of E. coli F4 binding to villi were significantly decreased in the E. coli 
treated with RGDSK-HRNs-FITC, RGDSK-FITC, or anti-F4 antibody compared with the group 
of E. coli F4 only without any treatment (P<0.05) (Figure 7.5). The E. coli F4 binding to villi was 
observed again in hematoxylin and eosin-stained tissues (Figure 7.6). We also observed DNA 
fragmentation of all groups by TUNEL assay staining on jejunal loops (Figure 7.8). However, we 
did not perform rating and statistical analysis on TUNEL assay staining as well as on hematoxylin 
and eosin. Compared with E. coli F4 treatment control, there was a significant decrease (P<0.05) 
in the number of viable E. coli F4 left in the content of the porcine jejunal lumen in RGDSK-FITC 





Figure 7.5. The number of E. coli F4 binding to 250 µm length of villi in the porcine jejunal loop 
model. 
RGDSK-HRNs-FITC prevented E. coli binding to porcine jejunal villi. Data were expressed as 
mean ± SEM. Asterisk (*) indicates a significant difference compared with the E. coli group 






Figure 7.6. Histopathological observation of porcine jejunum with hematoxylin and eosin staining.  
Jejunal loops with different treatments from (A) normal control, (B) E. coli F4, (C) RGDSK-HRNs-
FITC + F4 Ab + E. coli F4, (D) F4 Ab + E. coli F4, (E) RGDSK-HRNs-FITC + E. coli F4, (F) 
RGDSK-FITC + E. coli F4 groups. Arrows indicate E. coli. Abbreviations: L: lumen. Magnifica-




Figure 7.7. RGDSK-HRNs-FITC did not affect the proliferation of E. coli F4 significantly.  
Data were expressed as mean ± SEM. Asterisk (*) indicates a significant difference compared with 




Figure 7.8. TUNEL assay on jejunal loops.  
Jejunal loops with different treatments from (A) normal control, (B) E. coli F4, (C) RGDSK-HRNs-
FITC + F4 Ab + E. coli F4, (D) F4 Ab + E. coli F4, (E) RGDSK-HRNs-FITC + E. coli F4, (F) 






Our laboratory has previously provided evidence on the expression of integrin αvβ3 on 
the normal porcine gastrointestinal tract (213). In this present study, we continued exploring the 
specific and detailed expression of integrin αvβ3 on the porcine jejunum upon infection. We found 
integrin αvβ3 was present on the apical surface and abundant in the nucleus of the epithelium of 
healthy porcine jejunum. The integrin αvβ3 expression level was decreased in E. coli or E. coli – 
Salmonella infected pigs. Taken together, our results suggest that there is an association between 
the integrin αvβ3 and the bacteria upon infection. Recently, Zhang and colleagues reported that 
integrin αL of the host was related to sensibility to Salmonella Typhimurium infection in a mouse 
model (267). Moreover, in 2017, Garciarena and colleagues mentioned that cilengitide treatment 
targeted integrin αvβ3 on the human endothelial cell line and prevented E. coli adherence to the 
cell (73). 
Enterotoxigenic Escherichia coli (ETEC), which has a high economic impact on swine 
production and a threat to the safety of pork products, is one of the dangerous pathogens of diar-
rheal diseases worldwide in humans and animals (204, 249, 261). In this chapter, we continue to 
use the novel RGDSK-HRNs-FITC to investigate its function on preventing E. coli F4 binding to 
jejunum in vivo. The focus of our project was to evaluate the interactions of integrin αvβ3 with E. 
coli F4 and the RGDSK-HRNs-FITC using the innovative porcine gut-loop model and to find 
ways to exploit the interaction of the integrin and RGDSK-HRNs-FITC to manage bacterial colo-
nization of gut epithelium. The results from this study prove the hypothesis is true that RGDSK-
HRNs-FITC can inhibit bacterial colonization on the gut epithelium through blocking integrin 
αvβ3, thus preventing the epithelium-bacteria component attachment. 
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Recently, scientists reported that E. coli F4 infection-induced apoptosis on the jejunum 
of piglets (265) by activating caspase 3 as well as caspase 8, and increasing DNA fragmentation 
(264). However, to our knowledge, the effects of RGDSK-HRNs-FITC on the apoptosis of gut 
epithelium upon E. coli infection via blocking integrin αvβ3 have not been investigated. Our 
TUNEL staining showed that RGDSK-HRNs-FITC did not significantly increase the severity of 
DNA fragmentation compared to normal healthy control group. The most obvious implication for 
emerging from this study with previous in vitro study on IPEC1 cell line is that RGDSK-HRNs-
FITC can be a potential drug delivery vehicle and is biocompatible to the host.  
In conclusion, it is critical to understand the expression of integrin αvβ3. In this study, 
we detected integrin αvβ3 in the jejunum of pigs. Future studies are required to elucidate this 
signalling molecule function and the involvement of pathogenesis of intestinal diseases in the pig 
and human. 
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CHAPTER 8.  GENERAL DISCUSSION AND CONCLUSION 
Enterotoxigenic Escherichia coli, which has a high economic impact on swine produc-
tion and poses a threat to pork meat products, is one of the common causes of diarrheal diseases 
and public health concerns. To manage this outbreak, many scientists have attempted to reduce E. 
coli colonization in the intestine (34, 35, 185, 247). The intestinal epithelium is the earliest re-
sponders contacting pathogens in the gastro-intestinal tract in innate immune responses. The initial 
adhesion of E. coli to the gut epithelium is the first stage in the pathogenesis of this enteric disease 
(124). 
Our data collected through an in vitro experiment by western blot, immune-gold, and 
immunofluorescent staining using the IPEC1 cell line showed E. coli F4 infection decreased the 
expression of the integrin αvβ3 in the cell line. Moreover, considering the change of integrin αvβ3 
expression in the epithelium of porcine jejunal tissues in normal and E. coli or E. coli associated 
with Salmonella infected jejuna in our study, there is a clear need to fine-tune the function of 
integrin αvβ3 in the E. coli infected jejunums. The implications of the downregulation of the in-
tegrin expression are not clear, but it may be a mechanism that E. coli uses it to prevent the acti-
vation of the cells or to down regulate the immune response. In 2004, Janardhan and colleagues 
mentioned that the crosstalk between integrins is a possible reason for the decrease of integrin αv 
and integrin β3 subunits levels in E. coli infected rat lungs compared to control and S. pneumoniae 
infected groups (105). Although whether E. coli F4 containing an RGD peptide sequence is un-
clear, in this case, integrin αvβ3 of the host might bind to the RGD-containing peptide of E. coli 
F4. Another possible explanation is that E. coli F4 possesses the structure having the same char-
acteristic and properties, as is found in RGD-containing ligands. This RGD-like structure or pep-
tide can bind to the same site on the integrin αvβ3, promoting E. coli F4 attachment to and 
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penetration into intestinal epithelium. Similarly, a recent study reported that Staphylococcus au-
reus bound to integrin αvβ3 on the endothelium, leading to endothelial dysfunction (149). This 
binding was reduced by Cilengitide through inhibiting integrin αvβ3 (149). 
Moreover, scientists reported that eae gene (encoding Intimin adhesion protein) in enter-
ohemorrhagic E. coli enabled the pathogen to attach to and desquamate colonic epithelial cells, 
recruiting inflammatory cells and causing microvilli loss and edema (56). Here, we used the eae 
negative E. coli F4 strain and focused on the early adherence stage of E. coli. Another interesting 
observation in our study was the presence of an integrin αvβ3-like protein domain in E. coli F4, 
confirmed by western blot, immunohistochemical staining, 96-wells high binding assay, and a pi-
lot mass spectrometry analysis. The role of the integrin αvβ3-like protein on the surface of E. coli 
is unknown, but may have implications for the adherence to and invasion of the bacteria. 
Many scientists have provided a substantial amount of evidence about the bacteria-extra-
cellular matrix interaction (257). In this study, we found that E. coli F4 had an RGD-like binding 
site with integrin αvβ3 in the jejunal epithelium, and E. coli had an integrin αvβ3-like protein 
domain. Therefore, integrin αvβ3 maybe one of the possible receptor molecules of E. coli. Our 
findings provide insights into the function of integrin αvβ3 in intestinal physiology, E. coli infec-
tion, and pathology. We believe this provides a direct link to the first stage of E. coli pathobiology 
as we have quantified E. coli binding. 
Peptides are the alternatives of antibiotics to prevent bacteria and avoid antibiotic re-
sistance and antibiotic-residues in animal products (158). Generally, antimicrobial peptides have 
a broader spectrum and electrostatic interaction with the membrane lipid components to disrupt 
bacterial membrane (40). Integrin αvβ3 is a heterodimeric transmembrane receptor that recognizes 
and binds arginine-glycine-aspartic acid (RGD) containing peptides. In this study, we used 
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biocompatible RGDSK-HRNs-FITC to target integrin αvβ3 protein presenting on the gut cells to 
prevent the bacterial attachment to the gut to protect the host from infections. The project aims 
were to develop a proof of concept for nanomedicine, a potential alternative to antibiotics, to ame-
liorate this important public health concern. 
Here, we wanted to verify whether RGDSK-HRNs-FITC were able to mediate the 
integrins-dependent receptor in E. coli infection in vitro and in vivo. In an in vitro experiment, we 
found that RGDSK-HRNs-FITC could prevent the attachment of E. coli to IPEC1. Ex vivo villus 
adhesion assay showed that the best results were observed in RGDSK peptide treatment in 
maintaining inhibiting E. coli binding to the jejunal epithelium. RGDSK-HRNs-FITC treatment is 
efficient in a short-time period. It is difficult to interpret the findings from RGDSK-HRNs-FITC 
treatment because of the complexity of the interaction of multiple RGDSK on the nanotube surface 
with integrin αvβ3 on the jejunal epithelium and the integrin αvβ3-like function protein on E. coli 
in long-time period treatment. 
To have deeper understanding of the effect of RGDSK-HRNs-FITC in humans and ani-
mals, an in vivo experiment should be performed. However, the oral bacterial challenging experi-
ment is expensive and impractical due to the number of animals required, treatment variables and 
individual animal characteristics. Moreover, non-sentient animals would not provide the complete 
biological readouts necessary to evaluate the efficacy of RGDSK-HRNs-FITC to E. coli infection. 
Moreover, because the intestinal immune system of pigs is considered similar to that of humans, 
and both are the most common target mammalian species at high risk of E. coli infection (79, 154, 
165, 195), we used the adherence porcine gut loop model to determine efficacy of RGDSK-HRNs-
FITC in preventing the E. coli F4 colonization in diarrhea.  
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In this study, we found that RGDSK-HRNs-FITC reduced the number of E. coli F4 bind-
ing to villi compared with E. coli F4 treatment group. Moreover, RGDSK-FITC peptide but not 
RGDSK-HRNs-FITC treatment decreased the number of live E. coli F4 left in the jejunal lumen. 
Besides the ability in targeting integrin αvβ3 in the jejunal epithelium and integrin αvβ3-like pro-
tein in E. coli F4, RGDSK peptide itself likely effects the survival of E. coli F4. Our results high-
lighted the role of the RGDSK peptide functional group associated with the nanotubes vehicle 
down-regulated the toxicity of RGDSK peptide to the jejunal cells and E. coli F4. These data imply 
that the nanotubes vehicle mostly maintained the function of RGDSK and even reduced the ad-
verse effect of RGDSK on cell death. 
Integrin αvβ3 binds to RGD peptides, which are present in extracellular matrix molecules 
such as fibronectin, osteopontin, collagen, and vitronectin (196, 220). The integrin αvβ3 regulates 
cell functions such as activation, proliferation, and adherence through a variety of signals (196, 
220). This study added to our understanding that integrin αvβ3 was known as a receptor for bac-
teria (149). We confirmed that E. coli F4 efficiently binds to the IPEC1 cell line in vitro (126). 
Our findings support the previous statement that obstructing the receptor adhesion sites to inhibit 
E. coli attachment to the intestines, particularly epithelia, can result in a novel intervention to mod-
ify this enterotoxigenic pathogen-induced diarrhea in pigs (106). 
The literature review showed that LM609 monoclonal integrin αvβ3 antibody was used 
in many previous papers as its specific recognition of integrin αvβ3 (14, 167, 210). Some research-
ers mentioned that LM609 antibody blocked integrin αvβ3 via allosteric sites which reducing the 
activity of integrin αvβ3 such as a conformation change involving protein dynamics (14). In our 
study, RGDSK-HRNs-FITC interact with integrin αvβ3 mainly via the RGD binding site. This 
reason may explain the little difference in the effects of these two treatments in cell survival and 
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in preventing E. coli F4 binding to villi. RGDSK-HRNs-FITC had almost the same blocking func-
tion as LM609 monoclonal anti-integrin αvβ3 antibody treatment in preventing the E. coli F4 bind-
ing to jejunal epithelium at short time point. This suggests that integrin αvβ3 plays a role in the 
binding of E. coli F4 to the jejunal epithelium in an early stage of adherence. 
We also tested whether any advantages of combining RGDSK-HRNs-FITC and F4 anti-
body treatment. We did not observe significant additional efficacy of using both treatments at the 
same time in inhibiting E. coli F4 binding to porcine villi, implying that these F4 and integrins 
targets likely to be arranged in sequence or at the same binding site with integrin αvβ3. Integrin 
αvβ3 is possibly a coreceptor with the F4 receptor for E. coli F4 adhesion and colonization. Perhaps 
either integrin αvβ3 or F4 receptor is in the initial attachment step, and the other is in the subse-
quent post attachment step of the multistep process involving the E. coli-jejunal epithelium adher-
ence. Another explanation is that both integrin αvβ3 and F4 receptor are required as co-targets of 
the E. coli to attack the host cell at the same time. 
Taken together, this study added the information on the biology of integrin αvβ3 in the 
jejunum and the biocompatibility of helical rosette nanotubes and their potential use in inflamma-
tory diseases (Figure 8.1). This novel RGDSK-HRNs-FITC can target and interface with integrins 
conferring great promise as a potential drug-delivery system for intestinal inflammation, particu-
larly due to E. coli F4 in this study. The aim is to develop a proof of concept for nanotubes-based 
molecular interventions to reduce E. coli colonization of the gut. The investigation will contribute 
to offering new strategies in the prevention and management of these costly diseases, expecting 





Figure 8.1. The schematic diagram illustrates the effect of RGDSK-HRNs-FITC and other treat-
ments on the porcine jejunal epithelium. 
This diagram shows that E. coli infection induces p-p38MAPK and inhibits p-akt1. The RGD-
HRNs-FITC prevent E. coli binding to the intestinal epithelium, reduced the level of p-p53 and p-
p38MAPK compared with monoclonal anti-integrin αvβ3 antibody and RGDSK peptide, respec-
tively, in E. coli infection, lessened the DNA fragmentation, and slowed down the apoptosis pro-
cess. It leads to improve the survival of epithelium. Thinner arrows indicate inhibition, and thicker 




CHAPTER 9. SUPPLEMENTAL RESULTS 
 
Figure 9.1. Expression of integrin αvβ3 in the porcine gastrointestinal tract 
Immunohistochemical staining normal porcine gastrointestinal tract was performed with mono-
clonal anti-integrin αvβ3 antibody (clone LM609, Chemicon Inc., Temecula, USA). Integrin αvβ3 
is expressed in the epithelium, especially in the apical surface of the cells (dark purple). Negative 
controls for the specificity of primary, secondary antibody and protocol included mouse IgG1 iso-
type control, omission of primary antibody or both primary antibody and secondary antibody 
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conjugated HRP. All negative controls show the only green-blue color of methyl green counter-
staining, no positive staining reaction. The controls staining with the anti-endothelial marker von 
Willebrand factor (vWF, dark purple) served as a positive control for the protocol, which showed 
only positive staining of vWF in the endothelium.   
151 
 
9.1. Integrin αvβ3 expression in the equine lung and jejunum 
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9.1.1. Abstract 
Integrin αvβ3 recognizes arginine-glycine-aspartic acid (RGD) sequences and has im-
portant functions in cell adhesion, signalling, and survival. However, the expression of integrin 
αvβ3 in the equine lung and jejunum is not well understood. In this report, we used the lungs and 
jejuna of the horse to explore the hitherto unknown expression of integrin αvβ3 with light and 
electron immunocytochemistry. Immunohistochemistry showed integrin αvβ3 on the epithelium, 
the immune cells in Peyer’s patches, the smooth muscle, and the endothelium of equine jejuna. In 
equine lungs, we recognized integrin αvβ3 on the endothelium of blood vessels, the alveolar septa, 
the bronchial lymph nodes, and the cartilages. However, the expression of the integrin αvβ3 was 
weak on the epithelium of bronchioles. In conclusion, these are the first data to show the expression 
of integrin αvβ3 in equine lungs and jejuna.  





Integrins are heterodimeric transmembrane receptors, comprised of two subunits, α and 
β. The integrins are present in many species such as mammals, chicken, zebrafish, sponges, the 
nematode Caenorhabditis elegans (two α and one β subunits, forming two integrins) and the fruit-
fly Drosophila melanogaster (five α and one β subunits, forming five integrins) (229).  The integ-
rin family has 18 α and eight β subunits, forming 24 heterodimeric transmembrane receptors (29, 
229). All five integrins αv, two integrins β1 (α5β1, α8β1), and αΙΙbβ3 can recognize arginine-
glycine-aspartic acid (RGD) peptide ligands, known as a general integrin-binding motif (29). Each 
subunit has an extracellular domain, a single transmembrane region, and a short cytoplasmic 
domain (8). The extracellular domain, a ligand-binding site, transmits signals from outside into the 
cell interior and vice versa receives the intracellular signals to regulate back to the affinity of their 
ligand-binding site (11, 29, 229, 266). Although smaller than the extracellular domains, the cyto-
plasmic domains up-regulate the activation of integrins by their association with adaptor proteins, 
including Src, focal adhesion kinase, integrin-linked kinase, kindlin, paxillin, talin, and vinculin 
(103, 170). Consequently, these interactions rearrange the cytoskeleton, thus affecting the structure 
and function of extracellular domains (103). The activation state of the integrins is characterized 
by separation, twisting, pistoning, and hinging of their tails (103). The integrins with a highly bent 
physiologic conformation have low affinity for binding biological ligands (230). 
Integrin αvβ3, known as a vitronectin receptor, plays an essential role in cell adhesion, 
cell signalling, cell survival, angiogenesis, and leukocyte migration (159, 220). The expression of 
integrin αvβ3 is increased in neovascular endothelial cells (220). This protein serves as a marker 
on the cell surface, which recognizes and binds peptides containing RGD (159, 220). Our lab 
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reported that integrin αvβ3 is expressed on the bronchial vasculature in the lung of the calves and 
dogs, as well as the small intestine of the calves, dogs, and pigs (213). 
Horses suffer from many inflammatory diseases, including some of the infectious origin 
(49, 192).  The mechanisms of inflammatory cell recruitment, cell activation, and changes in vas-
cular permeability underlying diseases such as colic, virus as well as bacterial enteritis, and pneu-
monia, are not fully understood (49, 140, 146, 183). The occurrence of diarrhea is commonly seen 
in horses, and the altered gut barrier function underlies in increased secretion of water into the 
intestine (183). The integrin αvβ3 with roles in fundamental processes such as cell signalling, cell 
migration and vascular hydraulic conductivity (210, 239), may function in equine inflammatory 
diseases of the lung and the intestine. Currently, there are no data on the expression of the integrin 
αvβ3 in equine tissues.  Our data showed that integrin αvβ3 was expressed in equine lungs and 
jejuna. 
9.1.3. Materials and methods 
Materials 
Jejuna and lungs from horses (n = 4 each) were processed and embedded in paraffin 
blocks at Western College of Veterinary Medicine at the University of Saskatchewan. Mouse mon-
oclonal integrin αvβ3 antibody (clone LM609, Chemicon Inc., Temecula, USA.), polyclonal goat 
anti-mouse immunoglobulins/HRP secondary antibody (Dako, California, USA.), primary anti-
body polyclonal rabbit anti-human von Willebrant Factor (vWF) (Dako, Burlington, ON, Canada), 
Vector® VIP peroxidase substrate kit for peroxidase (Vector laboratories, Burlingame, CA, USA), 




Immunohistochemical staining integrin αvβ3 
Equine lungs and jejuna in paraffin blocks were sectioned at 5µm thickness for 
immunohistochemistry as per a previous protocol (213). Briefly, sections were de-paraffinized, 
followed by quenching the endogenous peroxidase activity and treatment with pepsin. Following 
two hours blocking with 1% BSA, the sections were incubated with monoclonal integrin αvβ3 
antibody (clone LM609, Chemicon Inc., Temecula, USA.) and appropriate polyclonal goat anti-
mouse immunoglobulins/HRP secondary antibody. The color development was carried out with 
Vector® VIP peroxidase substrate kit. The controls included staining with the anti-endothelial 
marker vWF serving as a positive control, or isotype antibody matching control (mouse IgG1) 
instead of primary antibody or the omission of primary antibody serving as negative controls. 
Immuno-gold electron microscopy for integrin αvβ3 
Equine lungs and jejuna in LR white resin were sectioned at 100nm thickness on nickel 
grids. The non-specific bindings were blocked by BSA 1% in Tris-buffered saline before one-hour 
incubation in the integrin αvβ3 antibody (50µg/ml). A section stained without primary antibody 
was used as a negative control. After three times being washed in Tris-buffered saline, the sections 
were incubated for 1 hour in 15−nm gold-conjugated anti-mouse secondary antibody with 1:100 
dilution. Following that, samples were incubated in 2% aqueous uranyl acetate, an indicator for 
negative staining, then Reynold’s lead citrate to enhance the electron-scattering properties of bio-
logical components inside the cells. The micrographs were imaged using a transmission electron 






Integrin αvβ3 was detected on the equine lungs and jejuna. Immunohistochemistry 
showed integrin αvβ3 on the endothelium of blood vessels, the alveolar septa, the bronchial lymph 
nodes, the cartilages, the epithelium of bronchioles in equine lungs, neutrophils, type 1 epithelium 
and pulmonary intravascular macrophages (Figure 9.2). Immuno-electron microscopy yielded data 
on the detailed subcellular expression of the integrin. We found that the integrin was present in 
type I alveolar epithelial cells, pulmonary capillary endothelium, and neutrophils (Figure 9.3). The 
integrin was localized on the plasma membrane, cytoplasm, and the nuclei of these cells. Pulmo-
nary intravascular macrophages also expressed integrin αvβ3 on their surface, cytoplasm, and the 
nucleus (Figure 9.3).  
In equine jejunum, integrin αvβ3 was found in the epithelium, lymphocytes in Peyer’s 
patches, smooth muscles, and endothelium lining lumen (Figure 9.4). Negative controls for the 
specificity of primary, or secondary antibody include mouse IgG1 isotype control instead of integ-
rin αvβ3 antibody, or the omission of primary antibody or both primary antibody and secondary 
antibody conjugated HRP. All negative controls show only the green-blue color of methyl green 




Figure 9.2. Equine lung immunohistochemistry for integrin αvβ3 
Lung sections from healthy normal horses, stained with BSA (B), or IgG1 isotype control (D), 
showed only the green-blue color of methyl green counterstaining while anti-vWF antibody (F) 
reacts with vascular endothelium (purple-pink color). Integrin αvβ3 staining (arrows to purple-
pink patchy deposition) is observed in alveolar (Av) septum (C), bronchiole (Br) epithelium (A), 
endothelium on blood vessel (BV, C), bronchial lymph node (LN, E), cartilage (Ca, E). Magnifi-






Figure 9.3. Immuno-gold electron microscopy for integrin αvβ3 of an equine lung. 
The transmission electron micrograph of the normal healthy equine lung showed staining for in-
tegrin αvβ3 (arrows) in the plasma membrane, nucleus (N) and cytoplasm of a neutrophil in a 
capillary (figure A), a pulmonary intravascular macrophages (PIM) (Figure B, and Figure C 
shows the boxed area highlighted), a type 1 epithelium on alveolar septa (EP, figure A and B ), 
endothelium (E, Figure A and B). The PIM was characterized as a giant and irregularly shaped 
leukocyte with a kidney bean-shaped nucleus, adhering to the capillary endothelial cell on the 
thicker side of the alveolar septum. The cytoplasm of PIM contains some vacuoles. Abbreviation: 
As: Alveolar space, Bv: blood vessel, Br: Bronchiole, E: endothelium, EP: epithelium, N: nucleus. 




Figure 9.4. Equine jejunum immunohistochemistry and immune-gold for integrin αvβ3 
Immunohistochemistry results show positive staining integrin αvβ3 (purple-pink) on epithelium on 
lumen (A), crypts (C), endothelium (D), cells in Peyer’s patches (E), and smooth muscle (F). The 
immune-gold electron micrograph of integrin αvβ3 expression on the epithelium of normal healthy 
horse jejunum shows integrin αvβ3 on the nucleus, cytoplasm, and apical surface of the epithelium 
(B). Abbreviation: L: lumen, EP: epithelium, BV: blood vessel, SM: smooth muscle, G: gland 





Figure 9.5. Integrin αvβ3 immunohistochemical staining controls of equine jejunum 
From top to bottom, the equine jejunal section, stained with bovine serum albumin (BSA) and 
omitted integrin αvβ3 primary antibody, showed only the green-blue color of methyl green counter 
staining. The equine jejunal section, stained with IgG1 rabbit isotype control instead of integrin 
αvβ3 primary antibody, also served as negative control and did not show any positive reaction. 
The equine jejunal section, stained with anti-vWF antibody, and served as a positive control for 




The financial losses due to intestinal and respiratory diseases are in the range of billions 
of dollars every year worldwide (183). The lung and intestine are two organs of the body that 
interact with the environment through air and food, respectively, all the time and are exposed to 
pathogens and allergens (140, 146). The unique and heterogenous lining of the epithelium in the 
intestine and the lungs is the first physical, physiological, and immunological barrier with a well-
developed system for handling the bacteria and viruses (140, 146). The epithelia employ a variety 
of molecular strategies to tackle invading microbes and interaction with the intestinal microbiota. 
We have previously provided evidence on the expression of integrin αvβ3, which is an important 
adhesion and signalling molecule in rat, calf, pig, dog, and human (175, 210, 211, 213). In this 
present study, we continued exploring the specific and detailed expression of integrin αvβ3 on the 
equine lung and jejunum. We found that integrin αvβ3 was present on the epithelium, endothelium, 
and immune cells in the lungs, and jejuna of the horse.  
We have previously reported the occurrence of the integrin αvβ3 on the porcine intestinal 
epithelia as well as the airway and alveolar epithelia of the lung of pigs, dogs, and cattle (213). 
The integrin αvβ3 may play an important role in the adhesion and uptake of bacteria and viruses 
by the epithelial cells and aid in keeping the epithelium clean (81). Recently, there has been major 
interest in understanding the formation and ecology of the microbiome in various organs, including 
the gut and the airways of animals (49, 140, 146, 183). The role of adhesive proteins as integrin 
αvβ3 in the maintenance of healthy microbiome and the interactions of microbiome with the eq-
uine epithelia remains unexplored and may be an area of interest. This could be especially im-
portant in species such as horses that have high incidence of intestinal diseases such as colic (49) 
and virus infection (183), as well as lung diseases such as heaves (192).  Similar to these data, 
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previously we also demonstrated the expression of integrin αvβ3 on the bronchiolar epithelia and 
alveolar macrophages in normal human lung (211). The expression of integrin αvβ3 in alveolar 
macrophages was intense in human sepsis lungs (211).  
There are differences in the anatomy and physiology of the lung between the horse and 
other mammal animals as well as humans since the horse lung supports its intense athletic perfor-
mance (108). The horse lung also has the population of pulmonary intravascular macrophages 
(PIMs), which humans do not have, in addition to the usual complement of alveolar macrophages 
(12, 13). These PIMs have electron-dense globular surface-coat (12). The equine PIMs have pre-
viously been shown to express TLR4 (214), which potentially may be a reason for enhanced sen-
sitivity of the horse to lipopolysaccharide endotoxin-induced lung injury (172, 173, 214). Here, 
we show the presence of integrin αvβ3 in PIMs. Considering the role of this integrin in cell sig-
nalling, it is possible that the integrin αvβ3 provides another mechanism for the activation of PIMs. 
It is important to note that depletion of PIMs, even in a spontaneous disease such as heaves, reduces 
lung inflammation and clinical signs of the disease (3, 212). The PIMs play an essential role in 
removing circulating particles in the capillaries (25) and the immune system in the lung (92, 201). 
There are recent data showing induction of PIMs in rodents that normally lack PIMs, and the in-
duced PIMs increase susceptibility of lung inflammation, which is abrogated upon their depletion 
(82). There is a need for studies to examine the occurrence of PIMs in humans (201). In this study, 
the expression of integrin αvβ3 in equine PIMs provides a mechanism for their activation. The 
integrin αvβ3 may play a role in the aggregation of platelets around PIMs in equine lungs, as has 
been reported previously in the lungs of cattle infected with Mannheimia hemolytica (212).  
Here, we also found integrin αvβ3 on neutrophils. Some of the earlier data have shown 
that the integrin αvβ3 is important in the locomotion of neutrophils  (14, 15, 133, 188). Moreover, 
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in this report, the occurrence of integrin αvβ3 on lung vascular endothelium is consistent with 
previous findings, and it may have a role in maintaining endothelial barrier function as demon-
strated previously by Bhattacharya lab and others (149, 218, 239) as well as angiogenesis (141). 
Taken together, this is the first elucidation of the cellular and subcellular expression of 
the integrin αvβ3 in equine lung and jejunum. Considering the role of the integrin αvβ3 in cell 
biology and signalling, this sets the stage for further studies to understand the expression and bi-
ology of the integrin in inflamed lungs and the intestines of the horse. 
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